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CHAPTER 1 
MIXED EFFICACY OPIOID LIGANDS 
 
1.1 Introduction 
 For thousands of years, alkaloids extracted from the opium-containing poppy 
plant have been used as analgesics.1 Even today, these naturally occurring opioids such as 
morphine and codeine (Figure 1) are considered the standard of care for the treatment of 
moderate to severe pain. Synthetic opioids, such as fentanyl and methadone (Figure 1) 
have also found widespread use as potent analgesics, and other classes of natural opioids 
have also been extracted from a number of non-poppy sources.2–4 
Figure 1. Chemical Structures of Morphine, Codeine, Fentanyl and Methadone 
 
 
 
 
 
 
Although opioid analgesics are certainly effective in the clinic, the prolonged 
usage of opioids is complicated by the development of serious side effects. These side 
effects include constipation, respiratory depression, and the development of dependence 
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and tolerance.5 There is thus a great unmet need to develop an efficacious opioid 
analgesic devoid of these negative side effects.  
 Opioids exert their pharmacological effects through binding to one or more of the 
G protein-coupled opioid receptors, the µ opioid receptor (MOR)6, the δ opioid receptor 
(DOR)7 and the κ opioid receptor (KOR).8 In general, clinically used opioid analgesics 
such as morphine evoke both the desired and undesired effects through activation of 
MOR. Activation of both DOR and KOR has also been shown to produce a mild 
analgesic effect, although the effectiveness of DOR and KOR-stimulating ligands is 
hampered by the possibility of convulsions and dysphoria, respectively.9 Numerous 
reports have indicated that the undesired MOR-related side effects may be ameliorated by 
concomitant ligand interaction with DOR.10 It has been shown that the co-administration 
of DOR-selective agonists11 or antagonists12 with a MOR agonist can attenuate the 
dependence and tolerance typically associated with the latter. The work presented here 
details the synthesis and evaluation of MOR agonist/DOR antagonist ligands for the 
purpose of developing effective opioid analgesics devoid of the aforementioned side 
effects.  
 
1.2 The Role of DOR in the Development of Dependence and Tolerance 
The role of DOR in the modulation of the biological effects of MOR has long 
been the subject of intense interest.13 It has been shown that DORs exist on the same 
neurons as MORs,14 and there is additional biological evidence for functionally distinct 
MOR/DOR heteromers.15,16 It has also been demonstrated that the density of DOR 
binding sites in mice is increased following chronic treatment with the MOR agonist 
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morphine, further demonstrating an interaction between MOR and DOR.17 In light of 
these studies, much work has been done on examining the biological effects of a DOR 
ligand on MOR-mediated processes. The therapeutic potential for the co-administration 
of a DOR antagonist with morphine was demonstrated in 1991. In this study, mice were 
given a subcutaneous (sc) dose of morphine for a period of 3 days. Compared to control 
mice that were given a placebo, morphine-receiving mice displayed an approximately 19-
fold increase in morphine ED50 after this time. Mice receiving naltrindole18 (a potent and 
selective DOR antagonist, Figure 2) along with morphine displayed a smaller (roughly 2-
fold) increase in the ED50 for morphine, highlighting the effectiveness of the co-
administration of a DOR antagonist in decreasing the development of chronic tolerance to 
a selective MOR agonist.  
Figure 2. Chemical Structure of Naltrindole  
 
 
 
 
Additionally, acute tolerance to morphine was completely eliminated in mice that were 
given naltrindole.12 The effects of naltrindole on morphine-induced tolerance and 
dependence have also been studied in rats. In one study, rats were pretreated with saline 
(control) or naltrindole, and given morphine for a period of 24 hours. Withdrawal was 
precipitated with the opioid antagonist naloxone, and all withdrawal symptoms were 
significantly reduced in the naltrindole-treated rats.19 
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 In another study, morphine was shown to maintain its analgesic properties in 
DOR-1 knockout mice, and in contrast to wild-type mice, these animals did not 
demonstrate tolerance following the daily sc administration of morphine.20 In an 
alternative approach, intracerebroventricular (icv) administration of a DOR-1 antisense or 
a mismatch control oligodeoxynucleotide showed no effect on baseline morphine 
analgesia compared to untreated or saline (control) mice. The development of tolerance 
to morphine was blocked in the antisense-receiving mice but not mismatch 
oligodeoxynucleotide or saline-treated mice. The same result was also shown for the 
development of dependence.21 These results lend further support to the involvement of 
DOR in the modulation of dependence and tolerance of MOR-selective ligands.  
 
 
1.3 The Development of MOR Agonist/DOR Antagonist Peptides 
The recognition that the simultaneous modulation of multiple targets may 
generate a more desirable drug profile has challenged the long prevailing, intuitive bias 
toward selectively targeted drugs as the optimal approach for the discovery and 
development of new therapeutics.22 As discussed, this concept is exemplified in the field 
of opioid analgesics by the observation that co-administration of a MOR agonist with a 
DOR antagonist retains MOR-mediated analgesia but displays reduced development of 
tolerance and dependence.12,19 For pharmacokinetic simplicity it is preferable to 
incorporate all desired activities into a single compound, and the development of bi-
functional opioid ligands has thus become a topic of increasing interest. The mounting 
evidence for the value of MOR agonist/DOR antagonist ligands has led to the 
development of a number of peptides featuring this bi-functional pharmacological profile.  
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Linear Peptides: A number of short, linear mixed efficacy MOR/DOR peptides 
have been developed.23 Among these are peptide sequences based on endomorphin 1 
(Tyr-Pro-Trp-Phe-NH2) and endomorphin 2 (Tyr-Pro-Phe-Phe-NH2), endogenous 
tetrapeptides with high selectivity for MOR (Figure 3).24 The endomorphins have been 
shown to produce an analgesic effect comparable to morphine, but without many of the 
negative side effects associated with the drug.25 Extensive modifications have therefore 
been performed on this sequence for the purpose of elucidating their pharmacological 
characteristics and improving biological activity.  
Figure 3. Chemical Structures of the Endomorphins 
 
 
 
 
 
 
 
Li and colleagues have demonstrated that alkylated phenylalanine (Phe) residues in the 
third position of endomorphin 2 can confer a mixed MOR agonist/DOR antagonist profile 
to the scaffold, which is interesting given that the endomorphins typically lack any type 
of interaction with the DOR. The MOR agonist/DOR antagonist peptides discussed 
feature the sequences Dmt-Pro-Dmp-Phe-NH2 and Dmt-Pro-Tmp-Phe-NH2, where Dmp 
is 2’,6’-dimethylphenylalanine, Tmp is 2’,4’,6’-trimethylphenylalanine, and Dmt is 2’,6’-
dimethyltyrosine.26 Other endomorphin-derived linear peptides have since been 
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developed, namely Dmt-Pro-Tmp-Tmp-NH2 and Dmt-Pro-1-Nal-NH2 (where 1-Nal is 1-
naphthylalanine), which display potent mixed MOR agonism/DOR antagonism and are 
also devoid of β-arrestin2 recruitment activity.27 Opioids that are selective for the G 
protein signaling pathway over the β-arrestin signaling pathway have also shown promise 
for the development of analgesics devoid of dependence and tolerance.28,29 
Schiller and colleagues have shown that the highly selective DOR antagonist 
peptide H-Tyr-TicΨ[CH2-NH]-Phe-Phe-OH (TIPP[Ψ], Figure 4) was more effective 
than naltrindole in the attenuation of morphine-induced dependence and tolerance in 
rats.30 Further modifications on the TIPP[Ψ] peptide sequence, namely the replacement of 
tyrosine with 2’,6’-dimethyltyrosine to confer agonist properties at MOR, and the 
replacement of the C-terminal acid with an amide, led to the peptide H-Dmt-TicΨ[CH2-
NH]-Phe-Phe-NH2 (DIPP-NH2[Ψ], Figure 4).  
Figure 4. Chemical Structures of TIPP[Ψ] and DIPP-NH2[Ψ] 
 
 
 
 
 
DIPP-NH2[Ψ] showed binding affinities in the subnanomolar range for both MOR and 
DOR, and represents the first example of a balanced MOR agonist/DOR antagonist 
peptide with high potency at MOR. After icv administration in rats, DIPP-NH2[Ψ] also 
demonstrated a potent analgesic effect in the warm water tail withdrawal (WWTW) 
assay. DIPP-NH2[Ψ] also displayed less acute tolerance than morphine and no physical 
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dependence after chronic administration at high doses. Despite these advances, DIPP-
NH2[Ψ] has not been shown to be active after peripheral administration.31 Efforts toward 
the development of a bioavailable MOR agonist/DOR antagonist ligand therefore remain 
ongoing.  
The Balboni group has also disclosed a number of linear peptide and 
peptidomimetic structures that build upon the DOR-antagonist pharmacophore dipeptide 
structure Dmt-Tic, where Tic is 1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid. In 
1999, Balboni and colleagues found that the addition of hydrophobic moieties to the C-
terminal end of Dmt-Tic peptides could give compounds that displayed MOR agonism in 
vitro, while preserving DOR antagonism. Namely, the peptide N,N-(Me)2Dmt-Tic-NH-1-
adamantane showed good binding affinities for both MOR and DOR (with some 
selectivity for DOR) and a MOR agonist/DOR antagonist selectivity profile.  The 
compound was not evaluated in an animal model.32 
In a later study, it was found that by adding a third aromatic center to Dmt-Tic 
peptides and by varying the length of the spacer between the Dmt-Tic pharmacophore 
and the new aromatic center, peptides with different mixed properties could be obtained. 
In short, it was observed that the peptide H-Dmt-Tic-Gly-NH-Ph had nearly equivalent 
potent MOR and DOR agonist properties, while H-Dmt-Tic-Gly-NH-CH2-Ph (the only 
difference being elongation by a methylene group) maintained MOR agonism, but 
became a DOR antagonist.33 Further substitution of H-Dmt-Tic-Gly-NH-CH2-Ph with an 
Aba-Gly scaffold (an expanded ring mimetic used to circumvent dioxopiperazine 
formation in small peptides) in place of Tic-Gly afforded the peptide H-Dmt-Aba-Gly-
NH-CH2-Ph, which loses some DOR binding affinity but maintains good MOR affinity 
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and efficacy.34 Conversely, it was found that the replacement of Gly in this sequence with 
aspartic acid could confer DOR selectivity by lowering MOR affinity.35 Balboni and 
colleagues have examined a number of other substituted aromatic moieties after the 
spacer unit of these Dmt-Tic peptides. The lead MOR agonist/DOR antagonist 
peptidomimetic H-Dmt-Tic-Gly-NH-CH2-Ph was modified by the addition of aromatic 
rings with different electronic characteristics, with certain new analogues (para-chloro) 
maintaining the MOR agonist/DOR antagonist profile of the parent compound.36  
Cyclic Peptides: [Leu5]-enkephalin (Tyr-Gly-Gly-Phe-Leu-OH) and [Met5]-
enkephalin (Tyr-Gly-Gly-Phe-Met-OH) (Figure 5) are endogenous pentapeptides 
selective for DOR.37 Chemical modifications on these structures have been extensively 
studied, one such ligand being the cyclic, bis-penicillamine pentapeptide DPDPE [D-
Pen2, D-Pen5]enkephalin (Figure 5), which is a remarkably potent and selective DOR 
agonist (penicillamine is β,β-dimethyl-D-cysteine).38 Removal of a glycine residue from 
DPDPE to contract the pentapeptide into a cyclic tetrapeptide resulted in a compound 
with improved DOR binding affinity and comparable selectivity to DPDPE.  
Figure 5. Chemical Structures of DPDPE and the Enkephalins  
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This cyclic tetrapeptide Tyr-c(SS)[DCys-Phe-DPen]OH (JOM-13, Figure 6) where DPen 
is D-penicillamine and c(SS) denotes cyclization through the side-chain sulfurs of DCys 
and DPen via a disulfide bridge, served as the starting point for a number of 
modifications aimed at conferring a MOR agonist/DOR antagonist profile. 
More recently, our group has described the development of MOR agonist/DOR 
antagonist opioid cyclic pentapeptides that are cyclized either through a disulfide or 
dithioether bridge. These pentapeptides display decreased DOR efficacy compared with 
DPDPE and JOM-13 due to steric interactions with the DOR active pocket resulting from 
the replacement of Phe3 and Phe4 residues with bulkier 1-naphthylalanine (1-Nal) or 2-
naphthylalanine (2-Nal) residues.39,40 Through similar types of modifications to JOM-13 
and the MOR selective tetrapeptide Tyr-c(SCH2CH2S)[DCys-Phe-DPen]NH2 (JOM-6, 
Figure 6),41 follow up studies have described a number of cyclic tetrapeptides, in 
particular Dmt-c(SCH2CH2S)[DCys-Aci-DPen]OH (KSK-103, Figure 6), which binds 
with equal affinity to MOR and DOR but acts as a MOR agonist with improved potency 
as compared to morphine.  
Figure 6. Chemical Structures of JOM-6, JOM-13 and KSK103 
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KSK-103 also behaved as a DOR antagonist in cellular assays measuring both G protein 
stimulation and adenylyl cyclase inhibition.42 KSK-103 features a C-terminal acid in 
place of the C-terminal amide of JOM-6, as well as substituting for Phe3 the bulky and 
conformational-constrained 2-aminoindane-2-carboxylic acid (Aci) residue. Like DIPP-
NH2[Ψ], a serious flaw with KSK103 and other MOR agonist/DOR antagonist peptides is 
poor bioavailability.  
Glycosylated Bifunctional MOR/DOR Peptides: It is known that the 
incorporation of a glycosylated amino acid residue into opioid peptides can result in 
compounds that improve CNS bioavailability.43 Although the initial hypothesis was that 
such analogues were crossing the BBB by acting as a substrate for the Glut-1 transporter, 
this was determined to be incorrect, and the mechanism by which these glycoside opioid 
ligands reach the brain still requires further study.44 It was also found that the optimal 
placement of the glycoside was near the C-terminal end of the peptide.44 Polt and 
colleagues have described a MOR agonist/DOR agonist glycopeptide featuring the 
sequence Tyr-D-Thr-Gly-Phe-Leu-Ser-(O-β-D-lactose)-CONH2 (MMP-2200, Figure 7). 
MMP-2200 showed dose-dependent antinociception in the WWTW assay after several 
different routes of administration (highlighting its ability to cross the BBB), and showed 
less chronic tolerance and dependence compared to morphine.45  
 
 
 
 
 
	   11	  
Figure 7. Chemical Structure of MMP-2200 
 
 
 
 
 
 
The C-terminal glycosylation strategy was also implemented for KSK103. It was 
found that the addition of a C-terminal serine carboxylic acid residue to KSK103 resulted 
in a compound with an analogous in vitro profile (balanced binding affinities for MOR 
and DOR with selectivity over KOR, and partial agonist activity at MOR without 
stimulation of DOR or KOR). The addition of a C-terminal serine carboxamide was also 
comparable. Glycosylation of this C-terminal carboxamide compound with β-D-glucose 
led to an analogue with a very similar in vitro profile to KSK103. This glycosylated 
KSK103 analogue, VRP26, was found to produce dose-dependent analgesia in the 
WWTW assay after ip administration (80% maximal effect at 10 mg/kg). At 32 mg/kg, 
the compound was found to display a maximal antinociceptive effect between 30 and 60 
minutes after administration, with a total duration of action of around 150 minutes 
(approximately half of morphine). Additionally, the compound displayed no acute 
tolerance at 10 mg/kg, in contrast to the acute tolerance observed for fentanyl.46 
Furthermore, after continuous infusion for a 7-day period, VRP26 shows no chronic 
tolerance or dependence (J. Anand, personal communication). While these results are 
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very promising, the compound’s short duration of action and complicated synthesis 
remain barriers for clinical development.  
 
1.4 The Development of MOR Agonist/DOR Antagonist Small Molecules 
 Despite the ease of synthesis and excellent target selectivity that can often be 
achieved by peptide ligands, peptides often make for poor drugs, especially in the realm 
of CNS research. Peptides often have very high molecular weight and polarity, making 
the crossing of the BBB problematic.47 Additionally, peptides are typically subject to 
extensive hydrolysis by peptidases. These common drawbacks for peptide ligands are 
exemplified in the opioid field, as peptidic opioid drugs such as the endomorphins48 and 
DIPP-NH2[Ψ]31 must be administered through an icv route in order to achieve the desired 
analgesic effect. While approaches such as glycosylation and increased hydrophobicity 
through ring closing metathesis cyclization techniques49 can often overcome the CNS 
bioavailability problems of peptides, the design of small molecule (or peptidomimetic) 
opioid ligands that maintain the key binding moieties of the endogenous and synthetic 
opioid peptides represents an important alternative strategy.   
 Many small molecule opioid MOR agonist/DOR antagonists have been derived 
from the naturally occurring alkaloids found in opium, namely morphine, codeine and 
thebaine. SoRI 9409 (Figure 8), a small molecule derived from naltrexone, displayed 
partial agonist activity in the WWTW assay (icv administration), and full agonist activity 
in the acetic assay writhing assay after ip administration. The compound was not active in 
the WWTW assay after ip administration.  
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Figure 8. Chemical Structure of SoRI 9409 
 
 
 
 
 
Additionally, the compound produced very little tolerance after repeated ip 
administrations in the acetic acid writhing test.50 Although SoRI 9409 displayed potent 
antagonist activity at DOR and agonist activity at MOR in the mouse vas deferens and 
guinea pig ileum assays respectively, the compound did not display MOR agonist activity 
in functional assays with MOR-expressing cells. The incorporation of alkoxy and 
arylalkoxy moieties at the 14 position of the morphinan-6-one scaffold, while 
maintaining the N-methylcyclopropyl group common in opioid antagonists, led to a new 
analogue which was not only shown to act as a MOR agonist/DOR antagonist in 
functional assays, it also displayed diminished chronic tolerance as compared to 
morphine. Unfortunately, the compound was only given through an icv route.51 
 A number of bioavailable MOR agonist/DOR antagonist compounds have been 
developed. The MOR/DOR bivalent ligands developed by Portoghese and colleagues 
have been demonstrated to be effective analgesics (MDAN-21 is 50-fold more potent 
than morphine after intravenous administration, Figure 9) with a dependence and 
tolerance profile that is modulated by the length of the spacer between the MOR agonist 
and DOR antagonist pharmacophores. This finding further supports the notion that 
physical interaction between MOR and DOR modulates MOR-mediated tolerance and 
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dependence.52 Portoghese has also used this bivalent ligand approach to target a number 
of other purported MOR-containing heteromers for the treatment of pain, namely a 
MOR-CB1 heteromer53 and a MOR-mGluR5 heteromer.54 
Recently the MOR/DOR heteromer-biased agonist CYM51010 (Figure 9) was 
also shown to display reduced antinociceptive tolerance as compared to morphine after sc 
administration.55 Additionally, UMB425 (Figure 9), a small-molecule MOR 
agonist/DOR antagonist derived from thebaine, was reported to display analgesia after sc 
administration with reduced tolerance compared with morphine.56  
Figure 9. Chemical Structures of MDAN-21, CYM51010 and UMB425 
 
 
 
 
 
 
 
Several other small molecule classes of MOR agonist/DOR antagonist peptidomimetics 
have also been developed, including a series of compounds where 2’,6’-dimethyltyrosine 
is linked to a pyrazinone ring platform.57 Additionally, the Mosberg group has used the 
pharmacophore of the previously reported MOR agonist/DOR antagonist peptide series to 
design a series of opioid peptidomimetics that retain the key binding features of the 
peptides, but feature a smaller and more drug-like tetrahydroquinoline (THQ) core (see 
Chapter 2).58,59  
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Although the compounds shown in Figure 9 are promising as MOR agonist/DOR 
antagonist leads for the purpose of developing safer opioids, the THQ compounds offer 
several advantages. The THQ scaffold is highly amenable to substitutions, and is thus a 
synthetically versatile and novel scaffold for SAR studies as compared to the morphinan 
scaffold of MDAN-21 or UMB425. Additionally, MDAN-21 and CYM51010 both target 
a purported MOR/DOR heteromer, a relatively unexplored biological target that requires 
further validation before such compounds can be useful clinically. In the case of 
UMB425, the compound is a drug-like small molecule that binds to MOR and DOR 
separately, but is very selective for MOR over DOR in competitive binding assays. The 
THQ compounds discussed in Chapter 2 are much more potent than UMB425 in these 
assays, particularly at DOR. In the WWTW assay, UMB425 requires a dose of 20 mg/kg 
to sustain a maximal effect (10 s cutoff time),56 roughly double the dosage required for 
the THQ lead compounds in vivo (20 s cutoff time).60,61  
 
 
1.5 MOR Agonist/DOR Antagonists for the Treatment of IBS-d 
 In addition to MOR agonist/DOR antagonist small molecules that cross the BBB, 
non CNS-penetrating ligands of this type are also of interest. Opioids have long been 
known to block gastrointestinal motility, and compounds such as loperamide62 have 
found widespread use for their ability to treat related disorders such as irritable bowel 
syndrome (IBS). Recently, Johnson & Johnson has developed a series of opioid ligands 
featuring an imidazole scaffold. These compounds were based on a cholecystokinin 
(CCK)-related dipeptide scaffold. The CCK dipeptide 1c (Figure 10) was known to be 
unstable though spontaneous cyclization to a diketopiperazine, and the imidazole moiety 
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was installed as a bioisostere for the unstable amide peptide bond. One of the imidazoles 
developed, (4a, Figure 10), was found to be devoid of antinociceptive activity when 
administered sc in a mouse model (but showed activity icv), despite binding to MOR (55 
nM) and DOR, with good selectivity for DOR (0.9 nM). In vitro, 4a also displayed potent 
agonism at DOR. It was also found that 4a reduced gastrointestinal motility in mice, 
which could be quantified in a dose dependent manner, as well as reversed by the opioid 
antagonist naloxone, showing that the effect was mediated through interaction with the 
opioid receptors.63 
For the purpose of synthetic accessibility, the authors continued their SAR study 
by breaking a bond in the tetrahydroisoquinoline (Tic) core of 4a and synthesizing a 
number of acyclic analogues. Additionally, the N-terminal tyrosine moiety of 4a was 
replaced with Dmt, for the purpose of improving potency at the opioid receptors. A 
number of other synthetic substitutions, such as the insertion of 4’-(aminocarbonyl)-2’,6’-
dimethyl-Phe (Cpa) as a bioisostere for Dmt64 led to the discovery of compound 5l, 
which displayed a potent MOR agonist/DOR antagonist profile in vitro.65 This 
compound, known as MuDelta and Eluxadoline (Figure 10), has found success in a 
Phase II Proof of Concept clinical trial in 800 patients suffering from diarrhea-
predominant irritable bowel syndrome (IBS-d). Recently, the compound was approved by 
the FDA for treatment of IBS-d.66,67 Although some of the THQ compounds developed 
by the Mosberg group show potent antinociception after peripheral administration, many 
of the analogues discussed in subsequent chapters are conversely inactive after being 
administered ip. Like Eluxadoline, such analogues may also found use for the treatment 
of IBS-d and similar disorders.  
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Figure 10. Chemical Structures of 1c, 4a and Eluxadolinea 
 
 
 
 
 
 
 
 
 
 
 
a. Compounds 1c and 4a from reference 63 
 
 All of the peptides and small molecules discussed here lend support to the idea 
that compounds featuring a mixed MOR/DOR efficacy profile are beneficial for the 
development of safer opioid analgesics, as well as compounds that are clinically useful 
for the treatment of IBS-d. In Chapter 2, the development of this MOR agonist/DOR 
antagonist profile in peptidomimetic compounds featuring a tetrahydroquinoline (THQ) 
core will be discussed.  
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CHAPTER 2 
SYNTHESIS OF THQ PEPTIDOMIMETICS MODIFIED AT THE 6 POSITIONa 
 
2.1 Introduction 
Peptidomimetic 1, which was initially synthesized as a mixture of diastereomers 
at the 4 position, was designed to incorporate the key opioid pharmacophore elements of 
the parent tetrapeptide Tyr-c(SS)[D-Cys-Phe-D-Pen]OH (JOM-13) and related cyclic 
tetrapeptides, namely a tyramine moiety and a second aromatic group, attached to a 
tetrahydroquinoline (THQ) scaffold. This design strategy proved to be successful, as the 
higher affinity 4R diastereomer of 1 (Figure 11) displayed high binding affinity to MOR, 
DOR, and KOR.59,68  
Figure 11. Chemical Structure of Lead THQ Peptidomimetic 1 (1E) 
 
 
 
The observation that Aic and other bulky aromatic replacements for Phe in cyclic 
peptides confer a MOR agonist/DOR antagonist profile suggested that 1 might be a 
promising starting point for the development of related peptidomimetics with similar 
profiles but with improved bioavailability compared to the peptides. The binding pocket 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
aSee references 59 and 60. In vitro assays were performed by Nicholas Griggs. In vivo work was done by Jessica Anand and Emily 
Jutkiewicz. Computational modeling was done by Irina Pogozheva. Compound 12 was synthesized by Michael Agius. Compounds 83, 
84, 103 and 104 were synthesized by Dylan Kahl. 
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in the region of the Phe3 side chain of the 6-benzyl substituent of the THQ scaffold of 1 
includes Asn125, Thr218, and Lys303 in MOR and the corresponding, bulkier Lys108, Met199, 
and Trp254 in DOR. The inactive state of both receptors can accommodate benzyl and 
even bulkier substituents; however, these bulkier substituents clash with the larger 
residues of DOR in the more compact binding pocket found in the active state of the 
receptor, reducing efficacy at this receptor (Figure 12). 1 was also found to be fully 
efficacious in the mouse WWTW assay after ip administration, with a total duration of 
action shorter than morphine.59 
Figure 12. (A) Comparison of 1 Docked in the MOR Active/DOR Active Sites (B) 
Comparison of DOR Active/DOR Inactive Sites  
A. 
B.  
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The initial SAR study done on compound 1 was focused on several additional 
hydrophobic, aromatic substitutions at the 6 position, including 1-methylnaphthyl, 2-
methylnaphthyl, 2-methylindanyl, and ethylphenyl. As expected, modifications featuring 
a more extended pendant (2-methylnaphthyl, 2-methylindanyl, ethylphenyl) were 
compatible with the larger DOR inactive binding pocket but not the smaller DOR active 
pocket, explaining the observed low efficacy at DOR. While these compounds displayed 
the desired MOR agonist/DOR antagonist efficacy profile, their binding profile was not 
optimal. The MOR affinity for all four compounds was at least an order of magnitude 
higher than the DOR affinity, and the 2-methylnaphthyl compound showed an over 2 
orders of magnitude preference for MOR. Ligands with more balanced binding affinities 
at MOR and DOR would provide a better starting point for further development of this 
type of mixed-efficacy opioid ligand.31,69 Additionally, although it was shown that an 
extended hydrophobic pendant translates to low DOR efficacy, changes in the electronic 
characteristics and polarity of the pendant were left unexplored. 
 
RESULTS AND DISCUSSION  
2.2 Modifications to the 6-Position of the Tetrahydroquinoline Scaffold 
 The original modifications to the 6-position of the THQ scaffold consisted of 2-
methylnaphthyl, 1-methylnaphthyl, 2-methylindanyl and ethylphenyl.59 To begin the 
expanded SAR at the 6-position, linear pentyl and hexyl chains were first examined. The 
length of these alkyl chains was chosen as to be approximately the same as the previous 
aromatic substitutions, and so would reach into the binding pocket at a similar distance. 
As shown in Scheme 1, the synthesis of these analogues began with commercially 
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available para-substituted anilines, which were acylated with 3-bromopropionyl chloride, 
and then cyclized with NaOtBu to form the β-lactam. The β-lactam was cyclized under 
Friedel-Crafts conditions to give the THQ core.70,71 After oxime formation, and 
subsequent hydrogenation to give the racemic primary amines, the scaffold could be 
coupled to Boc-protected 2’,6’-dimethyl-L-tyrosine (di-Boc-protection on NH2 and OH) 
under standard conditions, and deprotected with trifluoroacetic acid (TFA) in DCM. 
Diastereomers could then by separated on RP-HPLC and lyophilized to give powders 
suitable for in vitro testing.  
Scheme 1. Synthesis of Analogues 12 and 13 
 
 
 
 
 
 
 
 
 
 
 
As shown in Table 1, the early eluting diastereomer on RP-HPLC of 12 and 13 
(12E and 13E) have binding affinities at MOR and DOR that are comparable to 1, 
although analogues 12E and 13E have improved binding affinity at KOR. The late 
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eluting diastereomer of 13 (13L) was found to have binding affinities of several orders of 
magnitude lower than 13E, and so efficacies were not determined for this compound, and 
the late eluting diastereomer of 12 was not isolated. Although the MOR potency of 13E is 
comparable to lead compound 1E, the maximal percent stimulation of 13E is less. 12E 
was also inferior to 1E for MOR potency and efficacy. Because linear alkyl chain 
substitutions did not improve upon our lead compound 1E, substitutions of this type at 
the 6-position were not explored further. 
Table 1. Opioid Receptor Binding Affinities and Efficacies for Analogues 1E, 1L, 12E, 
13E, 13La 
 
 
  MOR DOR KOR 
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1E 
 
0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
1L 
 
2.6 ± 0.3 - - 56 ± 5 - - 220 ± 48 - - 
12E  0.22 ± 0.09 12 ± 6 20 ± 7 8.8 ± 3 dns dns 22 ± 10 540 ± 150 24 ± 1 
13E  0.13 ± 0.02 2.4 ± 0.08 36 ± 5 5.9 ± 0.8 dns dns 15 ± 6 770 ± 30 35 ± 1 
13L  300 ± 70 - - 1200 ± 400 - - 3900* - - 
a. Binding affinities (Ki) were obtained by competitive displacement of [3H]diprenorphine in membrane 
preparations expressing either MOR, DOR, or KOR. All values are mean ± standard error of the mean 
(SEM) of three separate assays performed in duplicate. Efficacy data were obtained using agonist-induced 
stimulation of [35S]GTPγS binding in membrane preparations expressing either MOR, DOR, or KOR. 
Potencies are represented as EC50 (nM) and efficacies as percent maximal stimulation relative to the 
standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 µM. All values are expressed 
as the mean ± SEM of three separate assays performed in duplicate. dns: does not stimulate. Dashed line 
indicates assay was not performed. * n = 1. 
 
 In order to determine the absolute stereochemistry at the 4 position of compound 
1, an asymmetric synthesis was completed (Scheme 2). Ketone 14 was first Boc protected 
on the THQ nitrogen to give ketone 15, which was reduced with the (S)-methyl-CBS 
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catalyst72 to give chiral, 4R alcohol 16 in 80% ee as determined by chiral HPLC, similar 
to previous reports for analogous scaffolds.72,73 The secondary chiral alcohol was then 
converted to an amine, with complete inversion of stereochemistry via a Mitsunobu 
reaction,74 yielding chiral, 4S amine 18 to which Boc protected 2’,6’-dimethyl-L-tyrosine 
was coupled. After deprotection of this unequivocal 4S diastereomer, HPLC revealed a 
9:1 ratio of late eluting to early eluting diastereomer of 1, confirming that the late eluting 
diastereomer is 4S and the (higher affinity) early eluting diastereomer is 4R (1 or 1E). 
Scheme 2. Asymmetric Synthesis of Compound 1 
 
 
 
 
 
 
 
 
 
 
 
 Additional analogues featuring modifications at the 6-position were also 
synthesized via an asymmetric synthesis to give the 4R diastereomers, but through a 
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methyl β-lactam. The β-lactam was cyclized under Friedel-Crafts conditions to give the 
THQ core.70,71 After TfOH-mediated cyclization, the THQ core was Boc-protected to 
give ketone 22, which was then brominated on the aryl methyl group as previously 
described.75 Benzyl bromide intermediate 23 can then be used as a useful later-stage 
intermediate for rapid diversification at the 6-position, either through Suzuki coupling or 
SN2 substitution. All substitutions on benzyl bromide intermediate 23 were 
straightforward, with some notable exceptions. In the case of 2-benzofuranyl intermediate 
31, it is necessary to perform the Suzuki coupling with 2-benzofuranyl boronic acid 
MIDA ester, as the unprotected boronic acid is known to be unstable.76 The synthesis of 
intermediate 45 was accomplished through first reducing 3-azaspiro[5.5]undecane-2,4-
dione to secondary amine 101 as previously described (Scheme 6)77 followed by SN2 
substitution of intermediate 23 to give 45.  
Additionally, the first steps in the synthesis of morpholinyl intermediate 28, 1,2,4-
triazolyl intermediate 29 and diphenylmethyl intermediate 35 were synthesized via an 
alternative route. 28 and 29 were synthesized starting from the appropriate commercially 
available para-substituted aniline (Scheme 4). 35 was synthesized as shown in Scheme 5, 
through a TfOH-catalyzed addition of benzene to 4-nitrobenzaldehyde,78 followed by 
reduction of nitro compound 99 to give aniline 100. This intermediate was then carried 
forward in a similar manner as shown in Scheme 4 to give 35.  
 Ketones 24-45 were converted to the corresponding imines with (R)-(+)-2-
methyl-2-propanesulfinamide and Ti(OEt)4 and could then be reduced asymmetrically 
with NaBH4 in situ to give tert-butanesulfinyl-protected amines 46-67 as single 
diastereomers as previously described for analogous scaffolds (Scheme 3).79,80 
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Deprotection with concentrated HCl gave the corresponding primary, enantiomerically 
pure (R)-amines as HCl salts. The stereochemistry of the HCl salts was verified by X-ray 
crystallography of 6-benzyl-1-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroquinolin-4-
aminium chloride, which was prepared by an identical synthetic route (Figure 13). Boc-
protected 2’,6’-dimethyl-L-tyrosine could then be coupled to the chiral HCl salt, and 
subsequent deprotection with TFA in DCM afforded final analogues 68-89, which were 
assayed for binding and efficacy at all three opioid receptor types (Table 2).60 The TFA 
content of analogue 103 (Chapter 2.3) was determined by 19F-NMR as previously 
described,81 and was found to be approximately 2.5 molecules of TFA per molecule of 
compound. 
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Scheme 3. Synthesis of Analogues 68-89 
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Scheme 4. Synthesis of Intermediates 28, 29, and 35 
 
 
 
 
 
 
 
 
 
Scheme 5. Synthesis of Intermediate 100 
 
 
 
 
 
 
 
Scheme 6. Synthesis of Intermediate 101 
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Figure 13. Crystal Structure of 6-benzyl-1-(tert-butoxycarbonyl)-1,2,3,4-
tetrahydroquinolin-4-aminium chloride 
 
 
 
 
 
 
 
 
 
Table 2. Opioid Receptor Binding Affinities and Efficacies for Analogues 68-89a 
 
  MOR DOR KOR 
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1 
 
0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
68  0.66 ± 0.08 93 ± 20 37 ± 7 17 ± 4 dns dns 66 ± 8 dns dns 
69 
 
0.3 ± 0.1 9 ± 1 73 ± 8 120 ± 29 dns dns 29 ±9 dns dns 
70  0.15 ± 0.02 25 ± 11 52 ± 2 61 ± 9 dns dns 3.6 ± 0.7 dns dns 
71  17 ± 7 dns dns 1560 ± 290 - - 12 ± 2** - - 
72  0.6 ± 0.1 60 ± 2 82 ± 2 140 ± 67 dns dns 170 ± 32 dns dns 
73  3.1 ± 0.6 dns dns 50 ± 14 dns dns 450 ± 14 dns dns 
74  0.8 ± 0.2 72 ± 24 18 ± 2 18 ± 6 dns dns 20 ± 3 >1000 >40 
75  0.11 ± 0.03 1.1 ± 0.5 98 ± 1 4.8 ± 2 dns dns 41 ± 20 dns dns 
76  0.12 ± 0.01 14 ± 3 36 ± 3 4.3 ± 0.8 dns dns 21 ± 2 dns dns 
77  0.35 ± 0.1 7.3 ± 2 88 ± 8 5.5 ± 0.8 dns dns 116 ± 70 dns dns 
78 
 
0.08 ± 0.01 2.7 ± 0.7 46 ± 5 4.6 ± 0.06** dns dns 4.9 ± 0.7 dns* dns* 
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   MOR   DOR   KOR  
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
79 
 
0.2 ± 0.02 13 ± 9 25 ± 0.3 2.3 ± 0.4 dns dns 6.9 ± 3 dns* dns* 
80  2.1 ± 0.6 23 ± 13 34 ± 6 23 ± 5 dns dns 120 ± 21 dns dns 
81  0.1 ± 0.02 2.2 ± 0.9 84 ± 6 1.5 ± 0.2 dns dns 16 ± 4 dns dns 
82  0.03 ± 0.01 0.4 ± 0.1 105 ± 6 3.1 ± 0.2 dns dns 2.2 ± 0.4 90 ± 65 25 ± 4 
83  0.17 ± 0.02 1.9 ± 1 111 ± 7 16.7 ± 2.5 dns dns 9.6 ± 0.4 dns dns 
84  0.17 ± 0.03 16.3 ± 8 49 ± 11 13.6 ± 1.3 dns* dns* 50 ± 20 dns* dns* 
85  0.17 ± 0.06 0.35 ± 0.1 111 ± 5 23.3 ± 2.5 dns dns 11.9 ± 6.1 dns dns 
86  0.15 ± 0.08 3 ± 1 96 ± 4 15 ± 5 dns dns 2 ± 1 15 ± 9 14 ± 2 
87  0.15 ± 0.01 2 ± 0.5 56 ± 2 4.8 ± 0.9 dns dns 37 ± 8 600 ± 400 14 ± 1 
88 
 
0.18 ± 0.03 1.9 ± 0.7 31 ± 8 9.5 ± 1.2 dns dns 7 ± 1 dns dns 
89  0.22 ± 0.1 dns dns 40 ± 20 dns dns 2.4 ± 1 92 ± 15 72 ± 4 
a. dns = does not stimulate. See Table 1 for further in vitro details. * = n of 1, ** = n of 2 
The phenyl pendant of the lead compound (1, Figure 11) was first replaced with a 
3-pyridine (68, Table 2). Not only was a slight loss in binding affinity at both MOR and 
DOR observed, but also a significant loss in MOR efficacy and potency (Table 2). 
Although 68 adopts a similar conformation in the MOR active site to the lead compound, 
this loss in MOR potency can be attributed to loss of hydrophobic contacts in this region 
of the receptor binding pocket (see Figure 14). Although this analogue did not improve 
upon the MOR agonist/DOR antagonist profile of the previous compounds, the drastic 
consequences that a simple change in pendant electronics had on both binding and 
efficacy was intriguing. Compared to 68 and the lead compound, replacement with 
piperidine in analogue 69 widened the binding affinity preference for MOR over DOR 
N
N
N
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N
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N
N
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even further, although this compound behaved as a moderately potent, full agonist at 
MOR, improving upon the MOR efficacy profile of 68. Expansion of the piperidine ring 
in 69 to azepane (70) resulted in improved binding at DOR and KOR. In contrast, 
morpholine analogue 72 displayed diminished binding affinities at DOR and KOR, and 
also decreased potency at MOR as compared to 69. N-piperazinyl analogue 71 displayed 
a marked loss in binding affinity and efficacy at MOR. Smaller aromatic systems, 
including a 1,2,4-triazole substitution (73) and a 3-furan (74) were also examined. While 
the overall binding profile of 74 was comparable to the previous substitutions, 73 
displayed a marked loss in binding affinity for MOR and KOR, and displayed no efficacy 
at MOR. Although 73 showed no efficacy at any of the three receptors, pan-opioid 
receptor antagonists are currently being developed,82 and may be of clinical value for the 
treatment of drug dependence.  
 In the initial series59 the 2-methylnaphthyl modification resulted in the highest 
MOR efficacy, but the MOR/DOR binding balance favored MOR by over 2 orders of 
magnitude. To see if changes in electronics to the naphthyl system could improve DOR 
binding while maintaining low DOR efficacy, 6-quinoline analogue 80 was synthesized. 
Interestingly, the binding affinity of 6-quinoline analogue 80 at all three receptors was 
considerably lower than the previous bicyclic analogues. This finding suggests that both 
an extended pendant and pendant electronic characteristics are important for maintaining 
binding for this series at DOR. Using previously published models of interactions of 
opioid ligands with the active states of the three receptors,40,42 80 was docked into the 
MOR active binding pocket. The quinoline nitrogen of 80 was found to extend much 
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deeper into the hydrophobic pocket of the MOR active pocket, disrupting important 
contacts with hydrophobic residues W133, V143, and I144 as shown in Figure 14. 
 
Figure 14. Docking of Analogue 80 in the MOR Active Sitea 
 
 
 
 
 
  
 
 
a. Key hydrophobic residues are highlighted in red (W133, I144, V143). 
These initial data suggested that superior MOR efficacy (and low DOR efficacy) 
might result from a fused ring pendant in which the six-membered, non-heteroatom 
containing aromatic moiety is located in the most distal position from the THQ core. To 
test this hypothesis, analogues 75-77, 81, 82, 86 and 87 were synthesized. 81 showed 
high efficacy at MOR, and improved DOR binding approximately tenfold as compared to 
the lead compound 1 and 80. 82 and 86 both behaved as potent, full MOR agonists that 
improved upon the efficacy of the original lead 1, with no efficacy at DOR. Several 
additional substitutions were made on the tetrahydroisoquinoline (THIQ) pendant of 
compound 82 (83-85), and small modifications (methyl and fluoro) at the 7 position were 
found to be well tolerated. On the other hand, MOR efficacy is reduced in the case of 3,4-
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(methylenedioxy)phenyl analogue 76. This is again consistent with the observation that 
distal electronegative substitutions can adversely affect MOR efficacy. Reduction of the 
aromatic ring of 82 to give decahydroisoquinoline analogue 87 maintained a comparable, 
if slightly inferior in vitro profile as compared to 82. Interestingly, the azaspiro analogue 
89 displayed good binding affinity for MOR and KOR, and features a MOR 
antagonist/KOR agonist profile that is unique to this series.60  
 
2.3 Acetylation of the THQ Nitrogen and In Vivo Data for Selected 
Analogues 
While 82 and 86 showed potent stimulation at MOR (while exhibiting no efficacy 
at DOR), binding affinities of each of these analogues at DOR left room for 
improvement. It was reasoned that the THQ aniline was synthetically accessible and 
amenable to substitutions, and would be the next logical site for diversification. 
Preliminary studies in related analogues suggested that N-acetylation at the THQ core 
improved DOR affinity without increasing DOR efficacy,61 so we likewise explored the 
effect of an acetyl substituent here, giving final analogues 102-106. These analogues 
were synthesized as shown in Scheme 7. Boc deprotection of the THQ nitrogen was 
performed prior to coupling to Boc-L-Dmt. After the amide coupling, the acetyl group 
was introduced by stirring the crude material in excess pyridine/acetic anhydride (1:1) 
overnight, followed by a second Boc deprotection and RP-HPLC purification. Binding 
and efficacy data for these analogues is shown in Table 3.  
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Scheme 7. Synthesis of Analogues 102-106 
 
This modification not only improved DOR binding relative to the un-acetylated 
counterpart compounds (82-84, 86, 87) but additionally, 102 showed similarly high 
affinity for MOR and DOR, and interestingly for KOR as well. 
 
Table 3. Opioid Receptor Binding Affinities and Efficacies for Analogues 102-106a 
 
  MOR DOR KOR 
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
102  0.19 ± 0.1 6 ± 2 91 ± 8 0.89 ± 0.2 dns dns 
0.78 ± 
0.1 
160 ± 36 46 ± 5 
103 
 
0.05 ± 0.01 0.54 ± 0.3 103 ± 1 0.77 ± 0.2 dns dns 16 ± 8 234 ± 70** 34 ± 8** 
104 
 
0.16 ± 0.01 1.3 ± 0.4 55 ± 3 3.1 ± 0.9 dns dns 59 ± 12 dns dns 
105  0.32 ± 0.09 0.9 ± 0.4 118 ± 5 2.6 ± 0.2 dns dns 7 ± 3 400 ± 130 32 ± 1 
106 
 
0.8 ± 0.2 40 ± 20 72 ± 3 2 ± 1 dns dns 15 ± 6 >2000 >20 
a. dns = does not stimulate. See Table 1 for further in vitro details, ** = n of 2. 
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62, R = N-1,2,3,4-THIQ(8-trifluoromethyl)
64, R = N-isoindolinyl
65, R = N-(4aR,8aS)-DHIQ
102, R = N-1,2,3,4-THIQ
103, R = N-1,2,3,4-THIQ(7-fluoro)
104, R = N-1,2,3,4-THIQ(8-trifluoromethyl)
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106, R = N-(4aR,8aS)-DHIQ
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 An overlay of 82 docked into the active site of all three receptors is shown in 
Figure 15. The compound fits nicely into the MOR active site, but clashes with M199 and 
L125 in the DOR active site. It is interesting to note that 82 and 102, both featuring the 
THIQ pendant at the 6-position, behave as partial KOR agonists (as does azaspiro 
analogue 89). As shown in Figure 15, 82 fits in the KOR active site, but clashes slightly 
with I294 (and thus displays lower efficacy as compared to MOR). Additionally, the 
THIQ nitrogen of 82 is positioned to make a polar contact with Y312, a residue unique to 
the KOR binding pocket at this position, which may account for the high affinity of 82 
and 102 for KOR. The MOR/KOR mixed efficacy profile has shown promise as a 
treatment for drug dependence, specifically cocaine addiction83,84 and additional SAR on 
MOR/KOR agonist peptides has recently been reported.85 Further substitutions on the 
THIQ pendant will have to be explored to fully optimize this profile, particularly for the 
purpose of improved potency at KOR. 
Figure 15. Overlay of Analogue 82 in the MOR, DOR and KOR Active Sitesa  
 
 
 
 
  
 
 
a. Grey, yellow and purple residues correspond to MOR, DOR and KOR respectively. 
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On the basis of their favorable in vitro profiles, compounds 82, 86, 102, and 105 
were initially chosen for in vivo studies. Effects of 82, 86, 102, and 105 were compared 
with the lead compound 1 by two-way ANOVA with Tukey’s multiple comparisons post 
hoc test. There was a significant interaction (F(12,76)=8.7, p< 0.0001) as well as 
significant main effects of dose (F(3,76)=82.7, p<0.0001) and compound (F(4,76)=24.6, 
p<0.0001). In the mouse warm water tail withdrawal (WWTW) assay (Figure 16), the 
benzyl pendant lead compound 1 and compounds 86 and 102 were fully efficacious and 
produced dose-dependent increases in latency to tail flick, with 3.2 (p < 0.05) and 10 
mg/kg (p < 0.001) significantly increasing latency times as compared with baseline. 102 
was not statistically different from the lead compound 1, but 86 produced slightly higher 
tail flick latencies at 3.2 (p < 0.001) and 10 (p < 0.05) mg/kg as compared with the lead 
compound. It is interesting to note that 82, which lacks only the N-acetyl group of 102, 
and 105, which is the N-acetylated counterpart to 86, did not significantly increase tail 
flick latency above baseline levels up to a dose of 10 mg/kg. Compounds 69, 75, 81, 103 
and 105 were also tested in the WWTW assay, and were found to be less efficacious than 
1, 86 and 102 (Figure 16). Compounds 77, 82, 83 and 87 exhibited no significant 
antinociceptive activity at 10 mg/kg in the mouse WWTW assay.  
To determine the duration of action of compounds 86 and 102, tail withdrawal 
latencies were measured at intervals following the administration of the 10 mg/kg dose 
(Figure 17). Compounds 86 and 102 showed a full antinociceptive response for 200 
minutes before returning to baseline. Compared with the lead compound 1 (Figure 11), 
these compounds both displayed a much longer duration of action after ip injection.  
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 From the 6-position SAR discussed in this chapter, as well as preliminary THQ 
N-acetylation of several analogues, a number of trends emerge. Firstly, placement of 
electron rich heteroatoms on the pendant is crucial for maintaining MOR potency. 
Furthermore, attachment of the pendant at a basic, tertiary nitrogen resulted in a number 
of analogues which showed superior binding affinity and potency at MOR, with 
improved binding affinity at KOR. In particular, N-acetylated, THIQ analogue 102 
showed equal, subnanomolar binding affinity for MOR, DOR and KOR, with a low 
nanomolar EC50 at MOR and no stimulation at DOR. 102, in addition to isoindoline 
analogue 86, were also shown to produce dose dependent antinociception in the WWTW 
assay, with both compounds having a total duration of action comparable to morphine, an 
improvement on lead peptidomimetic 1. These peptidomimetics are therefore promising 
leads for dependence and tolerance studies.  
 
Figure 16. Cumulative Antinociceptive Dose-Response Curves for Analogues 69, 75, 81, 
82, 86, 102, 103 and 105 in the Mouse WWTW Assay After ip Administration (n = 3-6)a  
 
 
 
 
 
 
 
a. Data are plotted as mean ± SEM. 
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Figure 17. Time Courses of Antinociceptive Response For Analogues 86 and 102 in the 
Mouse WWTW Assay After ip Administration of a 10 mg/kg Dose 
 
 
 
 
 
 
 
2.4 Experimental Procedures 
2.4.1 Chemistry 
All reagents and solvents were obtained from commercial sources and used 
without additional purification. Reactions were carried out in anhydrous solvents under 
an inert atmosphere unless otherwise specified. Suzuki couplings were performed on a 
Discover S-class (CEM) microwave in a closed vessel with maximum power input of 300 
W. Hydrogenations were performed on a Parr hydrogenator apparatus from Parr 
Instrument Company, model 3916EA, at the pressures specified. Flash column 
chromatography was carried out using P60 silica gel (230−400 mesh). Purification of 
final compounds was performed using a Waters semipreparative HPLC with a Vydac 
protein and peptide C18 reverse phase column, using a linear gradient of 10% solvent B 
(0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) to 60% solvent B in solvent 
A at a rate of 1% per minute. UV absorbance was monitored at 230 nm. Purity of 
synthesized compounds was determined on a Waters Alliance 2690 analytical HPLC 
instrument and a Vydac protein and peptide C18 reverse phase column, using a linear 
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gradient of 0% solvent B in solvent A to 45% solvent B in solvent A in 45 min, 
measuring UV absorbance at 230 nm. Purities of the final compounds used for testing 
were ≥95% as determined by HPLC and NMR. 1H-NMR and 13C-NMR data were 
obtained on either a 400 or 500 MHz Varian instrument. In chloroform-d, shifts are 
referenced to TMS. If TMS peak was not visible in 13C-NMR spectra, shifts were 
referenced to the solvent peak (δ 77.16). Samples in CD3OD are unreferenced. Mass spec 
analysis was performed using an Agilent 6130 LC−MS mass spectrometer in positive 
mode. 
 
(1E/1L) 2-Amino-N-((S)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6- 
dimethylphenyl)propanamide. Compound 18 (0.12 g, 0.358 mmol) was dissolved in 
DMF (5 mL) followed by the addition of the coupling reagents PyBOP (0.19 mg, 0.36 
mmol), HOBt-Cl (0.070 g, 0.36 mmol), and DIPEA (624 µL, 3.58 mmol). Boc-L-Dmt 
(0.15 g, 0.36 mmol) was dissolved in DMF (5 mL) and added to the reaction mixture via 
syringe, which was stirred for 18 h at r.t. After concentration under reduced pressure the 
product was re-suspended in EtOAc (30 mL) and washed with a solution of 5% citric 
acid in H2O (30 mL). The aqueous layer was then extracted with EtOAc (10 mL), and the 
combined organic extracts were washed with brine (1 × 10 mL), dried with MgSO4, 
filtered, and concentrated under reduced pressure. The crude residue was dissolved in a 
1:1 mixture of DCM and TFA (10 mL) and stirred for 3 h. The mixture was concentrated 
and purified by semipreparative RP-HPLC to yield the title compound in a 9:1 ratio of 
diastereomers. (1E): (MS)EI: 452.2 [M + Na], Retention Time: 25.50 min. 1H-NMR (400 
MHz, CD3OD) δ 8.17 (d, J = 7.9, 1H), 7.16 – 7.09 (m, 2H), 7.07 – 7.00 (m, 4H), 6.96 
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(dd, J = 8.3, 2.0, 1H), 6.77 (d, J = 8.3, 1H), 6.39 (s, 2H), 4.91 (t, J = 4.8, 1H), 3.83 – 3.75 
(m, 3H), 3.16 (dd, J = 13.6, 11.5, 1H), 3.11 – 3.03 (m, 1H), 2.95 (dd, J = 13.7, 5.2, 1H), 
2.66 – 2.54 (m, 1H), 2.17 (s, 6H), 1.84 – 1.72 (m, 1H), 1.53 – 1.43 (m, 1H). (1L): 
(MS)EI: 452.2 [M + Na], Retention Time: 28.85 min. 1H-NMR (400 MHz, CD3OD) δ 
7.19 – 7.11 (m, 2H), 7.10 – 7.01 (m, 3H), 6.82 (dd, J = 8.3, 1.9, 1H), 6.70 (d, J = 8.3, 
1H), 6.46 (s, 3H), 4.72 (t, J = 5.1, 1H), 3.87 – 3.67 (m, 3H), 3.28 – 3.12 (m, 3H), 2.90 
(dd, J = 13.8, 4.7, 1H), 2.20 (s, 6H), 2.06 – 1.97 (m, 2H).  
(2) 3-bromo-N-(4-pentylphenyl)propanamide 
To 4-pentylaniline (1.00 g, 6.13 mmol) and K2CO3 (1.69 g, 12.3 mmol) in DCM (15 mL) 
was added 3-bromopropionyl chloride (0.64 mL, 6.44 mmol) dropwise via syringe. The 
resulting cloudy mixture was stirred at r.t. overnight under an inert atmosophere, after 
which time the reaction was quenched with H2O (15 mL) and diluted with DCM (10 mL). 
The aqueous layer was extracted with DCM (3 x 15 mL), and combined organic extracts 
were dried with MgSO4. Solvents were filtered and removed under reduced pressure to 
give a light brown solid (1.74 g, 96%). 1H-NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.4, 
2H), 7.17 (br s, 1H), 7.13 (d, J = 8.3, 2H), 3.71 (t, J = 6.6, 2H), 2.92 (t, J = 6.6, 2H), 2.59 
– 2.52 (m, 2H), 1.63 – 1.56 (m, 2H), 1.33 – 1.25 (m, 4H), 0.87 (t, J = 6.9, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 167.65, 139.52, 134.89, 128.91, 120.04, 40.68, 35.31, 31.16, 27.16, 
22.51, 14.02. 
(3) 3-bromo-N-(4-hexylphenyl)propanamide 
Followed procedure for compound 2 with 4-hexylaniline (4.27 g, 24.1 mmol), K2CO3 
(6.66 g, 48.2 mmol) and 3-bromopropionyl chloride (2.55 mL, 25.3 mmol) in DCM (70 
mL), stirring for 2 h to give product as a white solid (7.16 g, 95%). 1H-NMR (400 MHz, 
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CDCl3) δ 7.40 (d, J  = 8.0, 2H), 7.29 (br s, 1H), 7.13 (d, J  = 8.0, 2H), 3.70 (t, J  = 6.5, 
2H), 2.92 (t, J  = 6.6, 2H), 2.56 (t, J  = 7.7, 2H), 1.58 (p, J  = 7.3, 2H), 1.36 – 1.23 (m, 
6H), 0.91 – 0.84 (m, 3H); 13C-NMR (101 MHz, CDCl3) δ 167.93, 139.69, 135.09, 
129.05, 120.30, 40.82, 35.52, 31.85, 31.59, 29.04, 27.32, 22.75, 14.23.  
 (4) 1-(4-pentylphenyl)azetidin-2-one 
To a solution of NaOtBu (0.59 g, 6.13 mmol) in dry DMF (15 mL) was added compound 
2 (1.74 g, 5.85 mmol) in DMF (20 mL) dropwise via syringe, under an inert atmosphere. 
The solution was stirred at r.t. overnight, after which time DMF was removed under 
reduced pressure. The crude residue was re-suspended in EtOAc (30 mL) and H2O (30 
mL). The aqueous layer was extracted with EtOAc (3 x 15 mL), and combined organic 
extracts were washed with brine, and dried with MgSO4. Solvents were filtered and 
removed, and crude residue was purified by column chromatography (4:1 hex/EtOAc) to 
give product as a white solid (1.21 g, 96%). 1H-NMR (400 MHz, CDCl3) δ 7.26 (d, J = 
8.4, 2H), 7.12 (d, J = 8.4, 2H), 3.57 (t, J = 5.9, 2.9, 2H), 3.06 (t, J = 4.4, 2H), 2.54 (t, 2H), 
1.61 – 1.52 (m, 2H), 1.35 – 1.24 (m, 4H), 0.87 (t, J = 6.9, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 164.22, 138.56, 136.285, 128.96, 116.04, 37.96, 35.99, 35.35, 31.38, 31.24, 
22.51, 14.03. 
(5) 1-(4-hexylphenyl)azetidin-2-one 
Followed procedure for compound 4 with compound 3 (7.16 g, 22.9 mmol), and NaOtBu 
(2.31 g, 24.1 mmol) in DMF (150 mL) to give product as a white solid (1.55 g, 29%). 1H-
NMR (400 MHz, CDCl3) δ 7.27 (d, J  = 9.0, 2H), 7.13 (d, J  = 8.2, 2H), 3.60 (t, J  = 4.5, 
2H), 3.09 (t, J  = 4.5, 2H), 2.56 (t, J  = 7.7, 2H), 1.56 (p, J = 7.5, 2H), 1.38 – 1.18 (m, 
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6H), 0.97 – 0.78 (m, 3H); 13C-NMR (400 MHz, CDCl3) δ 164.36, 138.74, 136.48, 
129.13, 116.23, 38.14, 36.18, 35.56, 31.86, 31.67, 29.03, 22.76, 14.23.  
 (6) 6-pentyl-2,3-dihydroquinolin-4(1H)-one 
To compound 4 (0.86 g, 3.96 mmol) in DCE (40 mL) was added TfOH (1.05 mL, 11.8 
mmol) carefully via syringe. The solution was allowed to stir at r.t. overnight, after which 
time the reaction was quenched with the addition of K2CO3 (4 g), and stirred for 40 min. 
MgSO4 was added to the reaction mixture, and solids were removed via filtration. 
Solvents were removed under reduced pressure, and crude residue was purified by 
column chromatography (4:1 hex/EtOAc) to give product as a yellow oil (0.70 g, 82%). 
1H-NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.09 (d, J = 8.4, 1H), 6.59 (d, J = 8.3, 1H), 
4.59 (br s, 1H), 3.52 – 3.45 (t, 2H), 2.62 (t, J = 7.2, 2.4, 2H), 2.48 – 2.39 (t, 2H), 1.56 – 
1.45 (m, 2H), 1.30 – 1.20 (m, 4H), 0.87 – 0.79 (m, 3H); 13C-NMR (101 MHz, CDCl3) δ 
194.18, 150.55, 135.86, 132.24, 126.32, 118.98, 116.00, 42.39, 38.22, 34.78, 31.34, 
31.12, 22.50, 14.03. 
(7) 6-hexyl-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 6 with compound 5 (1.54 g, 6.65 mmol) and TfOH 
(1.76 mL, 19.9 mmol) in DCE (75 mL), stirring at r.t. overnight to give product as a 
yellow solid (1.43 g, 93%). 1H-NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.14 (d, J  = 8.3, 
1H), 6.61 (d, J  = 8.4, 1H), 4.28 (brs, 1H), 3.55 (t, J  = 7.0, 2H), 2.68 (t, J  = 6.9, 2H), 2.49 
(t, J = 7.7, 2H), 1.66 – 1.47 (m, 2H), 1.37 – 1.19 (m, 6H), 0.86 (t, J  = 6.3, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 194.18, 150.53, 136.02, 132.85, 126.81, 119.56, 116.09, 42.80, 
38.53, 35.11, 31.96, 31.68, 29.12, 22.85, 14.34. 
(8) (E)-6-pentyl-2,3-dihydroquinolin-4(1H)-one oxime 
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To compound 6 (0.86 g, 3.96 mmol) in 1:1 EtOH/H2O (30 mL) was added NH2OHHCl 
(0.82 g, 11.9 mmol) and NaOAc3H2O (0.97 g, 11.9 mmol). The solution was stirred at 
reflux overnight, after which time EtOH was removed under reduced pressure. EtOAc 
was added, and the aqueous layer was extracted with EtOAc (2 x 15 mL). Combined 
organic layers were washed with brine and dried with MgSO4. Solvents were filtered and 
removed under reduced pressure. Crude residue was purified by column chromatography 
(2:1 hex/EtOAc) to give product as a light yellow solid (0.64 g, 70%). 1H-NMR (400 
MHz, CDCl3) δ 7.60 (s, 1H), 6.96 (dd, J = 8.2, 1.9, 1H), 6.55 (d, J = 8.2, 1H), 3.30 (t J = 
6.5, 2H), 2.91 (t, J = 6.8, 2.2, 2H), 2.52 – 2.44 (m, 2H), 1.61 -1.51 (t, 2H), 1.35 – 1.24 (m, 
4H), 0.87 (t, J = 6.9, 3H); 13C-NMR (101 MHz, CDCl3) δ 152.60, 145.00, 133.16, 
130.89, 123.66, 116.64, 115.77, 40.76, 35.12, 31.45, 31.31, 23.52, 22.53, 14.02. 
(9) (E)-6-hexyl-2,3-dihydroquinolin-4(1H)-one oxime 
Followed procedure for compound 8 with compound 7 (1.40 g, 6.06 mmol), 
NH2OHHCl (0.51 g, 7.27 mmol) and NaOAc3H2O (0.60 g, 7.27 mmol) in 1:1 
EtOH/H2O (90 mL), stirring at reflux for 40 h, to give product as a yellow solid (0.92 g, 
62%). 1H-NMR (400 MHz, CDCl3) δ 7.58 (d, J  = 2.0, 1H), 6.97 (dd, J  = 8.2, 2.0, 1H), 
6.55 (d, J  = 8.2, 1H), 3.30 (t, J  = 6.5, 2H), 2.93 (t, J  = 6.5, 2H), 2.48 (t, J  = 7.6, 2H), 
1.56 (p, J = 7.8, 2H), 1.37 – 1.22 (m, 6H), 0.90 – 0.80 (m, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 152.66, 145.28, 133.27, 131.07, 123.79, 116.75, 115.93, 40.93, 35.32, 31.90, 
31.75, 29.10, 23.81, 22.76, 14.26. 
 (10) 6-pentyl-1,2,3,4-tetrahydroquinolin-4-amine 
10% Pd/C (~0.2 g) was added to a hydrogenation vessel, followed by compound 8 (0.64 
g, 2.75 mmol) in MeOH (20 mL). Glacial AcOH (1 mL) was then added. The mixture 
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was allowed to shake under 40 psi H2 at r.t. overnight, after which time the reaction 
mixture was filtered through a pad of celite, washed with MeOH, and concentrated under 
reduced pressure. 2M NaOH (20 mL) and DCM (20 mL) were added to the crude 
residue, and the aqueous layer was washed with DCM (2 x 15 mL). Combined organic 
extracts were dried with MgSO4, and solvents were filtered and removed under reduced 
pressure. Crude residue was purified by column chromatography (9:1 DCM/MeOH) to 
give product as a yellow oil (0.42 g, 70%). 1H-NMR (400 MHz, CDCl3) δ 7.02 (d, J = 
1.6, 1H), 6.84 (dd, J = 8.1, 1.9, 1H), 6.43 (d, J = 8.1, 1H), 3.96 (t, J = 4.9, 1H), 3.38 – 
3.29 (m, 1H), 3.29 – 3.21 (m, 1H), 2.51 – 2.43 (t, 2H), 2.04 – 1.97 (m, 1H), 1.79 (ddd, J = 
13.9, 8.7, 5.4, 1H), 1.56 (dt, J = 15.2, 7.5, 2H), 1.35 – 1.27 (m, 4H), 0.88 (t, J = 6.9, 3H); 
13C-NMR (101 MHz, CDCl3) δ 141.94, 131.71, 128.57, 127.86, 125.46, 114.47, 46.89, 
37.79, 35.13, 31.86, 31.60, 22.58, 14.07. 
(11) 6-hexyl-1,2,3,4-tetrahydroquinolin-4-amine 
Followed procedure for compound 10 with compound 9 (0.59 g, 2.38 mmol), shaking at 
r.t. under 40 psi H2 overnight to give product as a white solid (0.32 g, 57%). 1H-NMR 
(400 MHz, CD3OD) δ 6.97 (d, J  = 1.6, 1H), 6.79 (dd, J  = 8.2, 1.9, 1H), 6.46 (d, J  = 8.1, 
1H), 3.91 (t, J  = 4.8, 1H), 3.32 – 3.11 (m, 2H), 2.46 (t, J  = 7.6, 2H), 2.00 – 1.91 (m, 1H), 
1.85 – 1.73 (m, 1H), 1.56 – 1.51 (m, 2H), 1.30 (s, 6H), 0.87 (t, J  = 7.4, 3H); 13C-NMR 
(101 MHz, CD3OD) δ 142.48, 131.11, 128.30, 127.91, 123.27, 114.80, 46.50, 37.04, 
34.97, 31.77, 31.67, 30.13, 28.83, 22.45, 13.38. 
 (12E) (2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-(6-pentyl-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide 
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To compound 10 (0.094 g, 0. 43 mmol), PyBOP (0.22 g, 0.43 mmol), HOBt-Cl (0.073 g, 
0.43 mmol) and Boc-L-Dmt (0.18 g, 0.43 mmol) was added DMF (10 mL) and DIPEA 
(0.75 mL, 4.31 mmol) via syringe. The mixture was allowed to stir overnight under an 
inert atmosphere, after which time DMF was removed under reduced pressure. The crude 
residue was re-suspended in EtOAc and 5% citric acid. The organic layer was washed 
with 5% citric acid (2 x 20 mL) and brine (1 x 15 mL). The organic layer was dried with 
MgSO4, and solvents were filtered and removed under reduced pressure. A solution of 
1:1 DCM/TFA was added (10 mL) and was allowed to stir for 1 h. DCM/TFA were 
removed under reduced pressure, and crude residue was purified by RP-HPLC and 
lyophilized to give a white powder. (MS)EI: 410.3 [M+H], Retention Time: 27.80 min. 
1H-NMR (400 MHz, CD3OD) δ 7.03 (m, J = 24.6, 9.0, 2H), 6.86 (d, J = 8.0, 1H), 6.47 (s, 
2H), 5.02 (d, J = 4.2, 1H), 3.88 (dd, J = 11.5, 5.1, 1H), 3.23 (d, J = 11.9, 1H), 3.20 – 3.12 
(m, 1H), 3.04 (dd, J = 13.6, 5.0, 1H), 2.69 (dd, J = 22.9, 12.0, 1H), 2.50 (t, J = 7.7, 2H), 
2.26 (s, 6H), 1.94 – 1.80 (m, 1H), 1.58 – 1.48 (m, 3H), 1.29 (m, J = 12.5, 6.4, 4H), 0.87 
(t, J = 6.9, 3H).  
(13E/13L) (2S)-2-amino-N-(6-hexyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide 
To compound 11 (0.086 g, 0.37 mmol) in DMF (5 mL) was added PyBOP (0.19 g, 0.37 
mmol) and HOBt-Cl (0.063 g, 0.37 mmol), and placed under an inert atmosphere. DIPEA 
(0.65 mL, 3.71 mmol) was then added via syringe, followed by Boc-L-Dmt (0.17 g, 0.41 
mmol) in DMF (3 mL). The solution was allowed to stir at r.t. for 24 h, after which time 
DMF was removed under reduced pressure. Crude residue was re-dissolved in EtOAc. 
5% citric acid was added, and extracted with EtOAc. Combined organic extracts were 
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washed with brine and dried with MgSO4. Solvents were filtered and removed under 
reduced pressure. A solution of 1:1 DCM/TFA was added (10 mL) and was allowed to 
stir for 1 h. DCM/TFA were removed under reduced pressure, and crude residue was 
purified by RP-HPLC to give the early and late diastereomers, and lyophilized to give a 
white powder. (13E): (MS)EI: 446.3 (M+Na), Retention Time: 32.30 min. 1H-NMR (400 
MHz, CD3OD) δ 6.97 (d, J = 8.2, 2H), 6.70 (d, J = 7.9, 1H), 6.47 (s, 2H), 4.97 (t, J = 4.6, 
1H), 3.85 (dd, J = 11.6, 5.1, 1H), 3.26 – 3.18 (m, 1H), 3.12 – 3.05 (m, 1H), 3.01 (dd, J = 
13.7, 5.1, 1H), 2.60 (t, J = 10.5, 1H), 2.46 (t, J = 7.6, 1H), 2.26 (s, 6H), 1.87 – 1.75 (m, 
1H), 1.57 – 1.44 (m, 2H), 1.27 (s, 6H), 0.87 (t, J = 6.7, 3H); 13C-NMR (400 MHz, 
CD3OD) δ 167.50, 155.97, 138.59, 129.68, 128.75, 121.84, 117.75, 114.96, 51.93, 44.30, 
37.57, 34.78, 31.47, 31.45, 30.44, 28.67, 27.26, 22.26, 19.02, 12.97. (13L): (MS)EI: 
446.3 (M+Na),  Retention Time: 35.03 min.  
(14) 6-benzyl-2,3-dihydroquinolin-4(1H)-one 
Compound 176 (3.90 g, 16.4 mmol) was dissolved in DCE (100 mL), and placed under 
an inert atmosphere. TfOH (4.36 mL, 49.3 mmol) was added via syringe. The resulting 
dark orange solution was stirred at r.t. for 18 h, after which time it was quenched with the 
addition of K2CO3 (15 g) and H2O (0.8 mL), and was allowed to stir for 1 h. The reaction 
mixture was filtered through a plug of MgSO4, and solvents were removed under reduced 
pressure to give product as a yellow oil (3.26 g, 84%). 1H-NMR (400 MHz, CDCl3) δ 
7.72 (d, J  = 1.5, 1H), 7.29 – 7.23 (m, 2H), 7.20 – 7.14 (m, 3H), 7.11 (dd, J  = 8.4, 2.2, 
1H), 6.59 (d, J  = 8.4, 1H), 4.31 (br s, 1H), 3.86 (s, 2H), 3.54 (t, J = 7.0, 2H), 2.68 (t, J = 
6.8, 2H); 13C-NMR (101 MHz, CDCl3) δ 193.72, 150.54, 141.19, 136.03, 130.74, 128.70, 
128.44, 127.24, 126.02, 119.23, 116.18, 42.39, 40.93, 38.15.  
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(15) tert-butyl 6-benzyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
To compound 14 (2.57 g, 10.8 mmol) in DCM (70 mL), was added (Boc)2O (3.06 g, 14.1 
mmol), DMAP (0.13 g, 1.08 mmol), and DIPEA (2.45 mL, 14.1 mmol). The mixture was 
stirred at reflux for 35 h, after which time it was quenched with 1M HCl (50 mL). The 
aqueous layer was extracted with DCM, and combined organic extracts were dried with 
MgSO4, filtered, and concentrated under reduced pressure. The crude residue was 
chromatographed on silica gel (1:2 EtOAc/hex) to yield product as a white solid (2.79 g, 
77%). 1H-NMR (400 MHz, CDCl3) δ 7.83 (d, J = 1.6, 1H), 7.69 (d, J = 1.6, 1H), 7.29 (dd, 
J = 8.6, 1.9, 1H), 7.26−7.19 (m, 2H), 7.18− 7.10 (m, 3H), 4.08 (t, J = 6.2, 2H), 3.90 (s, 
2H), 2.68 (t, J = 6.3, 2H), 1.53 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 194.23, 152.74, 
142.37, 140.39, 136.85, 134.61, 128.80, 128.54, 127.14, 126.26, 124.78, 123.81, 82.07, 
44.26, 41.14, 38.97, 28.27. 
(16) tert-butyl (R)-6-benzyl-4-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate 
Compound 15 (2.69 g, 7.97 mmol) in THF (30 mL) was stirred at r.t. with 4 Å molecular 
sieves (1.0 g) for 1 h. This solution was transferred to the (S)-(−)-2-methyl-CBS-
oxazaborolidine catalyst via cannula, and the reaction vessel was cooled to −20 °C. 
BH3·Me2S (3.99 mL, 7.97 mmol) was then added via syringe over a period of 10 min. 
The mixture was stirred at −20 °C for 6 h. After the addition of MeOH (7 mL) the 
mixture was allowed to reach r.t. The mixture was partitioned between 1 M HCl (10 mL) 
and Et2O (30 mL). The aqueous layer was extracted with Et2O (3 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried with MgSO4, filtered, 
and concentrated, and the residue was chromatographed on silica gel (1:2 EtOAc/hex) to 
yield the title compound as a colorless oil (2.19 g, 81%, 80% ee). 1H-NMR (400 MHz, 
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CDCl3) δ 7.72 (d, J = 8.5, 1H), 7.30−7.14 (m, 6H), 7.08 (dd, J = 8.16, 1.6, 1H), 4.53 (t, J 
= 4.8, 1H), 3.92 (s, 2H), 3.53 (ddd, J = 13.1, 9.5, 3.8, 1H), 3.40 (s, 1H), 1.98−1.90 (m, 
1H), 1.89−1.79 (m, 1H), 1.56 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 153.73, 141.15, 
136.11, 135.71, 131.04, 128.92, 128.49, 128.25, 126.10, 123.57, 81.08, 65.47, 41.33, 
40.74, 32.13, 28.43. Enantioselectivity determined by HPLC (Chiracel OD-RH column, 
45% acetonitrile/water, 230 nm, 25 °C): tmajor = 21.3 min, tminor = 25.2 min. 
(17) (S)-tert-Butyl 6-Benzyl-4-(1,3-dioxoisoindolin-2-yl)-3,4-dihy- droquinoline-
1(2H)-carboxylate. Compound 16 (2.12 g, 6.27 mmol) was dissolved in THF (25 mL) 
and added via syringe to a mixture of phthalimide (1.38 g, 9.40 mmol) and PPh3 (2.47 g, 
9.40 mmol). The reaction mixture was allowed to stir for 10 min and then cooled to 0 °C. 
Once cooled, a solution of DIAD (2.48 mL, 12.5 mmol) in THF (10 mL) was added to 
the reaction mixture over a period of 30 min. The mixture was allowed to reach room 
temperature and was then stirred for 24 h. The mixture was concentrated under reduced 
pressure, and the residue was dissolved in Et2O (30 mL). A solution of 2M NaOH (15 
mL) was added, and the aqueous layer was extracted with Et2O (3 × 10 mL). The 
combined organic extracts were washed with brine (15 mL), dried with MgSO4, filtered, 
and concentrated under reduced pressure, and the residue was chromatographed on silica 
gel (2:3 EtOAc/hexane) to yield the title compound as a colorless oil (1.00 g, 35%). 1H-
NMR (400 MHz, CDCl3) δ 7.79− 7.77 (m, 2H), 7.72−7.60 (m, 3H), 7.27−7.08 (m, 2H), 
7.08−6.95 (m, 4H), 6.73 (s, 1H), 5.49 (t, J = 7.8, 1H), 4.16 (dt, J = 10.0, 4.4, 1H), 3.79 (s, 
2H), 3.70 (ddd, J = 13.1, 9.8, 3.5, 1H), 2.56−2.44 (m, 1H), 2.26−2.16 (m, 1H), 1.54 (s, 
9H); 13C-NMR (101 MHz, CDCl3) δ 167.75, 153.57, 140.72, 137.40, 136.31, 134.14, 
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131.80, 128.78, 128.27, 127.87, 126.79, 126.40, 125.93, 124.50, 123.36, 80.98, 46.48, 
43.20, 41.01, 28.51, 28.40. 
(18) (S)-tert-Butyl 4-Amino-6-benzyl-3,4-dihydroquinoline-1(2H)- carboxylate. 
Compound 17 (0.93 g, 1.99 mmol) was dissolved in absolute EtOH (20 mL) followed by 
the addition of hydrazine monohydrate (460 µL, 5.97 mmol). The reaction mixture was 
stirred at room temperature for 48 h, during which time a white precipitate formed. The 
mixture was filtered, and the precipitate was washed with EtOH (20 mL) and the filtrate 
concentrated under reduced pressure. The residue was partitioned between EtOAc (20 
mL) and H2O (10 mL), and the aqueous layer was extracted with EtOAc (3 × 10 mL). 
Combined organic extracts were washed with brine (20 mL), dried with MgSO4, filtered, 
and concentrated under reduced pressure, and the residue was chromatographed on silica 
gel (1:9 MeOH/DCM) to yield the title compound as a colorless oil (0.24 g, 60%, 
78−80% ee). 1H-NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.5, 1H), 7.31−7.22 (m, 2H), 
7.21−7.12 (m, 4H), 7.01 (dd, J = 8.5, 1.7, 1H), 3.92 (s, 2H), 3.90 (t, J = 5.8, 1H), 
3.86−3.79 (m, 1H), 3.71−3.63 (m, 1H), 2.14−2.02 (m, 1H), 1.77−1.65 (m, 1H), 1.51 (s, 
9H); 13C-NMR (101 MHz, CDCl3) δ 153.73, 141.13, 136.11, 135.56, 133.26, 128.87, 
128.42, 127.44, 127.16, 126.02, 123.79, 80.89, 47.71, 41.57, 41.34, 33.21, 28.38. 
Enantioselectivity determined by HPLC (Chiracel OD- RH column, 34% 
acetonitrile/water, 1.0 mL/min, 230 nm, 25 °C): tmajor = 4.79 min, tminor = 8.87 min. 
(21) 6-methyl-2,3-dihydroquinolin-4(1H)-one 
p-toluidine (1.09 g, 10.2 mmol) and K2CO3 (2.8 g, 20.4 mmol) were added to a dry round 
bottomed flask, which was placed under an inert atmosphere. DCM (30 mL) was then 
added via syringe. After dissolution of p-toluidine, 3-bromopropionyl chloride (1.08 mL, 
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10.7 mmol) was added dropwise via syringe. The resulting cloudy mixture was stirred at 
r.t. for 1 h, after which time the reaction mixture was transferred to a separatory funnel 
and washed with sat. NaHCO3 (3x) and brine. Combined organic layers were dried with 
MgSO4. Solvents were filtered and removed to give a white solid which was dried under 
vacuum and used without further purification. The white solid was dissolved in DMF (20 
mL) and added via syringe to NaOtBu (0.89 g, 9.2 mmol) in DMF (20 mL). The mixture 
was stirred at r.t. under an inert atmosphere for 3 h, after which time DMF was removed 
under reduced pressure. EtOAc (20 mL) and H2O (20 mL) were added, and the aqueous 
layer was extracted with EtOAc (3x). Combined organic layers were dried with MgSO4. 
Solvents were filtered and removed to give a pale orange solid. The solid was 
immediately dissolved in DCE (50 mL). TfOH (2.33 mL, 26.4 mmol) was then added 
carefully via syringe. The orange mixture was stirred at r.t. for 2 h, after which time the 
mixture was quenched with the addition of H2O (40 mL), followed by slow addition of 
K2CO3 until the solution became a bright yellow color.  Aqueous layer was extracted 
with DCM (3x) and dried with MgSO4. Solvents were filtered and removed under 
reduced pressure, and the crude residue was purified by column chromatography (3:2 
hex/EtOAc) to give pure product as a yellow solid (1.06 g, 74%). 1H-NMR (400 MHz, 
CDCl3) δ 7.62 (s, 1H), 7.09 (dd, J = 8.4, 2.2, 1H), 6.62 (d, J = 8.3, 1H), 4.82 (br s, 1H), 
3.50 (t, J = 7.0, 2H), 2.64 (t, J = 7.0, 2H), 2.20 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 
194.05, 150.38, 136.30, 126.60, 126.57, 118.68, 115.95, 42.16, 38.01, 20.06. 
(22) tert-butyl 6-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate. Compound 
21 (1.06 g, 6.56 mmol) was dissolved in DCM (30 mL). DIPEA (2.3 mL, 13.1 mmol) 
was then added via syringe, followed by (Boc)2O (2.9 g, 13.1 mmol) and DMAP (0.08 g, 
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0.66 mmol). The yellow mixture was refluxed at 60°C for 16 h, after which time it was 
quenched with 1 M HCl (20 mL). The aqueous layer was extracted with DCM (3x). 
Combined organic extracts were dried with MgSO4. Solvents were filtered and removed 
under reduced pressure, and crude residue was purified by column chromatography (2:1 
hex/EtOAc) to give product as a white solid (1.4 g, 83%). 1H-NMR (400 MHz, CDCl3) δ 
7.76 (s, 1H), 7.65 (d, J = 8.5, 1H), 7.30 (d, J = 8.6, 1H), 4.12 (t, J = 6.3, 2H), 2.73 (t, J = 
6.3, 2H), 2.32 (s, 3H), 1.55 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 194.15, 152.67, 
141.74, 134.74, 133.37, 127.01, 124.61, 123.55, 81.78, 44.23, 38.93, 28.21, 20.51. 
(23) tert-butyl 6-(bromomethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
Compound 22 (0.54 g, 2.05 mmol), NBS (0.37 g, 2.09 mmol) and benzoyl peroxide (25 
mg) were added to a dry round bottomed flask and placed under an inert atmosphere. 
CCl4 (25 mL, degassed) was then added via syringe. The mixture was refluxed at 70°C 
under an infrared lamp for 3 h, after which time solids were removed by filtration, and 
solvent was removed under reduced pressure. The resulting crude residue was purified by 
column chromatography (10:1 petroleum ether/EtOAc) to give product as a white solid 
(0.27 g, 39%). 1H-NMR (400 MHz, CDCl3) δ 8.00 (d, J = 2.3, 1H), 7.80 (d, J = 8.7, 1H), 
7.53 (dd, J = 8.7, 2.4, 1H), 4.48 (s, 2H), 4.15 (t, J = 6.4, 2H), 2.77 (t, J = 6.4, 2H), 1.56 (s, 
9H); 13C-NMR (101 MHz, CDCl3) δ 193.66, 152.68, 144.20, 134.70, 133.40, 127.75, 
124.87, 124.30, 82.64, 44.36, 38.90, 32.49, 28.40. 
(24) tert-butyl 4-oxo-6-(pyridin-3-ylmethyl)-3,4-dihydroquinoline-1(2H)-
carboxylate)  
Compound 23 (0.082 g, 0.24 mmol), 3-pyridinylboronic acid (0.044 g, 0.26 mmol), 
K2CO3 (0.10 g, 0.72 mmol) and Pd(dppf)Cl2 (0.018 g, 0.024 mmol) were added to a 
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microwave vessel and placed under an inert atmosphere. 3:1 acetone/H2O (degassed and 
saturated with Argon gas) was then added via syringe. The mixture was placed in a 
microwave reactor, and stirred at 100°C for 30 min, after which time solvents were 
removed under reduced pressure. The crude residue was purified by column 
chromatography (100% EtOAc) to give product as a colorless oil (0.064 g, 78%). 1H-
NMR (400 MHz, CDCl3) δ 8.49 (d, J = 1.5, 1H), 8.47 (dd, J = 4.8, 1.6, 1H), 7.83 (d, J = 
1.8, 1H), 7.72 (d, J = 8.6, 1H), 7.46 (dt, J = 7.9, 2.0, 1H), 7.30 (dd, J = 8.6, 2.3, 1H), 7.21 
(ddd, J = 7.8, 4.8, 0.9, 1H), 4.14 (t, J = 6.4, 2H), 3.96 (s, 2H), 2.75 (t, J = 6.4, 2H), 1.55 
(s, 9H); 13C-NMR (101 MHz, CDCl3) δ 194.18, 152.79, 150.18, 147.99, 142.84, 136.35, 
135.93, 135.56, 134.55, 127.23, 124.98, 124.21, 123.60, 82.33, 44.37, 39.04, 38.37, 
28.39. 
(25) tert-butyl 4-oxo-6-(piperidin-1-ylmethyl)-3,4-dihydroquinoline-1(2H)-
carboxylate)  
To a stirring solution of 23 (0.087 g, 0.26 mmol) and K2CO3 (0.042 g, 0.31 mmol) in 
DMF (10 mL) was added piperidine (0.030 mL, 0.31 mmol) dropwise via syringe. The 
mixture was allowed to stir under an inert atmosphere for 16 h, after which time DMF 
was removed under reduced pressure. The crude reside was re-dissolved in EtOAc, and 
2M NaOH was added. The aqueous layer was extracted with EtOAc (3x) and combined 
organic extracts were dried with MgSO4. Solvents were filtered and removed to give a 
yellow oil which was isolated without further purification (0.080 g, 91% yield). 1H-NMR 
(500 MHz, CDCl3) δ 7.87 (d, J = 2.1, 1H), 7.72 (d, J = 8.6, 1H), 7.51 (dd, J = 8.6, 2.2, 
1H), 4.15 (t, J = 6.5, 2H), 3.45 (s, 2H), 2.76 (t, J = 6.5, 2H), 2.37 (br s, 4H), 1.60 – 1.52 
(m, 12H), 1.45 – 1.38 (m, 2H); 13C-NMR (126 MHz, CDCl3) δ 194.41, 152.87, 143.13, 
	   52	  
135.08, 134.40, 127.76, 124.55, 123.61, 82.20, 62.87, 54.43, 44.42, 39.11, 28.41, 25.97, 
24.39. 
(26) tert-butyl 6-(azepan-1-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate)  
Followed procedure for compound 25 with 23 (0.100 g, 0.29 mmol) and azepane (0.040 
mL, 0.35 mmol) to give product as a slightly yellow oil (0.101 g, 96%). 1H-NMR (500 
MHz, CDCl3) δ 7.89 (d, J = 2.2, 1H), 7.73 (d, J = 8.6, 1H), 7.57 (dd, J = 8.6, 2.2, 1H), 
4.15 (t, J = 6.4, 2H), 3.64 (s, 2H), 2.76 (t, J = 6.4, 2H), 2.66 – 2.61 (m, 4H), 1.69 – 1.58 
(m, 8H), 1.56 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 194.37, 152.86, 143.12, 135.37, 
134.79, 127.32, 124.58, 123.67, 82.18, 61.72, 55.48, 44.41, 39.09, 28.39, 28.02, 27.07. 
(27) tert-butyl 6-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 25 with 23 (0.095 g, 0.28 mmol) and N-Boc 
piperazine (0.062 g, 0.34 mmol) to give product as a white solid (0.090 g, 73%). 1H-
NMR (500 MHz, CDCl3) δ 7.86 (d, J = 2.1, 1H), 7.72 (d, J = 8.6, 1H), 7.48 (d, J = 8.0, 
1H), 4.12 (t, J = 6.3, 2H), 3.47 (s, 2H), 3.39 (t, J = 5.0, 4H), 2.73 (t, J = 6.3, 2H), 2.36 (t, J 
= 4.9, 4H), 1.52 (s, 9H), 1.42 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 194.08, 154.66, 
152.67, 143.29, 134.77, 133.44, 127.60, 124.52, 123.63, 82.15, 79.56, 61.93, 52.67, 
44.27, 43.48, 38.91, 28.38, 28.26. 
(28) tert-butyl 6-(morpholinomethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate) 
Followed procedure for compound 15 with 96 (0.07 g, 0.272 mmol) to give product as a 
colorless oil (0.056 g, 60%). 1H-NMR (500 MHz, CDCl3) δ 7.89 (d, J = 2.2, 1H), 7.74 (d, 
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J = 8.6, 1H), 7.51 (dd, J = 8.7, 2.2, 1H), 4.13 (t, J = 6.3, 2H), 3.69 (t, J = 4.6, 4H), 3.48 (s, 
2H), 2.74 (t, J = 6.4, 2H), 2.44 (t, J = 4.4, 4H), 1.54 (s, 9H); 13C-NMR (126 MHz, CDCl3) 
δ 194.13, 152.69, 143.32, 134.87, 133.15, 127.71, 124.53, 123.65, 82.18, 66.80, 62.32, 
53.39, 44.29, 38.93, 28.27.  
(29) tert-butyl 6-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate) 
Followed procedure for compound 15 with 97 (0.10 g, 0.438 mmol) to give product as a 
colorless oil (0.11 g, 76%). 1H-NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.97 (s, 1H), 7.93 
(d, J = 2.2, 1H), 7.82 (d, J = 8.7, 1H), 7.41 (dd, J = 8.7, 2.3, 1H), 5.33 (s, 2H), 4.16 (t, J = 
6.0, 2H), 2.77 (t, J = 6.4, 2H), 1.55 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 193.62, 
152.57, 152.41, 144.44, 143.13, 133.54, 130.14, 126.98, 124.91, 124.49, 82.66, 52.77, 
44.26, 38.82, 28.32. 
(30) tert-butyl 6-(furan-3-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 24 with 23 (0.094 g, 0.28 mmol) and 3-furanylboronic 
acid (0.046 g, 0.41 mmol) to give product as a colorless oil (0.07 g, 78%). 1H-NMR (400 
MHz, CDCl3) δ 7.84 (d, J = 2.3, 1H), 7.70 (d, J = 8.6, 1H), 7.38 – 7.31 (m, 2H), 7.22 (s, 
1H), 6.22 (s, 1H), 4.14 (t, J = 6.3, 2H), 3.75 (s, 2H), 2.75 (t, J = 6.3, 2H), 1.55 (s, 9H); 
13C-NMR (101 MHz, CDCl3) δ 194.35, 152.86, 143.33, 142.56, 139.69, 136.20, 134.41, 
126.96, 124.90, 123.93, 123.74, 111.18, 82.21, 44.39, 39.09, 30.50, 28.40. 
(31) tert-butyl 6-(benzofuran-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate 
Followed procedure for compound 24 with 23 (0.11 g, 0.33 mmol) and 2-benzofuranyl 
boronic acid MIDA ester (0.13 g, 0.49 mmol) to give product as a colorless oil (0.088 g, 
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72%). 1H-NMR (500 MHz, CDCl3) δ 7.95 (d, J = 2.3, 1H), 7.75 (d, J = 8.9, 1H), 7.50 – 
7.42 (m, 2H), 7.39 (d, J = 7.7, 1H), 7.24 – 7.13 (m, 2H), 6.41 (s, 1H), 4.14 (t, J = 6.2, 
2H), 4.08 (s, 2H), 2.76 (t, J = 6.2, 2H), 1.56 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 
194.06, 156.92, 154.98, 152.72, 142.93, 134.55, 132.95, 128.68, 127.37, 124.89, 123.99, 
123.56, 122.59, 120.49, 110.91, 103.56, 82.20, 44.27, 38.93, 34.19, 28.30. 
(32) tert-butyl 6-(benzo[d][1,3]dioxol-5-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate) 
 Followed procedure for compound 24 with 23 (0.13 g, 0.37 mmol) and 3,4-
(methylenedioxy)phenylboronic acid (0.091 g, 0.55 mmol) to give product as a colorless 
oil (0.12 g, 84%). 1H-NMR (400 MHz, CDCl3) δ 7.80 (d, J = 2.3, 1H), 7.68 (d, J = 8.6, 
1H), 7.30 (dd, J = 8.6, 2.2, 1H), 6.72 (d, J = 7.7, 1H), 6.64 (d, J = 8.1, 2H), 5.90 (s, 2H), 
4.13 (t, J = 6.3, 2H), 3.86 (s, 2H), 2.74 (t, J = 6.3, 2H), 1.55 (s, 9H); 13C-NMR (101 MHz, 
CDCl3) δ 194.32, 152.81, 147.84, 146.09, 142.47, 137.10, 134.59, 134.30, 127.11, 
124.86, 123.97, 121.79, 109.30, 108.31, 100.94, 82.16, 44.34, 40.86, 39.06, 28.37. 
(33) tert-butyl 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 24 with 23 (0.11 g, 0.31 mmol) and (2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)boronic acid (0.084 g, 0.47 mmol) to give product as a 
colorless oil (0.078 g, 63%). 1H-NMR (500 MHz, CDCl3) δ 7.81 (d, J = 2.2, 1H), 7.67 (d, 
J = 8.6, 1H), 7.30 (dd, J = 8.6, 2.3, 1H), 6.76 (d, J = 8.0, 1H), 6.67 – 6.62 (m, 2H), 4.21 
(s, 4H), 4.13 (t, J = 6.3, 2H), 3.84 (s, 2H), 2.74 (t, J = 6.3, 2H), 1.54 (s, 9H); 13C-NMR 
(126 MHz, CDCl3) δ 194.34, 152.86, 143.53, 142.45, 142.12, 137.18, 134.68, 133.86, 
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127.16, 124.90, 123.93, 121.81, 117.60, 117.34, 82.16, 64.47, 64.39, 44.38, 40.50, 39.10, 
28.40. 
(34) tert-butyl 6-(2,6-dichlorobenzyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 24 with 23 (0.11 g, 0.34 mmol) and 2,6-
dichlorophenylboronic acid (0.096 g, 0.50 mmol) to give product as a colorless oil (0.12 
g, 86%). 1H-NMR (400 MHz, CDCl3) δ 7.82 (d, J = 2.3, 1H), 7.67 (d, J = 8.7, 1H), 7.32 
(d, J = 8.2, 2H), 7.27 (t, J = 8.2, 1H), 7.13 (dd, J = 8.6, 7.7, 1H), 4.30 (s, 2H), 4.12 (t, J = 
8.0, 2H), 2.73 (t, J = 8.0, 2H), 1.54 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 194.16, 
152.82, 142.54, 136.06, 136.05, 134.08, 133.92, 128.51, 126.93, 126.91, 124.80, 123.78, 
82.15, 44.31, 39.06, 35.92, 28.37. 
(35) tert-butyl 6-benzhydryl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 15 with 98 (0.22 g, 0.70 mmol) to give product as a 
colorless oil (0.11 g, 37%). 1H-NMR (400 MHz, CDCl3) δ 7.79 (d, J = 2.2, 1H), 7.71 (d, J 
= 8.7, 1H), 7.31 – 7.24 (m, 5H), 7.24 – 7.18 (m, 2H), 7.10 (d, J = 7.2, 4H), 5.53 (s, 1H), 
4.13 (t, J = 6.2, 2H), 2.73 (t, J = 6.2, 2H), 1.54 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 
194.10, 152.75, 143.15, 142.50, 139.64, 135.03, 129.29, 128.44, 127.79, 126.52, 124.66, 
123.57, 82.17, 56.17, 44.25, 38.97, 28.30. 
(36) tert-butyl 4-oxo-6-(quinolin-6-ylmethyl)-3,4-dihydroquinoline-1(2H)-
carboxylate)  
Followed procedure for compound 24 with 23 (0.093 g, 0.27 mmol), and 6-
quinolineboronic pinacol ester (0.105 g, 0.41 mmol) to give product as a colorless oil 
(0.105 g, 99%). 1H-NMR (400 MHz, CDCl3) δ 8.86 (dd, J = 4.3, 1.7, 1H), 8.08 (d, J = 
8.3, 1H), 8.02 (d, J = 8.6, 1H), 7.89 (d, J = 2.2, 1H), 7.73 (d, J = 8.6, 1H), 7.59 (s, 1H), 
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7.54 (dd, J = 8.7, 2.0, 1H), 7.40 – 7.33 (m, 2H), 4.17 – 4.12 (m, 4H), 2.76 (t, J = 6.4, 2H), 
1.54 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 194.29, 152.78, 150.04, 147.26, 142.69, 
138.92, 136.18, 135.78, 134.76, 131.07, 129.75, 128.39, 127.40, 126.92, 124.93, 124.04, 
121.31, 82.25, 44.33, 41.15, 39.02, 28.35. 
(37) tert-butyl 4-oxo-6-(quinolin-3-ylmethyl)-3,4-dihydroquinoline-1(2H)-
carboxylate) 
Followed procedure for compound 24 with 23 (0.093 g, 0.27 mmol) and 3-
quinolineboronic acid (0.071 g, 0.41 mmol) to give product as a colorless oil (0.094 g, 
89%). 1H-NMR (400 MHz, CDCl3) δ 8.80 (d, J = 2.2, 1H), 8.08 (d, J = 8.5, 1H), 7.89 (s, 
2H), 7.77 – 7.71 (m, 2H), 7.67 (ddd, J = 8.5, 6.9, 1.4, 1H), 7.52 (td, J = 7.4, 6.8, 1.1, 1H), 
7.36 (dd, J = 8.6, 2.3, 1H), 4.18 – 4.11 (m, 4H), 2.76 (t, J = 6.0, 2H), 1.55 (s, 9H); 13C-
NMR (101 MHz, CDCl3) δ 194.21, 152.77, 151.81, 146.89, 142.87, 135.41, 135.09, 
134.63, 133.28, 129.14, 128.13, 127.56, 127.41, 127.37, 126.92, 125.01, 124.23, 82.34, 
44.33, 39.02, 38.55, 28.37. 
(38) tert-butyl 6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 25 with 23 (0.15 g, 0.44 mmol) and 1,2,3,4-
tetrahydroisoquinoline (0.066 mL, 0.53 mmol) to give product as a slightly yellow oil 
(0.16 g, 92%). 1H-NMR (400 MHz, CDCl3) δ 7.95 (d, J = 2.1, 1H), 7.75 (d, J = 8.6, 1H), 
7.59 (dd, J = 8.6, 2.2, 1H), 7.13 – 7.05 (m, 3H), 6.99 – 6.92 (m, 1H), 4.16 (t, J = 6.3, 2H), 
3.66 (s, 2H), 3.62 (s, 2H), 2.89 (t, J = 5.5, 2H), 2.79 – 2.70 (m, 4H), 1.56 (s, 9H); 13C-
NMR (101 MHz, CDCl3) δ 194.32, 152.86, 143.33, 134.82, 134.38, 134.30, 128.78, 
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127.63, 127.57, 126.65, 126.21, 125.68, 124.65, 123.83, 82.26, 61.92, 56.11, 50.69, 
44.43, 39.09, 29.24, 28.41. 
(39) tert-butyl 6-((7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 25 with 23 (0.15 g, 0.44 mmol) and 7-fluoro-1,2,3,4-
tetrahydroisoquinoline (0.10 g, 0.53 mmol) to give product as a yellow oil (0.21 g, 83%). 
1H NMR (400 MHz, CDCl3) δ 1.56 (s, 9H), 2.77 (m, 4H), 2.90 (br. s, 2H), 3.92 (br. s, 
2H), 3.94 (br. s, 2H), 4.09-4.19 (m, 2H), 6.82 (m, 1H), 6.99 (m, 1H), 7.13 (m, 2H), 7.52 
(br. s, 1H), 7.92 (m, 1H).  
(40) tert-butyl 4-oxo-6-((8-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-
yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 25 with 23 and 8-trifluoromethyl-1,2,3,4-
tetrahydroisoquinoline to give product as a yellow oil (61%). 1H-NMR (400 MHz, 
CDCl3) δ 1.56 (s, 9H), 2.71 (br. s, 2H), 2.78 (t, J = 5.6 Hz, 2H), 2.93 (br. s, 2H), 3.71 (br. 
s, 2H), 3.85 (br. s, 2H), 4.17 (t, J = 7.2 Hz, 2H), 7.23 (d, J = 7.6 Hz,1H), 7.27 (d, J = 3.2 
Hz, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.61 (br. s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.95 (s, 1H). 
(41) tert-butyl 6-((7-methyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 25 with 23 (0.11 g, 0.34 mmol) and 6-methyl-1,2,3,4-
tetrahydroisoquinoline HCl salt (0.074 g, 0.40 mmol) to give product as a slightly yellow 
oil (0.092 g, 68%). 1H-NMR (500 MHz, CDCl3) δ 7.94 (d, J = 2.1, 1H), 7.74 (d, J = 8.6, 
1H), 7.59 (dd, J = 8.6, 2.2, 1H), 7.00 – 6.91 (m, 2H), 6.78 (s, 1H), 4.16 (t, J = 6.5, 2H), 
3.65 (s, 2H), 3.57 (s, 2H), 2.84 (t, J = 5.9, 2H), 2.76 (t, J = 6.5, 2H), 2.72 (t, J = 5.9, 2H), 
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2.26 (s, 3H), 1.56 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 194.33, 152.87, 143.30, 
135.11, 134.88, 134.64, 134.41, 131.28, 128.64, 127.58, 127.16, 127.07, 124.64, 123.81, 
82.25, 61.89, 56.08, 50.88, 44.43, 39.10, 28.81, 28.41, 21.08. 
(42) tert-butyl 6-(isoindolin-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate) 
Followed procedure for compound 25 with 23 (0.12 g, 0.36 mmol) and isoindoline (0.051 
mL, 0.43 mmol) to give product as a slightly brown oil (0.10 g, 77%). 1H-NMR (400 
MHz, CDCl3) δ 7.97 (d, J = 2.2, 1H), 7.76 (d, J = 8.6, 1H), 7.61 (dd, J = 8.6, 2.2, 1H), 
7.17 (s, 4H), 4.16 (t, J = 6.4, 2H), 3.92 (s, 4H), 3.89 (s, 2H), 2.77 (t, J = 6.4, 2H), 1.56 (s, 
9H); 13C-NMR (101 MHz, CDCl3) δ 194.34, 152.83, 143.30, 140.10, 134.98, 134.69, 
127.17, 126.80, 124.70, 123.96, 122.40, 82.26, 59.36, 58.96, 44.39, 39.07, 28.39. 
(43) tert-butyl 6-(((4aR,8aS)-octahydroisoquinolin-2(1H)-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 25 with 23 (0.11 g, 0.34 mmol) and (4aR, 8aS)-
decahydroisoquinoline (0.056 g, 0.40 mmol) to give product as a colorless oil (0.11 g, 
82%). 1H-NMR (500 MHz, CDCl3) δ 7.85 (d, J = 2.1, 1H), 7.71 (d, J = 8.6, 1H), 7.49 (dd, 
J = 8.6, 2.2, 1H), 4.13 (t, J = 6.5, 2H), 3.44 (s, 2H), 2.87 – 2.81 (m, 1H), 2.74 (t, J = 6.5, 
2H), 2.68 (ddd, J = 10.9, 3.7, 1.7, 1H), 1.97 – 1.91 (m, 1H), 1.71 – 1.64 (m, 2H), 1.62 – 
1.14 (m, 17H), 1.01 – 0.79 (m, 3H); 13C-NMR (126 MHz, CDCl3) δ 194.40, 152.86, 
143.11, 135.04, 134.53, 127.70, 124.54, 123.60, 82.18, 62.57, 60.42, 54.42, 44.41, 41.89, 
41.87, 39.10, 33.07, 33.04, 30.74, 28.40, 26.59, 26.17. 
(44) tert-butyl 6-(((4aR,8aS)-octahydroquinolin-1(2H)-yl)methyl)-4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate 
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Followed procedure for compound 25 with 23 (0.11 g, 0.32 mmol) and trans-
decahydroquinoline (0.053 g, 0.38 mmol) to give product as a white solid (0.081 g, 64%). 
1H-NMR (500 MHz, CDCl3) δ 7.87 (d, J = 2.2, 1H), 7.74 (d, J = 8.6, 1H), 7.50 (dd, J = 
8.6, 2.2, 1H), 4.20 – 4.10 (m, 2H), 4.06 (d, J = 13.7, 1H), 3.32 (d, J = 13.7, 1H), 2.88 – 
2.81 (m, 1H), 2.79 – 2.72 (m, 2H), 2.28 – 2.21 (m, 1H), 2.00 (td, J = 12.0, 3.4, 1H), 1.86 
– 1.79 (m, 2H), 1.67 – 1.48 (m, 13H), 1.40 – 1.17 (m, 5H), 1.06 – 0.91 (m, 2H); 13C-
NMR (126 MHz, CDCl3) δ 194.33, 152.84, 143.12, 135.22, 134.20, 127.91, 124.52, 
123.57, 82.24, 66.78, 55.89, 53.59, 44.40, 41.77, 39.07, 33.31, 32.48, 30.48, 28.40, 25.98, 
25.83, 25.19.  
(45) tert-butyl 6-((3-azaspiro[5.5]undecan-3-yl)methyl)-4-oxo-3,4-dihydroquinoline-
1(2H)-carboxylate 
Followed procedure for compound 25 with 23 (0.091 g, 0.27 mmol) and 101 (0.061 g, 
0.32 mmol) to give product as a colorless oil (0.038 g, 34%). 1H-NMR (500 MHz, 
CDCl3) δ 7.86 (d, J = 2.0, 1H), 7.71 (d, J = 8.5, 1H), 7.50 (dd, J = 8.6, 2.2, 1H), 4.14 (t, J 
= 6.3, 2H), 3.47 (s, 2H), 2.75 (t, J = 6.2, 2H), 2.35 (t, J = 5.6, 4H), 1.55 (s, 9H), 1.44 (t, J 
= 5.6, 4H), 1.40 – 1.28 (m, 10H); 13C-NMR (126 MHz, CDCl3) δ 194.29, 152.76, 142.98, 
134.94, 134.49, 127.64, 124.44, 123.49, 82.07, 62.56, 49.21, 44.30, 38.99, 36.57, 36.21, 
30.71, 28.30, 26.86, 21.48. 
(46) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(pyridin-3-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Compound 24 (0.064 g, 0.19 mmol) was dissolved in THF (17 mL) and placed under an 
inert atmosphere. (R)-(+)-2-methyl-2-propanesulfinamide (0.069 g, 0.58 mmol) was then 
added, and allowed to dissolve. The mixture was cooled to 0°C, and Ti(OEt)4 (0.30 mL, 
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1.13 mmol) was added dropwise via syringe. The mixture was warmed to r.t., and then 
allowed to reflux at 75°C for 20 h, after which time the mixture was cooled to r.t. under 
an inert atmosphere, and immediately added via syringe to a stirring solution of NaBH4 
(0.043 g, 1.13 mmol) in THF (3 mL, cooled with a bath of xylenes/dry ice). The resulting 
yellow mixture was warmed back to r.t. and stirred for 1.5 h, after which time the 
reaction was quenched with the slow addition of MeOH. Solids were removed by 
filtration, and the resulting crude material was purified directly by column 
chromatography (100% EtOAc) to give product as a colorless oil (0.035 g, 42%). 1H-
NMR (400 MHz, CDCl3) δ 8.48 – 8.42 (m, 2H), 7.81 – 7.71 (m, 2H), 7.42 (dd, J = 8.0, 
5.9, 1H), 7.24 (d, J = 2.2, 1H), 7.02 (dd, J = 8.6, 2.2, 1H), 4.53 (q, J = 4.1, 1H), 3.97 (s, 
2H), 3.94 (t, J = 4.7, 1H), 3.60 (ddd, J = 13.0, 10.8, 3.9, 1H), 3.27 (d, J = 3.4, 1H), 2.20 – 
2.11 (m, 1H), 2.06 – 1.93 (m, 1H), 1.52 (s, 9H), 1.22 (s, 9H); 13C-NMR (101 MHz, 
CDCl3) δ 153.57, 147.63, 145.44, 139.50, 139.26, 137.66, 133.16, 129.42, 129.39, 
128.64, 125.18, 124.64, 81.58, 55.89, 51.10, 40.46, 38.17, 30.02, 28.45, 22.72. 
(47) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(piperidin-1-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 25 (0.080 g, 0.23 mmol) to give crude product 
as a colorless oil (0.011 g, 11%) which was filtered through a plug of silica and used 
without further purification.  
(48) tert-butyl (R)-6-(azepan-1-ylmethyl)-4-(((R)-tert-butylsulfinyl)amino)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 26 (0.103 g, 0.29 mmol) to give product as a 
colorless oil (0.027 g, 24% yield). 1H-NMR (500 MHz, CD3OD) δ 7.83 (d, J = 8.6, 1H), 
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7.44 (d, J = 2.1, 1H), 7.33 (dd, J = 8.6, 2.2, 1H), 4.58 (q, J = 3.9, 1H), 4.02 (dt, J = 13.0, 
4.6, 1H), 3.86 (s, 2H), 3.58 (ddd, J = 13.0, 11.0, 3.7, 1H), 3.31 (d, J = 3.0, 1H), 3.13 – 
2.87 (m, 4H), 2.18 (dq, J = 14.0, 4.2, 1H), 2.06 – 1.98 (m, 1H), 1.94 – 1.80 (m, 1H), 1.63 
– 1.46 (m, 16H), 1.22 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.35, 138.94, 133.39, 
132.49, 127.86, 127.12, 123.01, 81.51, 66.55, 60.55, 59.82, 55.69, 50.41, 40.23, 29.49, 
29.21, 28.31, 22.58. 
(49) tert-butyl (R)-6-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-4-(((R)-tert-
butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 27 (0.090 g, 0.20 mmol) to give product as a 
colorless oil (0.021 g, 19%). 1H-NMR (500 MHz, CDCl3) δ 7.86 (d, J = 8.6, 1H), 7.40 (d, 
J = 2.2, 1H), 7.24 (dd, J = 8.6, 2.2, 1H), 4.58 (q, J = 4.1, 1H), 4.06 – 3.94 (m, 3H), 3.88 – 
3.66 (m, 4H), 3.61 (ddd, J = 13.6, 10.8, 3.7, 1H), 3.29 (d, J = 3.3, 1H), 2.88 – 2.78 (m, 
2H), 2.71 – 2.59 (m, 2H), 2.18 (dq, J = 13.5, 4.4, 1H), 2.06 – 1.99 (m, 1H), 1.53 (s, 9H), 
1.43 (s, 9H), 1.22 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 154.25, 153.35, 139.34, 
133.71, 132.72, 128.35, 124.82, 123.34, 81.70, 80.30, 68.52, 55.76, 55.44, 55.22, 50.78, 
40.42, 29.67, 28.32, 28.30, 22.58. 
(50) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(morpholinomethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 28 (0.056 g, 0.16 mmol) to give product as a 
colorless oil (0.013 g, 18%). 1H-NMR (400 MHz, CDCl3) δ 7.86 (d, J = 8.6, 1H), 7.41 (d, 
J = 2.0, 1H), 7.25 (dd, J = 6.8, 2.0, 1H), 4.58 (q, J = 3.8, 1H), 4.41 – 4.26 (m, 2H), 4.04 – 
3.93 (m, 3H), 3.74 – 3.55 (m, 3H), 3.29 (d, J = 3.2, 1H), 2.93 – 2.74 (m, 4H), 2.20 (dq, J 
= 13.5, 4.3, 1H), 2.09 – 1.96 (m, 1H), 1.54 (s, 9H), 1.22 (s, 9H); 13C-NMR (101 MHz, 
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CDCl3) δ 153.48, 139.46, 133.87, 133.01, 128.53, 124.94, 123.58, 81.85, 69.09, 62.22, 
55.92, 55.66, 55.48, 50.94, 50.92, 40.53, 29.78, 28.45, 22.74. 
(51) tert-butyl (R)-6-((1H-1,2,4-triazol-1-yl)methyl)-4-(((R)-tert-
butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 29 (0.11 g, 0.34 mmol) to give product as a 
colorless oil (0.094 g, 65%). 1H-NMR (400 MHz, CDCl3) δ 8.49 (s, 1H), 8.02 (s, 1H), 
7.92 – 7.83 (m, 1H), 7.52 (d, J = 2.2, 1H), 7.25 – 7.15 (m, 1H), 5.28 (s, 2H), 4.54 (q, J = 
4.5, 1H), 4.02 – 3.90 (m, 1H), 3.70 – 3.56 (m, 1H), 3.43 (d, J = 4.3, 1H), 2.18 – 1.94 (m, 
2H), 1.53 (s, 9H), 1.22 (s, 9H). 
 (52) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(furan-3-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 30 (0.070 g, 0.21 mmol) to give product as a 
colorless oil (0.051 g, 55%). 1H-NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.5, 1H), 7.34 (t, 
J = 1.7, 1H), 7.25 – 7.18 (m, 2H), 7.10 (dd, J = 8.6, 2.2, 1H), 6.24 (dd, J = 1.8, 0.9, 1H), 
4.54 (q, J = 3.6, 1H), 3.96 (dt, J = 12.9, 4.5, 1H), 3.71 (s, 2H), 3.58 (ddd, J = 12.9, 11.2, 
3.8, 1H), 3.26 (d, J = 3.3, 1H), 2.19 (dq, J = 13.9, 4.0, 1H), 2.02 – 1.91 (m, 1H), 1.51 (s, 
9H), 1.21 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 153.68, 143.16, 139.63, 136.71, 
135.97, 128.86, 128.70, 128.41, 124.11, 111.31, 111.28, 81.26, 55.76, 50.58, 40.18, 
30.48, 29.63, 28.46, 22.71. 
(53) tert-butyl (R)-6-(benzofuran-2-ylmethyl)-4-(((R)-tert-butylsulfinyl)amino)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 31 (0.088 g, 0.23 mmol) to give product as a 
colorless oil (0.078 g, 70%). 1H-NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.5, 1H), 7.46 (d, 
	   63	  
J = 7.8, 1H), 7.38 (d, J = 8.2, 1H), 7.30 (s, 1H), 7.22 – 7.12 (m, 3H), 6.41 (s, 1H), 4.55 (q, 
J = 3.7, 1H), 4.04 (s, 2H), 3.95 (dt, J = 13.1, 5.0, 1H), 3.64 – 3.50 (m, 1H), 3.30 (s, 1H), 
2.22 – 2.15 (m, 1H), 2.02 – 1.92 (m, 1H), 1.51 (s, 9H), 1.19 (s, 9H); 13C-NMR (126 MHz, 
CDCl3) δ 157.38, 154.93, 153.53, 137.16, 132.62, 129.10, 128.78, 128.75, 128.61, 
124.16, 123.39, 122.49, 120.42, 110.88, 103.34, 81.22, 55.66, 50.44, 40.12, 34.19, 29.50, 
28.33, 22.58. 
(54) tert-butyl (R)-6-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(((R)-tert-
butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 32 (0.12 g, 0.30 mmol) to give product as a 
colorless oil (0.071 g, 48%). 1H-NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.5, 1H), 7.15 (d, 
J = 2.1, 1H), 7.05 (dd, J = 8.5, 2.1, 1H), 6.72 (d, J = 8.5, 1H), 6.65 (d, J = 7.1, 2H), 5.90 
(s, 2H), 4.53 (q, J = 3.5, 1H), 3.94 (dt, J = 12.9, 4.5, 1H), 3.82 (s, 2H), 3.57 (td, J = 12.1, 
3.9, 1H), 3.26 (d, J = 2.3, 1H), 2.19 (dq, J = 12.9, 4.1, 1H), 2.03 – 1.90 (m, 1H), 1.51 (s, 
9H), 1.20 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 153.67, 147.80, 146.00, 136.89, 
136.68, 134.85, 128.99, 128.77, 128.62, 124.18, 124.13, 121.80, 109.48, 109.41, 108.29, 
100.92, 81.24, 55.75, 50.52, 40.95, 40.16, 29.53, 28.46, 22.72. 
(55) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 33 (0.078 g, 0.20 mmol) to give product as a 
colorless oil (0.060 g, 61%). 1H-NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.5, 1H), 7.15 (d, 
J = 2.1, 1H), 7.06 (dd, J = 8.6, 2.2, 1H), 6.76 (d, J = 8.1, 1H), 6.68 – 6.63 (m, 2H), 4.52 
(q, J = 3.6, 1H), 4.22 (s, 4H), 3.94 (dt, J = 12.9, 4.5, 1H), 3.80 (s, 2H), 3.57 (ddd, J = 
12.9, 11.3, 3.9, 1H), 3.29 (d, J = 1.1, 1H), 2.20 (dq, J = 14.0, 4.0, 1H), 2.00 – 1.89 (m, 
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1H), 1.51 (s, 9H), 1.20 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.68, 143.48, 142.01, 
136.92, 136.63, 134.36, 128.99, 128.73, 128.69, 124.15, 121.85, 117.62, 117.25, 81.20, 
64.47, 64.41, 55.76, 50.48, 40.54, 40.15, 29.50, 28.46, 22.73. 
(56) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(2,6-dichlorobenzyl)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 34 (0.12 g, 0.28 mmol) to give product as a 
colorless oil (0.032 g, 22%). 1H-NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.6, 1H), 7.32 (d, 
J = 8.0, 2H), 7.18 – 7.10 (m, 2H), 7.08 (dd, J = 8.6, 2.2, 1H), 4.52 (q, J = 3.4, 1H), 4.27 
(s, 2H), 3.93 (dt, J = 12.9, 4.5, 1H), 3.55 (ddd, J = 12.8, 11.3, 3.9, 1H), 3.26 (br s, 1H), 
2.20 (dq, J = 14.2, 4.1, 1H), 2.02 – 1.88 (m, 1H), 1.50 (s, 9H), 1.20 (s, 9H); 13C-NMR 
(101 MHz, CDCl3) δ 153.67, 136.83, 136.54, 136.09, 133.56, 128.74, 128.67, 128.52, 
128.35, 128.17, 124.10, 81.23, 55.73, 50.18, 40.11, 35.94, 29.28, 28.46, 22.72. 
(57) tert-butyl (R)-6-benzhydryl-4-(((R)-tert-butylsulfinyl)amino)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 35 (0.11 g, 0.26 mmol) to give product as a 
colorless oil (0.063 g, 47%). 1H-NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.6, 1H), 7.30 – 
7.24 (m, 4H), 7.23 – 7.17 (m, 2H), 7.14 – 7.07 (m, 5H), 7.01 (dd, J = 8.7, 2.2, 1H), 5.48 
(s, 1H), 4.48 (q, J = 3.4, 1H), 3.94 (dt, J = 12.8, 4.5, 1H), 3.58 (ddd, J = 12.9, 11.3, 4.0, 
1H), 3.21 (d, J = 2.8, 1H), 2.21 (dq, J = 14.0, 4.0, 1H), 2.02 – 1.89 (m, 1H), 1.51 (s, 9H), 
1.16 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 153.70, 143.83, 143.76, 139.37, 136.86, 
129.58, 129.47, 129.44, 129.26, 128.63, 128.46, 128.45, 126.48, 123.86, 81.30, 56.30, 
55.76, 50.20, 40.18, 29.24, 28.48, 24.33, 22.70. 
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(58) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(quinolin-6-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 36 (0.099 g, 0.26 mmol) to give crude product 
as a colorless oil (0.016 g, 14%) which was filtered through a plug of silica and used 
without further purification. 
(59) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(quinolin-3-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 37 (0.093 g, 0.24 mmol) to give crude product 
as a colorless oil (0.020 g, 17%) which was filtered through a plug of silica and used 
without further purification. 
(60) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((3,4-dihydroisoquinolin-
2(1H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 38 (0.16 g, 0.41 mmol) to give product as a 
colorless oil (0.094 g, 46%). 1H-NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 12.8, 8.6, 1H), 
7.43 (dd, J = 4.6, 2.1, 1H), 7.25 – 7.14 (m, 4H), 7.06 – 6.96 (m, 1H), 4.56 (dd, J = 9.1, 
3.7, 1H), 4.06 – 3.84 (m, 5H), 3.63 – 3.52 (m, 1H), 3.38 (d, J = 2.8, 1H), 3.30 – 3.19 (m, 
2H), 3.14 – 2.93 (m, 2H), 2.27 – 2.15 (m, 1H), 2.03 – 1.94 (m, 1H), 1.52 (s, 9H), 1.21 (s, 
9H); 13C-NMR (126 MHz, CDCl3) δ 153.45, 139.20, 133.80, 133.61, 132.51, 132.28, 
131.26, 131.23, 130.75, 130.71, 128.71, 128.60, 128.26, 128.15, 127.37, 127.30, 126.83, 
126.81, 125.99, 123.21, 81.65, 81.61, 63.78, 62.84, 58.10, 57.37, 55.83, 55.82, 54.93, 
54.30, 50.47, 50.28, 40.36, 40.27, 29.35, 29.31, 28.41, 25.01, 24.83, 22.71. 
(61) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((7-fluoro-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
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Followed procedure for compound 46 with 39 to give product as a white solid (40%). 1H-
NMR (400 MHz, CDCl3) δ 1.21 (s, 9H), 1.51 (s, 9H), 1.96-2.19 (m, 2H), 2.85-3.03 (m, 
2H), 3.20 (m, 2H), 3.90-4.04 (m, 4H), 4.56 (q, J = 4 Hz, 2H), 6.72 (qd, J = 8, 4 Hz, 1H), 
6.91 (m, 1H), 7.10 (td, J = 4, 4 Hz, 1H), 7.16 (qd, J = 16, 4 Hz, 1H), 7.45 (s, 1H), 7.82 (t, 
J = 8 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 22.54, 22.63, 28.29, 40.29, 40.37, 54.12, 
54.56, 55.76, 63.83, 64.68, 81.59, 114.47, 123.30, 125.54, 126.87, 128.32, 130.08, 
132.43, 132.56, 133.63, 139.21, 153.37, 162.52. 
(62) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((8-(trifluoromethyl)-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 40 (0.12 g, 0.26 mmol) to give product as a 
white solid (22%). 1H-NMR (400 MHz, CDCl3) δ 1.21 (s, 9H), 1.51 (s, 9H), 1.98-2.22 
(m, 2H), 2.94-3.08 (m, 2H), 3.18-3.33 (m, 2H), 3.95-4.04 (m, 2H), 4.07-4.17 (m, 2H), 
4.18-4.55 (dd, J = 116, 16 Hz, 2H), 7.28 (m, 1H), 7.30-7.35 (m, 2H), 7.40 (s, 1H), 7.52 
(d, J = 12 Hz, 1H), 7.83 (dd, J = 4, 4 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 22.52, 
22.61, 28.26, 39.08, 40.28, 52.79, 55.74, 55.79, 65.42, 65.43, 81.58, 121.08, 123.40, 
125.19, 125.22, 126.77, 128.32, 128.37, 129.17, 132.48, 133.22, 133.32, 139.22, 158.34. 
(63) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((7-methyl-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 41 (0.092 g, 0.23 mmol) to give product as a 
colorless oil (0.032 g, 28%). 1H-NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 10.4, 8.5, 1H), 
7.44 (s, 1H), 7.19 (ddd, J = 34.1, 8.6, 2.1, 1H), 7.09 – 7.00 (m, 2H), 6.83 (d, J = 19.9, 
1H), 4.60 – 4.53 (m, 1H), 4.04 – 3.84 (m, 5H), 3.63 – 3.53 (m, 1H), 3.37 (d, J = 2.7, 1H), 
3.30 – 2.88 (m, 4H), 2.31 (s, 3H), 2.26 – 2.15 (m, 1H), 2.04 – 1.93 (m, 1H), 1.52 (s, 9H), 
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1.22 (d, J = 3.3, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.49, 139.21, 136.50, 136.49, 
133.88, 133.69, 132.52, 132.30, 130.56, 130.54, 128.61, 128.51, 128.31, 128.26, 128.24, 
128.14, 128.11, 127.27, 127.26, 126.14, 123.21, 81.67, 81.64, 63.62, 62.72, 58.26, 57.48, 
55.85, 55.14, 54.51, 50.46, 50.29, 40.39, 40.29, 29.37, 29.33, 28.44, 24.66, 24.48, 22.75, 
21.19, 21.16. 
 (64) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(isoindolin-2-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 42 (0.10 g, 0.28 mmol) to give product as a 
colorless oil (0.062 g, 47%). 1H-NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.5, 1H), 7.40 (d, 
J = 2.1, 1H), 7.25 – 7.12 (m, 5H), 4.52 (q, J = 4.0, 1H), 4.47 – 4.29 (m, 4H), 4.09 (s, 2H), 
3.94 (dt, J = 12.9, 4.7, 1H), 3.58 (ddd, J = 12.8, 10.8, 3.8, 1H), 3.28 (d, J = 3.2, 1H), 2.16 
(dq, J = 13.4, 4.3, 1H), 2.00 – 1.93 (m, 1H), 1.52 (s, 9H), 1.22 (s, 9H); 13C-NMR (126 
MHz, CDCl3) δ 153.43, 139.13, 136.98, 136.90, 133.10, 132.16, 128.40, 127.92, 127.88, 
127.10, 123.41, 122.69, 122.60, 81.65, 65.17, 64.78, 64.48, 55.86, 50.74, 40.42, 29.57, 
28.40, 22.71. 
(65) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(((4aR,8aS)-
octahydroisoquinolin-2(1H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate) 
Followed procedure for compound 46 with 43 (0.11 g, 0.27 mmol) to give product as a 
colorless oil (0.020 g, 7%). 1H-NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 8.6, 3.4, 1H), 
7.35 (dd, J = 5.9, 2.1, 1H), 7.30 – 7.22 (m, 1H), 4.58 (br s, 1H), 4.05 – 3.88 (m, 3H), 3.58 
(ddd, J = 12.9, 11.1, 3.7, 1H), 3.28 (d, J = 2.8, 1H), 2.98 – 2.88 (m, 1H), 2.80 – 2.69 (m, 
1H), 2.61 – 2.51 (m, 1H), 2.25 – 1.01 (m, 31H), 0.82 – 0.68 (m, 2H); 13C-NMR (126 
MHz, CDCl3) δ 153.55, 139.15, 133.77, 133.11, 128.13, 125.91, 123.29, 81.75, 70.03, 
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62.69, 57.28, 55.86, 50.51, 41.17, 40.40, 36.56, 32.20, 30.64, 29.60, 28.51, 28.46, 26.39, 
25.76, 22.72. 
(66) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(((4aR,8aS)-
octahydroquinolin-1(2H)-yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 44 (0.17 g, 0.42 mmol) to give product as a 
colorless oil (0.029 g, 14%) which was filtered through a plug of silica and used without 
further purification.  
(67) tert-butyl (R)-6-((3-azaspiro[5.5]undecan-3-yl)methyl)-4-(((R)-tert-
butylsulfinyl)amino)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 45 (0.038 g, 0.092 mmol) to give product as a 
colorless oil (0.031 g, 65%). 1H-NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.6, 1H), 7.39 (d, 
J = 2.1, 1H), 7.31 (dd, J = 8.6, 2.1, 1H), 4.57 (q, J = 3.7, 1H), 4.00 (dt, J = 13.0, 4.6, 1H), 
3.89 (s, 2H), 3.56 (ddd, J = 13.1, 11.2, 3.7, 1H), 3.30 (d, J = 2.7, 1H), 2.91 – 2.77 (m, 
2H), 2.77 – 2.64 (m, 2H), 2.20 (dq, J = 14.0, 4.1, 1H), 2.03 – 1.85 (m, 1H), 1.52 (s, 9H), 
1.44 – 1.23 (m, 14H), 1.20 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 153.37, 138.91, 
133.41, 132.71, 127.77, 126.29, 123.02, 81.50, 55.66, 52.87, 52.23, 50.20, 40.12, 31.12, 
30.08, 29.20, 28.31, 26.54, 22.61, 22.13, 21.41. 
(68) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(pyridin-3-ylmethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Compound 46 (0.035 g, 0.079 mmol) was dissolved in 1,4-dioxane (7 mL). Conc. HCl 
(0.039 mL, 0.47 mmol) was then added dropwise via syringe. The mixture was stirred at 
r.t. for 1 h, after which time 1,4-dioxane was removed under reduced pressure, and Et2O 
was added to the reaction vessel, precipitating the HCl salt as a white solid, which was 
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subsequently washed with Et2O (3x). This solid was dried under vacuum and used 
without further purification. The HCl salt (0.022 g, 0.08 mmol) was dissolved in DMF 
(10 mL). DIPEA (0.14 mL, 0.80 mmol, 10 eq) was then added dropwise via syringe, 
followed by PyBOP (0.042 g, 0.08 mmol, 1 eq) and HOBt-Cl (0.014 g, 0.08 mmol, 1 eq). 
Boc-L-2’,6’-dimethyltyrosine (0.033 g, 0.08 mmol, 1 eq) was dissolved in DMF (2 mL) 
and added to the reaction mixture dropwise via syringe. The yellow solution was stirred 
at r.t. under an inert atmosphere for 5 h, after which time DMF was removed under 
reduced pressure. The crude residue was redissolved in 1:1 DCM/TFA (10 mL) and 
stirred at r.t. for 1 h. DCM/TFA were then removed under reduced pressure. The crude 
residue was then purified by semi-prep RP-HPLC and lyophilized to give product as a 
white solid. (MS)EI: 431.2 (M+H), Retention Time: 13.77 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.65 (d, J = 5.6, 1H), 8.61 (s, 1H), 8.34 (d, J = 8.0, 1H), 8.14 (d, J = 7.8, 1H), 
7.92 (t, J = 6.8, 1H), 6.98 (s, 1H), 6.90 (d, J = 8.2, 1H), 6.56 (d, J = 8.2, 1H), 6.47 (s, 2H), 
4.96 – 4.91 (m, 1H), 4.02 (s, 2H), 3.88 (dd, J = 11.6, 4.8, 1H), 3.28 – 3.19 (m, 1H), 3.02 
(dd, J = 13.5, 4.5, 2H), 2.55 (t, J = 11.6, 1H), 2.27 (s, 6H), 1.76 – 1.63 (m, 1H), 1.56 – 
1.44 (m, 1H). 
(69) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(piperidin-1-ylmethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Followed procedure for compound 68 with 47 (0.008 g, 0.021 mmol) to give product as a 
white solid. (MS)EI: 459.3 (M+Na), Retention Time: 17.91 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.10 (d, J = 8.0, 1H), 7.05 (d, J = 2.1, 1H), 7.03 (dd, J = 8.3, 2.2, 1H), 6.52 (d, 
J = 8.3, 1H), 6.49 (s, 2H), 4.95 – 4.91 (m, 1H), 4.07 – 3.98 (m, 2H), 3.88 (dd, J = 11.7, 
4.9, 1H), 3.38 (d, J = 12.5, 2H), 3.28 (dd, J = 13.6, 11.7, 1H), 3.03 (dd, J = 13.4, 5.2, 2H), 
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2.83 (t, J = 12.5, 2H), 2.55 (td, J = 12.2, 3.1, 1H), 2.29 (s, 6H), 1.93 – 1.77 (m, 3H), 1.76 
– 1.60 (m, 3H), 1.55 – 1.42 (m, 2H). 
(70) (S)-2-amino-N-((R)-6-(azepan-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with 48 (0.027 g, 0.058 mmol) to give product as a 
white solid. (MS)EI: 473.3 (M+Na), Retention Time: 19.54 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.10 (d, J = 7.9, 1H), 7.05 (s, 1H), 7.03 (d, J = 1.9, 1H), 6.52 (d, J = 8.1, 1H), 
6.48 (s, 2H), 4.94 – 4.90 (m, 1H), 4.12 – 4.03 (m, 2H), 3.87 (dd, J = 11.7, 4.9, 1H), 3.41 – 
3.34 (m, 2H), 3.27 (dd, J = 13.6, 11.7, 1H), 3.11 – 2.99 (m, 4H), 2.56 – 2.49 (m, 1H), 
2.28 (s, 6H), 1.96 – 1.60 (m, 9H), 1.54 – 1.47 (m, 1H). 
(71) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(piperazin-1-ylmethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 49 (0.021 g, 0.038 mmol) to give product as a 
white solid. (MS)EI: 460.3 (M+Na), Retention Time: 14.44 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.06 (d, J = 8.0, 1H), 7.08 (d, J = 2.1, 1H), 7.01 (dd, J = 8.3, 2.1, 1H), 6.51 (d, 
J = 8.3, 1H), 6.48 (s, 2H), 4.95 – 4.90 (m, 1H), 3.99 (q, J = 12.9, 2H), 3.87 (dd, J = 11.6, 
4.8, 1H), 3.46 – 3.40 (m, 4H), 3.34 – 3.32 (m, 1H), 3.26 – 3.22 (m, 4H), 3.03 (td, J = 
13.3, 12.2, 5.1, 2H), 2.63 – 2.56 (m, 1H), 2.28 (s, 6H), 1.68 – 1.61 (m, 1H), 1.53 – 1.46 
(m, 1H). 
(72) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(morpholinomethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Followed procedure for compound 68 with 50 (0.13 g, 0.029 mmol) to give product as a 
white solid. (MS)EI: 461.3 (M+Na), Retention Time: 15.53 min. 1H-NMR (500 MHz, 
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CD3OD) δ 8.07 (d, J = 7.8, 1H), 7.07 (d, J = 1.7, 1H), 7.03 (dd, J = 8.4, 1.9, 1H), 6.51 (d, 
J = 8.3, 1H), 6.48 (s, 2H), 4.92 (t, J = 4.2, 1H), 4.15 – 4.05 (m, 2H), 4.01 (d, J = 12.5, 
2H), 3.87 (dd, J = 11.6, 4.8, 1H), 3.69 (t, J = 12.5, 2H), 3.28 – 3.22 (m, 3H), 3.11 – 2.99 
(m, 4H), 2.60 – 2.51 (m, 1H), 2.28 (s, 6H), 1.69 – 1.58 (m, 1H) 1.54 – 1.46 (m, 1H). 
(73) (S)-N-((R)-6-((1H-1,2,4-triazol-1-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with 51 (0.094 g, 0.22 mmol) to give product as a 
white solid. (MS)EI: 443.2 (M+Na), Retention Time: 15.29 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.46 (s, 1H), 8.11 (d, J = 7.9, 1H), 7.99 (s, 1H), 7.04 (d, J = 2.1, 1H), 6.99 (dd, 
J = 8.3, 2.1, 1H), 6.52 (d, J = 8.3, 1H), 6.47 (s, 2H), 5.24 – 5.13 (m, 2H), 4.95 – 4.89 (m, 
1H), 3.85 (dd, J = 11.6, 4.9, 1H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.05 – 2.96 (m, 2H), 2.58 
– 2.47 (m, 1H), 2.27 (s, 6H), 1.73 – 1.61 (m, 1H), 1.55 – 1.46 (m, 1H). 
(74) (S)-2-amino-N-((R)-6-(furan-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with 52 (0.051 g, 0.12 mmol) to give product as a 
white solid. (MS)EI: 420.2 (M+H), Retention Time: 20.22 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.21 (d, J = 7.9, 1H), 7.36 (t, J = 1.7, 1H), 7.21 (dd, J = 1.6, 0.9, 1H), 7.06 – 
7.00 (m, 2H), 6.76 (d, J = 8.3, 1H), 6.48 (s, 2H), 6.18 (dd, J = 1.9, 0.9, 1H), 5.01 – 4.95 
(m, 1H), 3.86 (dd, J = 11.5, 5.1, 1H), 3.64 (s, 2H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.15 – 
3.07 (m, 1H), 3.02 (dd, J = 13.6, 5.1, 1H), 2.63 (td, J = 12.0, 2.8, 1H), 2.27 (s, 6H), 1.88 – 
1.77 (m, 1H), 1.60 – 1.51 (m, 1H). 
(75) (S)-2-amino-N-((R)-6-(benzofuran-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
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Followed procedure for compound 68 with 53 (0.078 g, 0.16 mmol) to give product as a 
white solid. (MS)EI: 492.2 (M+Na), Retention Time: 30.25 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.13 (d, J = 8.0, 1H), 7.44 (d, J = 6.6, 1H), 7.31 (d, J = 7.9, 1H), 7.20 – 7.10 
(m, 2H), 7.00 (s, 1H), 6.98 (d, J = 2.1, 1H), 6.57 (d, J = 8.1, 1H), 6.48 (s, 2H), 6.34 (s, 
1H), 4.97 – 4.93 (m, 1H), 3.98 – 3.87 (m, 2H), 3.85 (dd, J = 11.5, 5.0, 1H), 3.25 (dd, J = 
13.6, 11.6, 1H), 3.04 – 2.96 (m, 2H), 2.52 (td, J = 11.7, 2.5, 1H), 2.27 (s, 6H), 1.77 – 1.69 
(m, 1H), 1.56 – 1.49 (m, 1H). 
(76) (S)-2-amino-N-((R)-6-(benzo[d][1,3]dioxol-5-ylmethyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with 54 (0.071 g, 0.15 mmol) to give product as a 
white solid. (MS)EI: 474.2 (M+H), Retention Time: 24.70 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.19 (d, J = 8.1, 1H), 7.01 – 6.88 (m, 2H), 6.67 (d, J = 7.9, 2H), 6.62 – 2.55 
(m, 2H), 6.48 (s, 2H), 5.85 (s, 2H), 4.99 – 4.92 (m, 1H), 3.86 (dd, J = 11.5, 5.1, 1H), 3.73 
(s, 2H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.12 – 2.97 (m, 2H), 2.64 – 2.52 (m, 1H), 2.27 (s, 
6H), 1.83 – 1.72 (m, 1H), 1.58 – 1.49 (m, 1H). 
(77) (S)-2-amino-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 55 (0.060 g, 0.12 mmol) to give product as a 
white solid. (MS)EI: 488.3 (M+H), Retention Time: 24.49 min. 1H-NMR (500 MHz, 
CD3OD) δ 6.96 (d, J = 2.0, 1H), 6.93 (dd, J = 8.2, 2.0, 1H), 6.67 (dd, J = 8.1, 6.8, 2H), 
6.58 – 6.54 (m, 2H), 6.48 (s, 2H), 4.96 (t, J = 4.6, 1H), 4.17 (s, 4H), 3.86 (dd, J = 11.5, 
5.1, 1H), 3.69 (s, 2H), 3.25 (dd, J = 13.6, 11.5, 1H), 3.07 (dt, J = 12.4, 4.5, 1H), 3.02 (dd, 
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J = 13.6, 5.1, 1H), 2.58 (td, J = 11.7. 2.7, 1H), 2.27 (s, 6H), 1.83 – 1.74 (m, 1H), 1.58 – 
1.50 (m, 1H).  
(78) (S)-2-amino-N-((R)-6-(2,6-dichlorobenzyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-
(4-hydroxy-2,6-dimethylphenyl)propanamide 
 Followed procedure for compound 68 with 56 (0.032 g, 0.63 mmol) to give product as a 
white solid. (MS)EI: 520.2 (M+Na), Retention Time: 30.67 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.20 (d, J = 7.6, 1H), 7.37 (d, J = 8.0, 2H), 7.21 (dd, J = 8.5, 7.5, 1H), 7.01 – 
6.93 (m, 1H), 6.77 – 6.72 (m, 1H), 6.54 (d, J = 8.3, 1H), 6.47 (s, 2H), 4.93 – 4.89 (m, 
1H), 4.22 – 4.11 (m, 2H), 3.86 (dd, J = 11.5, 5.1, 1H), 3.25 (dd, J = 13.6, 11.5, 1H), 3.00 
(dd, J = 13.4, 5.1, 2H), 2.52 – 2.40 (m, 1H), 2.27 (s, 6H), 1.78 – 1.66 (m, 1H), 1.58 – 1.49 
(m, 1H). 
(79) (S)-2-amino-N-((R)-6-benzhydryl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 57 (0.063 g, 0.12 mmol) to give product as a 
white solid. (MS)EI: 528.2 (M+Na), Retention Time: 35.41 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.19 (d, J = 7.9, 1H), 7.28 – 6.98 (m, 10H), 6.89 (d, J = 1.8, 1H), 6.76 (dd, J = 
8.4, 1.9, 1H), 6.57 (d, J = 8.4, 1H), 6.47 (s, 2H), 5.38 (s, 1H), 4.89 – 4.86 (m, 1H), 3.82 
(dd, J = 11.5, 5.1, 1H), 3.23 (dd, J = 13.5, 11.7, 1H), 3.05 – 2.92 (m, 2H), 2.46 (td, J = 
12.0, 2.4, 1H), 2.26 (s, 6H), 1.78 – 1.66 (m, 1H), 1.58 – 1.47 (m, 1H). 
(80) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(quinolin-6-ylmethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Followed procedure for compound 68 with 58 (0.017 g, 0.04 mmol) to give product as an 
oily yellow solid. (MS)EI: 481.3 (M+H), Retention Time: 16.70 min. 1H-NMR (500 
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MHz, CD3OD) δ 8.95 (d, J = 4.4, 1H), 8.68 (d, J = 8.3, 1H), 8.01 (d, J = 8.7, 1H), 7.86 (s, 
1H), 7.79 (d, J = 8.9, 2H), 6.95 (d, J = 2.0, 1H), 6.88 (dd, J = 8.6, 1.9, 1H), 6.49 (t, J = 
4.2, 1H), 6.48 (s, 2H), 4.92 – 4.90 (m, 1H), 4.04 (s, 2H), 3.85 (dd, J = 11.8, 5.2, 1H), 3.25 
(dd, J = 13.7, 11.6, 1H), 2.99 (td, J = 13.5, 4.7, 2H), 2.52 – 2.44 (m, 1H), 2.27 (s, 6H), 
1.73 – 1.64 (m, 1H), 1.54 – 1.47 (m, 1H). 
(81) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(quinolin-3-ylmethyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Followed procedure for compound 68 with 59 (0.020 g, 0.04 mmol) to give product as a 
pale yellow solid. (MS)EI: 481.3 (M+H), Retention Time: 18.69 min. 1H-NMR (400 
MHz, CD3OD) δ 8.92 (d, J = 2.0, 1H), 8.67 (s, 1H), 8.19 – 8.10 (m, 3H), 8.01 (ddd, J = 
8.4, 6.9, 1.4, 1H), 7.85 (ddd, J = 8.1, 6.9, 1.1, 1H), 7.03 (d, J = 2.0, 1H), 6.96 (dd, J = 8.3, 
2.1, 1H), 6.58 (d, J = 8.3, 1H), 6.47 (s, 2H), 4.97 – 4.92 (m, 1H), 4.14 (s, 2H), 3.87 (dd, J 
= 11.6, 5.0, 1H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.01 (dd, J = 13.3, 4.8, 2H), 2.54 (t, J = 
10.7, 1H), 2.27 (s, 6H), 1.75 – 1.64 (m, 1H), 1.56 – 1.44 (m, 1H).  
(82) (S)-2-amino-N-((R)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with 60 (0.040 g, 0.08 mmol) to give product as a 
white solid. (MS)EI: 507.3 (M+Na), Retention Time: 22.15 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.08 (d, J = 7.9, 1H), 7.33 – 7.21 (m, 3H), 7.18 – 7.05 (m, 3H), 6.54 (d, J = 
8.5, 1H), 6.48 (s, 2H), 4.98 – 4.90 (m, 1H), 4.38 – 4.16 (m, 5H), 3.87 (dd, J = 11.6, 4.9, 
1H), 3.78 – 3.65 (m, 1H), 3.28 – 3.21 (m, 1H), 3.21 – 3.10 (m, 2H), 3.09 – 2.98 (m, 2H), 
2.55 (t, J = 11.6, 1H), 2.28 (s, 6H), 1.70 – 1.60 (m, 1H), 1.58 – 1.46 (m, 1H). 
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(83) (S)-2-amino-N-((R)-6-((7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 61 to give product as a white solid. (MS)EI: 
525.3 (M+Na), Retention Time: 23.6 min. 1H-NMR (400 MHz, CD3OD) δ 1.43-1.59 (m, 
2H), 2.19 (s, 6H), 2.46 (m, 2H), 2.91-2.97 (m, 2H), 3.17 (m, 2H), 3.23 (m, 2H), 3.77 (dd, 
J = 5.2, 4 Hz, 2H), 4.16 (d, J = 10.4 Hz, 2H), 4.24 (m, 1H), 4.86 (m, 1H), 6.39 (s, 2H), 
6.45 (d, J = 6.8 Hz, 1H), 6.86 (m, 1H), 6.94-7.02 (m, 3H), 7.17 (dd, J = 4.4, 2.4 Hz, 1H), 
7.70 (m, 1H), 7.99 (d, J = 6.4 Hz, 1H), 8.62 (m, 1H).  
(84) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-((8-(trifluoromethyl)-
3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-
yl)propanamide 
Followed procedure for compound 68 with 62 (0.025 g, 0.044 mmol) to give product as a 
white solid. (MS)EI: 575.3 (M+Na), Retention Time: 27.7 min. 1H-NMR (400 MHz, 
CD3OD) δ 1.41-1.59 (m, 2H), 2.18 (s, 6H), 2.44 (m, 2H), 2.92 (m, 2H), 3.15 (m, 2H), 
3.23 (m, 2H), 3.77 (dd, J = 5.6, 4 Hz, 2H), 4.18-4.24 (m, 2H), 4.40 (m, 1H), 4.84 (m, 
1H), 6.39 (s, 2H), 6.45 (d, J = 6.8 Hz, 1H), 6.98 (d, J = 1.2 Hz, 1H), 7.03 (s, 1H), 7.39-
7.57 (dd, J = 42.8, 6.4 Hz, 2H), 7.44 (t, J = 6 Hz, 1H), 7.80 (m, 1H), 7.99 (d, J = 6.4 Hz, 
1H), 8.28 (m, 1H), 8.68 (s, 1H). 
(85) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-((7-methyl-3,4-
dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 63 (0.032 g, 0.063 mmol) to give product as a 
white solid. (MS)EI: 521.3 (M+Na), Retention Time: 25.70 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.14 – 7.05 (m, 4H), 6.96 (s, 1H), 6.55 (d, J = 8.3, 1H), 6.49 (s, 2H), 4.98 – 
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4.91 (m, 1H), 4.34 – 4.15 (m, 5H), 3.87 (dd, J = 11.7, 4.9, 1H), 3.75 – 3.65 (m, 1H), 3.29 
– 3.22 (m, 1H), 3.14 – 2.99 (m, 4H), 2.56 (t, J = 11.6, 1H), 2.30 (s, 3H), 2.28 (s, 6H), 
1.70 – 1.63 (m, 1H), 1.56 – 1.48 (m, 1H). 
 (86) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(isoindolin-2-
ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide) 
Followed procedure for compound 68 with 64 (0.062 g, 0.13 mmol) to give product as a 
white solid. (MS)EI: 493.3 (M+Na), Retention Time: 20.69 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.14 (d, J = 8.1, 1H), 7.38 (s, 4H), 7.12 (d, J = 2.1, 1H), 7.09 (dd, J = 8.3, 2.1, 
1H), 6.54 (d, J = 8.3, 1H), 6.48 (s, 2H), 4.98 – 4.89 (m, 1H), 4.68 – 4.51 (m, 4H), 4.42 – 
4.28 (m, 2H), 3.88 (dd, J = 11.7, 4.8, 1H), 3.25 (dd, J = 12.0, 4.0, 1H), 3.09 – 2.97 (m, 
2H), 2.57 (td, J = 12.1, 11.5, 3.1, 1H), 2.28 (s, 6H), 1.72 – 1.59 (m, 1H), 1.57 – 1.45 (m, 
1H). 
 (87) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(((4aR,8aS)-
octahydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-
yl)propanamide)  
Followed procedure for compound 68 with 65 (0.028 g, 0.056 mmol) to give product as a 
white solid. (MS)EI: 491.3 (M+H), Retention Time: 25.96 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.09 (d, J = 7.9, 1H), 7.05 (s, 1H), 7.02 (dd, J = 8.5, 1.7, 1H), 6.52 (d, J = 8.4, 
1H), 6.48 (s, 2H), 4.95 – 4.90 (m, 1H), 4.09 – 3.95 (m, 2H), 3.87 (dd, J = 11.7, 4.9, 1H), 
3.43 – 3.36 (m, 1H), 3.30 – 3.18 (m, 2H), 3.06 – 2.99 (m, 2H), 2.92 – 2.82 (m, 1H), 2.61 
– 2.50 (m, 2H), 2.28 (s, 6H), 1.86 – 0.95 (m, 14H). 
(88) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(((4aR,8aS)-
octahydroquinolin-1(2H)-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide 
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Followed procedure for compound 68 with 66 (0.029 g, 0.058 mmol) to give product as a 
white solid. (MS)EI: 513.3 (M+Na), Retention Time: 24.07 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.05 – 6.97 (m, 2H), 6.53 (dd, J = 8.0, 2.5, 1H), 6.49 (s, 2H), 4.96 – 4.91 (m, 
1H), 4.52 – 4.43 (m, 1H), 3.87 (dd, J = 11.5, 4.7, 1H), 3.80 – 3.71 (m, 1H), 3.28 – 3.21 
(m, 2H), 3.06 – 2.99 (m, 2H), 2.83 – 2.68 (m, 2H), 2.60 – 2.48 (m, 2H), 2.28 (s, 6H), 2.02 
– 1.10 (m, 14H). 
(89) (S)-N-((R)-6-((3-azaspiro[5.5]undecan-3-yl)methyl)-1,2,3,4-tetrahydroquinolin-
4-yl)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 67 (0.031 g, 0.060 mmol) to give product as a 
white solid. (MS)EI: 505.4 (M+H), Retention Time: 28.68 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.09 (d, J = 7.9, 1H), 7.05 (d, J = 2.1, 1H), 7.02 (dd, J = 8.4, 2.1, 1H), 6.51 (d, 
J = 8.3, 1H), 6.48 (s, 2H), 4.96 – 4.91 (m, 1H), 4.11 – 3.96 (m, 2H), 3.87 (dd, J = 11.7, 
4.9, 1H), 3.28 – 3.16 (m, 3H), 3.07 – 2.95 (m, 4H), 2.59 – 2.50 (m, 1H), 2.28 (s, 6H), 
1.86 (d, J = 14.6, 2H), 1.70 – 1.23 (m, 14H). 
(90) 3-bromo-N-(4-(morpholinomethyl)phenyl)propanamide 
To a stirring solution of 4-(morpholinomethyl)aniline (0.44 g, 2.26 mmol) and K2CO3 
(0.63 g, 4.53 mmol) in DCM (20 mL) was added 3-bromopropionyl chloride (0.24 mL, 
2.38 mmol) dropwise via syringe. The resulting cloudy solution was stirred at r.t. for 2 h, 
after which time the reaction mixture was transferred to a separatory funnel, and washed 
with sat. NaHCO3 (3x) and brine. The organic layer was dried with MgSO4, and solvents 
were filtered and removed under reduced pressure to give product as a white solid (0.68 
g, 91%). 1H-NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 7.52 (d, J = 8.4, 2H), 7.27 (d, J = 
8.4, 2H), 3.72 (t, J = 4.8, 2H), 3.70 – 3.63 (m, 6H), 3.50 (s, 2H), 2.95 (t, J = 6.6, 2H), 2.47 
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(t, J = 4.8, 2H); 13C-NMR (101 MHz, CDCl3) δ 168.52, 137.04, 129.94, 120.15, 66.65, 
62.63, 53.29, 40.26, 27.43. 
(91) N-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)-3-bromopropanamide) 
Followed procedure for compound 90 with 4-((1H-1,2,4-triazol-1-yl)methyl)aniline (0.51 
g, 2.92 mmol) to give product as a pale, spongy solid (0.79 g, 87%). 1H-NMR (400 MHz, 
CDCl3) δ 8.07 (s, 1H), 7.98 (s, 1H), 7.88 (s, 1H), 7.53 (d, J = 8.4, 2H), 7.22 (d, J = 8.4, 
2H), 5.30 (s, 2H), 3.70 (t, J = 6.5, 2H), 2.94 (t, J = 6.5, 2H); 13C-NMR (101 MHz, CDCl3) 
δ 168.29, 152.19, 143.11, 138.12, 130.57, 129.03, 120.59, 53.30, 40.65, 27.17. 
(92) N-(4-benzhydrylphenyl)-3-bromopropanamide 
Followed procedure for compound 90 with compound 100 (0.53 g, 2.0 mmol) to give 
product as a white solid (0.64 g, 80%). 1H-NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.5, 
2H), 7.33 – 7.05 (m, 12H), 5.51 (s, 1H), 3.69 (t, J = 6.5, 2H), 2.91 (t, J = 6.5, 2H); 13C-
NMR (101 MHz, CDCl3) δ 167.99, 143.83, 140.55, 135.71, 130.15, 129.50, 128.47, 
126.49, 120.16, 56.37, 40.78, 27.27. 
(93) 1-(4-(morpholinomethyl)phenyl)azetidin-2-one) 
To a dry round bottomed flask was added NaOtBu (0.21 g, 2.17 mmol) and placed under 
an inert atmosphere. DMF (30 mL) was then added via syringe. Compound 90 (0.68 g, 
2.06 mmol) was dissolved in DMF (20 mL) and added to the dissolved NaOtBu via 
cannula. The reaction was stirred under an inert atmosphere for 5 h, after which time 
DMF was removed under reduced pressure. The crude residue was redissolved in EtOAc 
(20 mL) and H2O (20 mL) was added. The aqueous layer was extracted with EtOAc (3x). 
Combined organic layers were washed with brine, and dried with MgSO4. Solvents were 
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filtered and removed, and the resulting yellow oil was used immediately without further 
purification.   
(94) 1-(4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)azetidin-2-one) 
Followed procedure for compound 93 with 91 (0.79 g, 2.56 mmol) to give product as a 
pale orange solid (0.38 g, 65%). 1H-NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.96 (s, 1H), 
7.36 (d, J = 8.5, 2H), 7.26 (d, J = 8.5, 2H), 5.30 (s, 2H), 3.63 (t, J = 4.5, 2H), 3.13 (t, J = 
4.5, 2H); 13C-NMR (101 MHz, CDCl3) δ 164.61, 152.30, 143.01, 138.86, 129.82, 129.24, 
116.72, 53.29, 38.22, 36.39. 
(95) 1-(4-benzhydrylphenyl)azetidin-2-one 
Followed procedure for compound 93 with 92 (0.64 g, 1.6 mmol) to give product as a 
white solid (0.23 g, 45%). 1H-NMR (400 MHz, CDCl3) δ 7.29 – 7.23 (m, 6H), 7.22 – 
7.16 (m, 2H), 7.11 – 7.04 (m, 6H), 5.50 (s, 1H), 3.52 (t, J = 4.5, 2H), 3.03 (t, J = 4.5, 2H); 
13C-NMR (101 MHz, CDCl3) δ 164.36, 143.81, 139.52, 136.88, 130.14, 129.38, 128.39, 
126.41, 116.13, 56.32, 38.04, 36.14. 
(96) 6-(morpholinomethyl)-2,3-dihydroquinolin-4(1H)-one 
Compound 93 (0.51 g, 2.06 mmol) was dissolved in DCE (30 mL). TfOH (0.55 mL, 6.18 
mmol) was then added carefully via syringe. The resulting bright red solution was stirred 
at r.t. for 3 h, after which time H2O (20 mL) was added. The reaction mixture was 
transferred to a separatory funnel, and sat. NaHCO3 was added. The aqueous layer was 
extracted with DCM (3x). Combined organic layers were dried with MgSO4, and solvents 
were filtered and removed under reduced pressure to give product as a yellow oil  (0.13 g, 
26%). 1H-NMR (400 MHz, CDCl3) δ 7.72 (d, J = 2.1, 1H), 7.32 (dd, J = 8.4, 2.1, 1H), 
6.66 (d, J = 8.4, 1H), 3.72 – 3.66 (m, 4H), 3.56 (td, J = 7.5, 7.1, 1.9, 2H), 3.38 (s, 2H), 
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2.68 (t, J = 7.0, 2H), 2.44 – 2.39 (m, 4H); 13C-NMR (101 MHz, CDCl3) δ 194.01, 151.60, 
136.56, 129.84, 119.97, 118.72, 116.15, 66.97, 62.62, 53.41, 42.49, 38.11. 
(97) 6-((1H-1,2,4-triazol-1-yl)methyl)-2,3-dihydroquinolin-4(1H)-one) 
Followed procedure for compound 96 with 94 (0.38 g, 1.67 mmol) to give product as a 
yellow oil that solidified upon standing after purification by column chromatography 
(12:1 DCM/MeOH, 1% Et3N), (0.10 g, 26%). 1H-NMR (400 MHz, CDCl3) δ 8.05 (s, 
1H), 7.94 (s, 1H), 7.81 (d, J = 2.0, 1H), 7.23 (dd, J = 8.5, 2.2, 1H), 6.69 (d, J = 8.5, 1H), 
5.21 (s, 2H), 4.80 (br s, 1H), 3.58 (td, J = 7.8, 7.4, 2.0, 2H), 2.69 (t, J = 6.8, 2H); 13C-
NMR (101 MHz, CDCl3) δ 193.24, 152.21, 152.17, 142.84, 135.11, 127.78, 123.62, 
118.96, 116.88, 53.16, 41.99, 37.83. 
(98) 6-benzhydryl-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 96 with 95 (0.23 g, 0.73 mmol) to give product as a 
yellow oil (0.24 g, 100%). 1H-NMR (400 MHz, CDCl3) δ 7.62 (d, J = 2.0, 1H), 7.27 – 
7.21 (m, 4H), 7.20 – 7.14 (m, 2H), 7.09 (d, J = 7.3, 4H), 7.05 (dd, J = 8.5, 2.2, 1H), 6.55 
(d, J = 8.5, 1H), 5.41 (s, 1H), 4.44 (br s, 1H), 3.45 (t, J = 6.5, 2H), 2.61 (t, J = 7.2, 2H); 
13C-NMR (101 MHz, CDCl3) δ 193.84, 150.82, 143.82, 136.42, 133.50, 129.30, 128.39, 
127.77, 126.36, 119.00, 116.16, 56.02, 42.46, 38.15. 
(99) ((4-nitrophenyl)methylene)dibenzene 
4-nitrobenzaldehyde (0.36 g, 2.4 mmol) was dissolved in anhydrous benzene (30 mL). 
TfOH (6 mL) was then added via syringe. The resulting bright red solution was stirred at 
50 °C under an inert atmosphere for 45 min, after which time it was poured slowly and 
carefully into cold water. The aqueous layer was extracted with DCM (3x). Combined 
organic extracts were washed with brine and dried with MgSO4. Solvents were filtered 
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and removed under reduced pressure to give product as a yellow solid (0.64 g, 93%). 1H-
NMR (500 MHz, CDCl3) δ 8.11 – 8.07 (m, 2H), 7.32 – 7.20 (m, 8H), 7.08 (d, J = 7.3, 
4H), 5.62 (s, 1H); 13C-NMR (126 MHz, CDCl3) δ 151.65, 146.53, 142.35, 130.29, 
129.35, 128.72, 126.98, 123.58, 56.65. 
(100) 4-benzhydrylaniline 
To 10% Pd/C in a hydrogenation vessel was added compound 99 (0.64 g, 2.2 mmol) 
dissolved in 1:1 MeOH/EtOAc (30 mL). The mixture was shaken under 40 psi H2 for 1 h 
at r.t, after which time the mixture was filtered through a plug of Celite, and solvents 
were removed under reduced pressure. The residue was re-dissolved in DCM, and 2M 
NaOH was added. The aqueous layer was extracted with DCM (3x). Combined organic 
extracts were washed with brine and dried with MgSO4. Solvents were filtered and 
removed under reduced pressure to give product as an orange solid (0.53 g, 92%). 1H-
NMR (400 MHz, CDCl3) δ 7.22 (t, J = 7.6, 4H), 7.14 (t, J = 6.9, 2H), 7.09 (d, J = 7.6, 
4H), 6.85 (d, J = 8.3, 2H), 6.51 (d, J = 8.2, 2H), 5.41 (s, 1H), 3.43 (br s, 2H); 13C-NMR 
(101 MHz, CDCl3) δ 144.67, 144.54, 133.92, 130.24, 129.41, 128.24, 126.13, 115.03, 
56.03. 
(101) 3-azaspiro[5.5]undecane 
To a stirring solution of LAH (0.60 g, 15.9 mmol) in THF (20 mL) was added 3-
azaspiro[5.5]undecane-2,4-dione (0.29 g, 1.6 mmol) dropwise. The solution was heated 
to 70 °C and stirred at reflux for 26 h, after which time it was cooled to 0 °C and 
quenched with H2O (0.4 mL), 2M NaOH (0.4 mL) and H2O (2 mL) sequentially. The 
resulting slurry was diluted with DCM and filtered. The organic layer was washed with 
brine. Solvents were filtered and removed under reduced pressure to give product as a 
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yellow oil (0.16 g, 65%). 1H-NMR (500 MHz, CDCl3) δ 2.82 (t, J = 5.8, 4H), 1.43 (t, J = 
5.8, 4H), 1.39 – 1.24 (m, 10H); 13C-NMR (126 MHz, CDCl3) δ 41.16, 36.50, 35.93, 
30.97, 26.64, 21.22. 
(102) (S)-N-((R)-1-acetyl-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with the following modification: before coupling 
to Boc-Dmt, the HCl salt was stirred in 1:1 TFA/DCM (10 mL) for 30 minutes. 
TFA/DCM were removed under reduced pressure, and residue was dried under vacuum. 
After coupling to Boc-Dmt, DMF was removed under reduced pressure and the crude 
residue was passed through a plug of silica (1:1 hex/EtOAc). Solvents were removed 
under reduced pressure and residue was dried under vacuum. The residue was then stirred 
in excess 1:1 acetic anhydride/pyridine overnight under an inert atmosphere, after which 
time solvents were removed under reduced pressure and then stirred with 1:1 TFA/DCM 
(10 mL) to give a white solid after HPLC purification. (MS)EI: 527.3 (M+H), Retention 
Time: 22.35 min. 1H-NMR (400 MHz, CD3OD) δ 7.76 (s, 1H), 7.45 (s, 1H), 7.41 (dd, J = 
8.5, 2.1, 1H), 7.34 – 7.22 (m, 3H), 7.14 (d, J = 7.7, 1H), 6.52 (s, 2H), 4.98 (t, J = 6.0, 1H), 
4.43 (s, 2H), 4.36 (s, 2H), 3.87 (dd, J = 11.7, 4.9, 1H), 3.83 – 3.74 (m, 1H), 3.28 – 3.11 
(m, 4H), 3.05 (dd, J = 13.7, 4.9, 1H), 2.28 (s, 6H), 2.26 (s, 3H), 1.95 – 1.79 (m, 1H), 1.61 
– 1.44 (m, 1H). 
(103) (S)-N-((R)-1-acetyl-6-((7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
	   83	  
Followed procedure for compound 68 with the following modification: before coupling 
to Boc-Dmt, the HCl salt was stirred in 1:1 TFA/DCM (10 mL) for 30 minutes. 
TFA/DCM were removed under reduced pressure, and residue was dried under vacuum. 
After coupling to Boc-Dmt, DMF was removed under reduced pressure and the crude 
residue was passed through a plug of silica (1:1 hex/EtOAc). Solvents were removed 
under reduced pressure and residue was dried under vacuum. The residue was then stirred 
in excess 1:1 acetic anhydride/pyridine overnight under an inert atmosphere, after which 
time solvents were removed under reduced pressure and then stirred with 1:1 TFA/DCM 
(10 mL) to give a white solid after HPLC purification. (MS)EI: 545.3 (M+H), Retention 
Time: 22.8 min. 1H-NMR (400 MHz, CD3OD) δ 1.38-1.81 (m, 2H), 2.16 (s, 3 H), 2.19 (s, 
6 H), 2.94-3.81 (qd, J = 312.8, 4.8 Hz, 2H), 3.10 (m, 2H), 3.16 (m, 2H), 3.70-3.73 (m, 
1H), 4.27 (s, 2H), 4.34 (s, 2H), 4.88 (m, 1H), 6.42 (s, 2H), 6.85 (dd, J = 6.8, 2.4 Hz, 1H), 
6.96 (td, J = 6, 2.4 Hz, 1H), 7.17 (dd, J = 5.2, 3.2 Hz, 1H), 7.31 (dd, J = 6.4, 2 Hz, 1H), 
7.36 (s, 1H). 
(104) (S)-N-((R)-1-acetyl-6-((8-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-
yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
Followed procedure for compound 68 with the following modification: before coupling 
to Boc-Dmt, the HCl salt was stirred in 1:1 TFA/DCM (10 mL) for 30 minutes. 
TFA/DCM were removed under reduced pressure, and residue was dried under vacuum. 
After coupling to Boc-Dmt, DMF was removed under reduced pressure and the crude 
residue was passed through a plug of silica (1:1 hex/EtOAc). Solvents were removed 
under reduced pressure and residue was dried under vacuum. The residue was then stirred 
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in excess 1:1 acetic anhydride/pyridine overnight under an inert atmosphere, after which 
time solvents were removed under reduced pressure and then stirred with 1:1 TFA/DCM 
(10 mL) to give a white solid after HPLC purification. (MS)EI: 595.3 (M+H), Retention 
Time: 26.5 min. 1H-NMR (400 MHz, CD3OD) δ 1.46-1.90 (m, 2H), 2.25 (s, 3 H), 2.28 (s, 
6 H), 3.03-3.89 (qd, J = 289.2, 4.8 Hz, 2H), 3.24-3.30 (m, 4H), 3.60 (br. s, 2H), 3.80-3.85 
(m, 1H), 4.48 (m, 1H), 4.56 (s, 2H), 4.97 (m, 1H), 6.51 (s, 2H), 7.42 (d, J = 6.4 Hz, 1H), 
7.48-7.55 (m, 3H), 7.66 (d, J = 6.8 Hz, 1H), 7.74 (m, 1H), 8.24 (d, J = 8 Hz, 1H). 
(105) (S)-N-((R)-1-acetyl-6-(isoindolin-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide) 
Followed procedure for compound 68 with the following modification: before coupling 
to Boc-Dmt, the HCl salt was stirred in 1:1 TFA/DCM (10 mL) for 30 minutes. 
TFA/DCM were removed under reduced pressure, and residue was dried under vacuum. 
After coupling to Boc-Dmt, DMF was removed under reduced pressure and the crude 
residue was passed through a plug of silica (1:1 hex/EtOAc). Solvents were removed 
under reduced pressure and residue was dried under vacuum. The residue was then stirred 
in excess 1:1 acetic anhydride/pyridine overnight under an inert atmosphere, after which 
time solvents were removed under reduced pressure and then stirred with 1:1 TFA/DCM 
(10 mL) to give a white solid after HPLC purification. (MS)EI: 513.3 (M+H), Retention 
Time: 20.87 min. 1H-NMR (500 MHz, CD3OD) δ 7.75 (br s, 1H), 7.49 – 7.34 (m, 6H), 
6.52 (s, 2H), 4.99 (t, J = 6.1, 1H), 4.69 – 4.59 (m, 4H), 4.58 – 4.49 (m, 2H), 3.89 (dd, J = 
11.7, 4.8, 1H), 3.86 – 3.75 (m, 1H), 3.29 – 3.19 (m, 2H), 3.06 (dd, J = 13.7, 4.8, 1H), 2.29 
(s, 6H), 2.26 (s, 3H), 1.94 – 1.83 (m, 1H), 1.55 – 1.46 (m, 1H). 
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(106) (S)-N-((R)-1-acetyl-6-(((4aR,8aS)-octahydroisoquinolin-2(1H)-yl)methyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide) 
Followed procedure for compound 68 with the following modification: before coupling 
to Boc-Dmt, the HCl salt was stirred in 1:1 TFA/DCM (10 mL) for 30 minutes. 
TFA/DCM were removed under reduced pressure, and residue was dried under vacuum. 
After coupling to Boc-Dmt, DMF was removed under reduced pressure and the crude 
residue was passed through a plug of silica (1:1 hex/EtOAc). Solvents were removed 
under reduced pressure and residue was dried under vacuum. The residue was then stirred 
in excess 1:1 acetic anhydride/pyridine overnight under an inert atmosphere, after which 
time solvents were removed under reduced pressure and then stirred with 1:1 TFA/DCM 
(10 mL) to give a white solid after HPLC purification. (MS)EI: 533.3 (M+H), Retention 
Time: 25.60 min. 1H-NMR (500 MHz, CD3OD) δ 7.75 (br s, 1H), 7.35 (d, J = 7.3, 2H), 
6.52 (s, 2H), 4.98 (t, J = 5.8, 1H), 4.27 – 4.13 (m, 2H), 3.87 (dd, J = 11.7, 4.8, 1H), 3.83 – 
3.74 (m, 1H), 3.48 – 3.39 (m, 1H), 3.36 – 3.32 (m, 1H), 3.29 – 3.22 (m, 1H), 3.22 – 3.13 
(m, 1H), 3.05 (dd, J = 13.6, 4.8, 1H), 3.01 – 2.90 (m, 1H), 2.66 (t, J = 12.0, 1H), 2.28 (s, 
6H), 2.25 (s, 3H), 1.92 – 0.95 (m, 14H). 
2.4.2 In Vitro Assays 
Binding affinity (Ki) was measured by the competitive displacement of [3H]-
diprenorphine (a non-selective opioid antagonist) in C6 cells stably expressing MOR or 
DOR, or Chinese Hamster Ovary (CHO) cells stably expressing KOR. In vitro potencies 
(EC50) and efficacies (as maximal % stimulation) were obtained by agonist-stimulated 
[35S]-GTPγS binding in the same cell types using previously described protocols.42,86 
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2.4.3 Animals and Antinociception  
Adult male C57BL/6 mice, purchased from Harlan Laboratories (IN, USA) and 
weighing between 20-30g at 8-16 weeks old, were used for the described experiments. 
Mice were group-housed and had free access to food and water at all times. Experiments 
were conducted in the housing room, which was maintained on a 12h light/dark cycle 
(with lights on at 0700). Each mouse was used only once and experiments were 
conducted between 9 am and 5 pm. Studies were performed in accordance with the 
University of Michigan Committee on the Use and Care of Animals and the Guide for the 
Care and Use of Laboratory Animals. 
All compounds were dissolved in sterile saline and administered by 
intraperitoneal injection in a volume of 10 mL/kg of body weight. Antinociceptive effects 
were evaluated in the warm water tail withdrawal (WWTW) assay. Tail withdrawal 
latencies were determined by briefly placing a mouse into a plastic, cylindrical restrainer 
and putting 2-3 cm of the tail tip into a water bath maintained at 50°C.  The latency to tail 
withdrawal or rapidly flicking the tail back and forth was recorded with a maximum 
cutoff time of 20 sec. If the mouse did not remove its tail by the cutoff time, the 
experimenter removed its tail from the water to prevent tissue damage.  
Acute antinociceptive effects were determined using a cumulative dosing 
procedure. Each animal received an injection of saline ip and then 30 min later, baseline 
withdrawal latencies (3-6 sec) were recorded. Following baseline determinations, 
increasing cumulative doses of the test compound were given ip at 30 min intervals. 
Thirty min after each injection, the tail withdrawal latency was measured as described 
above.  
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CHAPTER 3 
FURTHER MODIFICATIONS TO THE THQ PEPTIDOMIMETICSb 
 
3.1 Introduction 
 In order to better understand the metabolism of the THQ peptidomimetics in order 
to develop compounds with a longer total duration of action in vivo, compound 1 was 
incubated in mouse liver microsomes, and the resulting metabolites were analyzed via 
LC/MS/MS.  The compound was found to have a half-life of < 5 minutes in this assay, 
and several major phase 1 metabolic hotspots were identified, as shown in Figure 18.  
Figure 18. Metabolic Hotspots of Compound 1 in Mouse Liver Microsomes 
 
 
 
 
 
 The three major areas of the compound found to be the most subject to oxidation 
were the benzyl pendant, the THQ core, and the aromatic portion of the 2’6’-dimethyl-L-
tyrosine moiety. This information was used to guide further SAR on the THQ scaffold, 
namely the replacement of the proposed metabolically labile positions with substitutions 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
b In vitro assays were performed by Nicholas Griggs and Mary Clark. In vivo work was done by Jessica 
Anand. Compound 199 was synthesized by Aubrie Harland. Compounds 138, 139, 141 and 142 were 
synthesized by Jeff Zwicker. 
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known to block or slow phase 1 metabolism. It was thought that compounds with a longer 
half-life in mouse liver microsomes would lead to analogues with a longer duration of 
action in vivo. Modifications were thus made (1) on the di-benzylic position between the 
pendant and the THQ core, and (2) to the THQ core itself to discourage aromatization. 
Although none of the compounds subsequently tested in mouse liver microsomes were 
found to improve upon the metabolic half-life of compound 1 (the half-life of all 
compounds tested was found to be < 5 minutes), the modifications made to these three 
areas led to a number of analogues with interesting in vitro profiles. Changes to areas of 
this scaffold other than the aromatic pendant group (discussed in Chapter 2) have proven 
invaluable as a means by which to toggle selectivity between the different opioid receptor 
types.  
 
RESULTS AND DISCUSSION 
3.2 Modifications to the Di-Benzylic Position 
 Carbon atoms adjacent to an aromatic system are known to be particularly 
susceptible to phase 1 metabolic oxidation,87 and it was hypothesized based on 
LC/MS/MS analysis that the THQ analogues submitted for stability testing in mouse liver 
microsomes were likely getting hydroxylated at the di-benzylic position adjacent to the 
pendant (Chapter 2). This position was therefore initially replaced with oxygen, resulting 
in a diaryl ether system. An oxygen substitution at this position would certainly block any 
type of oxidation, and diaryl ether compounds are known to be particularly resistant to 
metabolic degradation.88 
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The first two analogues in this series, 115 and 116, were synthesized as shown in 
Scheme 8. Commercially available 4-phenoxyaniline was acylated with 3-
bromopropionyl chloride to give 107, which was then cyclized as the β-lactam and 
rearranged under Friedel-Crafts conditions to give ketone intermediate 109.  
Scheme 8. Synthesis of Analogues 115 and 116 
 
 
 
 
 
 
 
 
 
 
Ketone 109 was then carried forward without modification, and with first introducing an 
acetyl group (110). Since it was found that substituting the THQ nitrogen with an acyl 
group often increased binding affinity at DOR (Chapter 2), a similar modification in this 
series was attempted. Oxime formation on both intermediates and subsequent 
hydrogenation gave racemic amine intermediates 113 and 114, to which Boc-protected 
2’,6’-dimethyl-L-tyrosine could be coupled and deprotected with TFA to give 115 and 
116 as two different diastereomers which could be separated by RP-HPLC to give four 
total analogues (115E, 115L, 116E, and 116L). 
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 Given that the early eluting diastereomer for both of these compounds (115E and 
116E) showed a much better in vitro profile than the late eluting diastereomer as shown 
in Table 4 (like the straight chain alkyl analogues discussed in Chapter 2), the remainder 
of the analogues in this series were synthesized asymmetrically to give the presumed R 
stereochemistry at position 4, similar to the chemistry shown in Scheme 3 (Chapter 2). 
The synthesis of these analogues was carried forward starting from commercially 
available substituted 4-phenoxyanilines, as shown in Scheme 9.  
Scheme 9. Synthesis of Analogues 138-143 
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In addition to oxygen, the di-benzylic position was also replaced with a thioether 
and a sulfonyl moiety (Scheme 11), both starting from commercially available (4-
nitrophenyl)(phenyl)sulfane (Scheme 10) to give analogues 157 and 158. 
Scheme 10. Synthesis of Intermediates 144 and 146 
 
Scheme 11. Synthesis of Analogues 157 and 158 
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tetrahydronaphthalene (THN) core were synthesized (169-173, Scheme 12), as well as a 
THN analogue without any substitution at the 6 position (174). 
 
Scheme 12. Synthesis of Analogues 169-174a 
 
 
 
 
 
 
 
 
a. See ref. 61 for synthesis of N-Boc and N-Ac starting materials. 
Binding affinity and efficacy data for analogues modified at the benzylic position 
is summarized in Table 4.  
 
Table 4. Opioid Receptor Binding Affinities and Efficacies for Analogues Modified at 
the di-benzylic Positiona 
 
  MOR DOR KOR 
 R X Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1E  NH 0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
115E  NH 0.42 ± 0.04 15 ± 5 68 ± 2 14 ± 7 dns dns 65 ± 10** 957* 24* 
115L  NH 41 ± 6 - - 277 ± 50** 2000* 20* - - - 
116E  NAc 0.09 ± 0.02 6.5 ± 3 77 ± 3 4.2 ± 1.3 222* 16* 33 ± 0.1** 1084* 37* 
X
R
HN
OH
O
NH2
O
O
O
X
Br
O
X
R
O
X
R
HN S
O
X
R
HN
OH
O
NH2
1) conc. HCl, dioxane
2) Boc-Dmt, PyBOP, HOBt-Cl, 
DIPEA, DMF
3) TFA, DCM
S
O
H2N
1) Ti(OEt)4, THF, reflux
2) NaBH4, THF
159, R = phenyl, X = NBoc
160, R = phenyl, X = NAc
161, R = phenyl, X = CH2
162, R = 1-naphthyl, X = CH2
163, R = 2-naphthyl, X = CH2
boronic acid, Pd(dppf)Cl2, 
K2CO3, acetone, H2O, 
microwave
164, R = phenyl, X = NBoc
165, R = phenyl, X = NAc
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173, R = 2-naphthyl, X = CH2
174, R = H, X = CH2
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    MOR   DOR   KOR  
 R X Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
116L  NAc 6.3 ± 1.4 600 ± 300 60 ± 2 93 ± 20** 204* 16* 787* - - 
138  NH 0.36 ± 0.04 33 ± 14 41 ± 6 10 ± 0.7** dns* dns* - - - 
139  NH 0.08 ± 0.01 9.1 ± 2 46 ± 19 2.59* - - - - - 
140  NH 0.1 ± 0.03 9.7 ± 1.3 53 ± 4 12.1 ± 3.5 dns dns 24.8* - - 
141  NAc 0.27 ± 0.05 32.3 ± 14 42 ± 12 2.7* - - - - - 
142  NAc 0.05 ± 0.01 8.1 ± 4.8 72 ± 2 5.0 ± 0.3 dns dns 21.02* 791.2* 55* 
143  NAc 0.1 ± 0.03 7 ± 1.5 61 ± 7 3.1 ± 0.7 dns dns 45 ± 7** 1819* 47* 
157  NH 0.45 ± 0.1 4.7 ± 1.4 52 ± 6 5.1 ± 0.5 dns* dns* 11 ± 6 1120* 22* 
158  NH 3.01 ± 1.9 32 ± 20 64 ± 9 2.9 ± 0.4 dns* dns* 26 ± 7 1307* 38* 
169  NH 1.1 ± 0.4 19 ± 3 31 ± 5 13.4 ± 4.3 dns dns 54 ± 4 930 ± 220 57 ± 3 
170  NAc 0.88 ± 0.4 5.6 ± 0.4 51 ± 8 1.3 ± 0.4 92 ± 9 47 ± 6 35.8 ± 17 291 ± 33 69 ± 5 
171  CH2 0.57 ± 0.3 9.5 ± 3 29 ± 2 4.0 ± 1.3 181 ± 28 21 ± 11 21 ± 4** 
321 ± 
180** 
46 ± 
2** 
172 
 
CH2 5.4 ± 3 dns dns 46 ± 30 dns dns 131 ± 42** dns dns 
173  CH2 0.24 ± 0.1 dns dns 6.03 ± 2 dns dns 
316 ± 
0.91** 
dns dns 
174 H CH2 25.7 ± 11 dns dns 
640 ± 
220** 
dns dns 2060 ± 580 dns* dns* 
a. dns = does not stimulate. See Table 1 for further in vitro details. * = n of 1, ** = n of 2. Dashed line 
indicates assay was not performed. Structure above table does not distinguish if compound was synthesized 
asymmetrically to give the 4R stereochemistry, or as a mixture. See individual schemes for specific 
stereochemistry information. 
 
The in vitro data for the diastereomeric pairs of diarylether analogues 115 and 116 
show a trend that is consistent with the analogous carbon analogues discussed in Chapter 
2. In both cases, the early eluting (and presumably R) diastereomer shows better binding 
affinity at both MOR and DOR, and N-acetylated compound 116E exhibits improved 
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DOR binding affinity as compared to 115E. Preliminary aryl substitutions on the 
diarylether pendant (138-143) are fairly well tolerated in terms of maintaining binding 
affinity at MOR and DOR, although MOR potency and efficacy is somewhat reduced in 
the case of ortho-methoxy substituted compounds 138 and 141. Thioether analogue 157 
displays improved MOR binding affinity as compared to sulfone analogue 158, although 
both compounds exhibit low nanomolar potency and moderately high MOR stimulation.  
Analogues 169-173, in which the aryl pendant is fused directly to the core of the 
molecule, display a broad range of binding affinities for MOR. N-acetylated analogue 
170 displays superior MOR stimulation (and DOR binding affinity) compared to the 
other analogues in this series. Additionally, 1-naphthyl analogue 172 shows a marked 
loss in MOR and DOR binding affinity as compared to 2-naphthyl analogue 173. Neither 
172 or 173 showed any stimulation at MOR or DOR, presumably due to steric clash 
between residues in the active site and the rigid, bulkier naphthyl group (as compared to 
the phenyl analogues). Compound 174, in which the 6-position pendant is removed 
entirely, leads to a loss of binding affinity and efficacy at MOR. 
 
3.3 Modifications to the THQ Core  
Given the observation that an acetyl substitution on the THQ nitrogen (Chapter 2) 
improves binding affinity at DOR, it was decided that a number of additional 
modifications should be made to this position. As shown in Scheme 13, commercially 
available 4-benzylaniline was acylated with 3-bromopropionyl chloride, and cyclized to 
the corresponding β-lactam with NaOtBu, and cyclized again to give substituted 
tetrahydroquinoline 14. Preliminary modifications to 14 at the THQ nitrogen were short 
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alkyl chains, namely a methyl and a 1-propyl substitution (introduced by heating with 
base and the appropriate alkyl iodide) to give ketone intermediates 177 and 178. These 
intermediates were carried forward as described previously in Scheme 8 to give final 
analogues 183 and 184 (Scheme 13). Additionally, ketone 14 was first reduced to give 
substituted tetrahydroquinoline 185, which was cyclized with N,N-dimethylacrylamide 
and trifluoromethanesulfonic anhydride to give tricyclic intermediate 18689 which was 
carried forward asymmetrically as previously described in Scheme 12 to give tricyclic 
analogue 188 (Scheme 14). Despite the superior MOR efficacy afforded by these 
analogues (Table 5), N-alkyl analogues of this nature were found to oxidize rapidly when 
left at room temperature, and further alkyl substitutions of this type were not explored.  
Scheme 13. Synthesis of Analogues 183 and 184 
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of varying length at this position. Starting again from ketone intermediate 14, these 
substitutions were introduced by stirring with the appropriate acid chloride and Et3N, or 
with the appropriate acid anhydride and pyridine to give N-acyl intermediates 189-193 
(Scheme 15). From the resulting N-acyl intermediates were then prepared the 
corresponding tert-butanesulfinamides as previously discussed, which were then cleaved 
with concentrated HCl, coupled to Boc-Dmt and deprotected to give final intermediates 
199-203 (Scheme 15).  
Scheme 14. Synthesis of Analogue 188 
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Scheme 15. Synthesis of Analogues 199-203 
 
  
 
 
 
 
 
 
The in vitro data for MOR, DOR and KOR for analogues with substitutions on the THQ 
nitrogen are summarized in Table 5. 
 
Table 5. Opioid Receptor Binding Affinities and Efficacies for Analogues Substituted at 
the THQ Nitrogena 
 
  MOR DOR KOR 
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1E H 0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
183E Me 0.56 ± 0.2 4 ± 0.9 102 ± 5 7.3 ± 4 dns dns 27.8 ± 0.7 2200 ± 1000 44 ± 8 
183L Me 71 ± 18 214 ± 40 72 ± 4 138 ± 30 dns dns 632 ± 80 dns dns 
184E 1-Pro 0.34 ± 0.2 16 ± 8 83 ± 3 1.7 ± 0.6 
2300 ± 
1000 
39 ± 5 72 ± 20 5000 ± 1000 38 ± 3 
188 
Scheme 
14 
0.39 ± 0.1 1.1 ± 0.5 95 ± 4 2.3 ± 0.8 
570 ± 
300** 
50 ± 14** 6.6 ± 3 1002* 78* 
199  0.13 ± 0.2 6 ± 1 76 ± 4 1.7 ± 0.6 68 ± 2 26 ± 3 87 ± 11 1340 ± 93 
29 ± 5 
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   MOR   DOR   KOR  
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
200  0.12 ± 0.01 5.1 ± 2 90 ± 7 
0.76 ± 
0.4 
41 ± 17 58 ± 6 27 ± 2** 1339* 14* 
201  0.1 ± 0.03 18 ± 15 53 ± 3 0.41* 8.1 ± 0.9** 44 ± 3** 99.6* 
1530 ± 
200** 
21 ± 
3** 
202 
 
0.1 ± 0.03 1.8 ± 0.3 82 ± 4 
0.35 ± 
0.01 
17.8 ± 8.5 70 ± 12 25 ± 5 dns dns 
203 
 
0.14 ± 0.09 2.1 ± 0.2 94 ± 5 
0.15 ± 
0.07 
5.6 ± 3 66 ± 10 41 ± 20 dns dns 
 a. dns = does not stimulate. See Table 1 for further in vitro details. * = n of 1, ** = n of 2. Structure above 
table does not distinguish if compound was synthesized asymmetrically to give the 4R stereochemistry, or 
as a mixture. See individual schemes for specific stereochemistry information. 
 
The early eluting diastereomer of methyl and propyl substituted analogues (183 
and 184 respectively) both display subnanomolar binding affinity for MOR and low 
nanomolar binding affinity for DOR, and both compounds are fully efficacious at MOR. 
Analogue 188, in which the propyl substituent is tied into the adjacent aromatic ring, 
displays a similar overall profile, but with improved binding affinity for KOR. In the case 
of N-acylated analogues 199-203, a longer and more bulky aliphatic group on the acyl 
chain corresponds to improved DOR binding affinity, and several of the analogues in this 
series, particularly cyclopropyl analogue 202 and cyclobutyl analogue 203, display high 
efficacy at DOR. 
 In addition to alkylation and acetylation of the THQ aniline, a number of other 
modifications to the THQ core were explored. Replacement at this position with an 
oxygen gave chroman analogue 210 (Scheme 16). This synthesis was accomplished 
through a Suzuki coupling between benzylboronic acid pinacol ester and iodo 
intermediate 206, which was synthesized as previously described from commercially 
O
O
O
O
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available chroman-4-one.90 Replacement with sulfur gave corresponding thiochroman 
analogue 214 (Scheme 17).  
Scheme 16. Synthesis of Analogue 210 
 
Scheme 17. Synthesis of Analogue 214 
 
Oxidation of thiochroman intermediate 212 gave sulfone analogue 217 (Scheme 18).  
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Scheme 18. Synthesis of Analogue 217 
 
In order to explore changes to the flexibility and orientation of the fused 6-
membered ring THQ core, analogues 223 and 224 (Scheme 19) were synthesized. In the 
case of analogue 224, the THQ core was replaced with a 5-6 fused indanyl core. 224 was 
tested as a racemic mixture, as the resulting diastereomers proved inseparable by RP-
HPLC. In the case of analogue 223, the THQ core is replaced with an open phenethyl 
core, and the resulting diastereomers were separated by RP-HPLC and tested 
individually.  
Scheme 19. Synthesis of Analogues 223 and 224 
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Lastly, the THQ core was widened by one methylene to give benzo[b]azepine derivative 
228 (Scheme 20). The results of these further modifications are summarized in Table 6.  
Scheme 20. Synthesis of Analogue 228 
 
 
 
 
 
 
 
 
Table 6. Opioid Receptor Binding Affinities and Efficacies for Analogues Featuring 
Replacements to the THQ Nitrogena 
 
   MOR DOR KOR 
 X n Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1E NH 1 0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
210E O 1 0.046 ± 0.03 4.9 ± 2 70 ± 6 8.7 ± 1.6 dns dns 58 ± 14 662 ± 150 28 ± 7 
210L O 1 6.1 ± 2 dns dns 260 ± 60** dns dns 354 ± 40 dns dns 
214 S 1 0.15 ± 0.04 1.9 ± 0.5 80 ± 8 4.8 ± 1 dns dns 48 ± 23 dns dns 
217 SO2 1 0.06 ± 0.01 0.72 ± 0.1 94 ± 3 1.9 ± 1 100 ± 60 44 ± 4 27 ± 6 720 ± 320 36 ± 2 
223E H 0 11.2 ± 6 201 ± 130 45 ± 13 75 ± 10** dns dns 516 ± 150** dns* dns* 
223L H 0 0.62 ± 0.1 55 ± 6 42 ± 10 62 ± 12 
1500 ± 
700 
12 ± 9 203 ± 13** dns dns 
224 Scheme 19 0.55 ± 0.09 18 ± 8 43 ± 9 30 ± 10** dns dns 143 ± 45** dns dns 
228 NH 2 0.41 ± 0.2 72 ± 23 73 ± 4 23 ± 2** dns dns 40 ± 20** dns* dns* 
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a. dns = does not stimulate. See Table 1 for further in vitro details. * = n of 1, ** = n of 2. Structure above 
table does not distinguish if compound was synthesized asymmetrically to give the 4R stereochemistry, or 
as a mixture. See individual schemes for specific stereochemistry information. 
 
 The early eluting diastereomer (presumably 4R) of chroman analogue 210 shows 
subnanomolar binding affinity and is fully efficacious at MOR. The same is true for 
thiochroman analogue 214 and sulfone analogue 217. 217 in particular displays superior 
potency at MOR, as well as the best DOR binding affinity in this series. This is consistent 
with the earlier observation that extensions at this position of the core ring result in 
improved binding affinity at DOR, and can often increase potency and simulation as well. 
Interestingly, the late-eluting diastereomer of phenethyl analogue 223 displays a better in 
vitro profile at MOR than the early eluting diastereomer, although both show a 
comparable maximal stimulation at this receptor. 223, 224 and 228 are all less potent at 
MOR than parent THQ compound 1, suggesting that these changes to the THQ ring’s 
size and flexibility profile are less than optimal.  
 
3.4 Preliminary Amide Bond Substitutions  
 Preliminary alkyl substitutions were also made to the amide bond between the 
THQ core and 2’,6’-dimethyl-L-tyrosine. Initially, a methyl substitution was examined, 
creating a tertiary amide bond that was hypothesized to be more resistant to metabolic 
degradation  (231, Scheme 21). Like the other analogues described herein, 231 was not 
found to improve upon the metabolic half-life of 1 (t1/2 < 5 min). Although the methyl 
substitution was found to not improve metabolic stability, analogue 232, in which the 
amide bond was substituted with a cyclopropyl group (known to be highly resistant to 
metabolic de-alkylation91,92) was also synthesized.  
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 231 and 232 were synthesized as shown in Scheme 21. In the case of 231, ketone 
intermediate 14 was subject to reductive amination conditions in the presence of 
Ti(OiPr)4, CH3NH2HCl, Et3N and NaBH4 as a reducing agent.93 In the case of analogue 
232, the reductive amination was performed with cyclopropylamine and NaBH3CN as the 
reducing agent under microwave conditions.94 Both intermediates were then coupled to 
Boc-2’,6’-dimethyl-L-tyrosine, deprotected, and purified by RP-HPLC to give two 
diastereomers that were tested separately (Table 7).  
 
Scheme 21. Synthesis of Analogues 231 and 232 
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Table 7. Opioid Receptor Binding Affinities and Efficacies for Both Diastereomers of 
Analogues 231 and 232a 
 
  MOR DOR KOR 
 R Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1E H 0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
231E Me 9 ± 0.3 3 ± 0.3 81 ± 5 16 ± 4 410 ± 140 13 ± 6 116 ± 30 dns dns 
231L Me 0.8 ± 0.04 0.46 ± 0.1 66 ± 4 8.5 ± 0.2 dns dns 4.1 ± 0.4 dns dns 
232E  26 ± 10 131 ± 20 16 ± 4 23 ± 11** 150 ± 40 20 ± 3 60 ± 30 dns dns 
232L  11 ± 6 28 ± 4 40 ± 11 53 ± 20 dns dns 29 ± 7** dns dns 
a. dns = does not stimulate. See Table 1 for further in vitro details. ** = n of 2. All analogues in this series 
were synthesized as a mixture of diastereomers.  
 
 Unlike previous analogues, the early eluting diastereomer of 231 (231E) displays 
weaker binding at all three opioid receptors than the late eluting diasteromer (231L). 
Presumably, the late eluting analogue in this case has the 4R stereochemistry, although 
the superior MOR maximal stimulation of 231E leaves this stereochemical assignment a 
bit ambiguous. Both diastereomers of cyclopropyl-substituted analogue 232 displayed 
low efficacy at MOR, and consequently bulkier substitutions on the amide bond were not 
explored.  
 
3.5 In Vivo Data for Selected Analogues 
 On the basis of their favorable in vitro profiles, compounds 116E, 143, 188, 202, 
203, 214, and 217 were chosen for in vivo studies. In the mouse warm water tail 
withdrawal (WWTW) assay (Figure 19), thiochroman analogue 214 was fully 
efficacious, and produced dose-dependent increases in latency to tail flick. All other 
N
H
N
OH
O
NH2
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analogues (including N-methyl amide analogue 231L) produced either weak or 
insignificant antinociception at 10 mg/kg.  
Figure 19. Cumulative Antinociceptive Dose-Response Curves for Analogues 116E, 
143, 188, 202, 203, 214, and 217 in the Mouse WWTW Assay After ip Administration (n 
= 3-6)a  
 
 
 
 
 
 
 
a. Data are plotted as mean ± SEM. 
To determine the duration of action of compound 214, tail withdrawal latencies 
were measured at intervals following the administration of a 10 mg/kg dose (Figure 20). 
Compound 214 showed a full antinociceptive response for just over 200 minutes before 
returning to baseline. Compared with the lead compound 1 (Figure 11), this compound 
displayed a much longer duration of action after ip injection (comparable to compounds 
86 and 102, see Figure 17, Chapter 2).  
Although compound 214 was the only analogue in this series that displayed 
potent, dose-dependent antinociception at a dose of up to 10 mg/kg, the SAR discussed 
here on the THQ core revealed a number of important trends. Substitution on the THQ 
nitrogen with short alkyl or acyl substitutions was generally well tolerated in terms of 
preserving the desired MOR agonist/DOR antagonist profile, and such substitutions 
generally increased binding affinity at DOR. Longer and bulkier acyl chains at this 
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position resulted in improved DOR potency and efficacy relative to DPDPE, and 
heteroatom replacements of the THQ aniline preserved sub-nanomolar binding affinities 
and good potencies at MOR. Conversely, entire replacement of the THQ core through 
ring expansion or contraction resulted in analogues that did not improve upon the 
unaltered THQ core. Furthermore, removal of flexibility in the 6-position pendant 
resulted in analogues with diminished potency and efficacy at MOR. 
 
Figure 20. Time Course of Antinociceptive Response For Analogue 214 in the Mouse 
WWTW Assay After ip Administration of a 10 mg/kg Dose 
 
 
 
 
 
 
 
 
3.6 Experimental Procedures 
3.6.1 Chemistry 
For further general chemistry, in vitro and in vivo experimental detail, see section 2.4. 
(107) 3-bromo-N-(4-phenoxyphenyl)propanamide 
To a dry flask was added 4-phenoxyaniline (5.03 g, 27.2 mmol) and K2CO3 (7.50 g, 54.3 
mmol), and placed under an inert atmosphere. DCM (70 mL) was then added via syringe, 
and 4-phenoxyaniline was allowed to dissolve. 3-bromopropionyl chloride (2.88 g, 28.5 
mmol) was then added dropwise, and the resulting cloudy mixture was stirred at r.t. for 2 
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h. The reaction was quenched with the addition of H2O, and transferred to a separatory 
funnel. The organic layer was washed with H2O (2x) and dried with MgSO4. Solvents 
were filtered and removed under reduced pressure to give product as a beige solid (7.72 
g, 89%). 1H-NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.51 – 7.42 (m, 2H), 7.32 (t, J = 7.9, 
2H), 7.08 (t, J = 7.4, 1H), 7.01 – 6.92 (m, 4H), 3.70 (t, J = 6.5, 2H), 2.93 (t, J = 6.5, 2H); 
13C-NMR (101 MHz, CDCl3) δ 168.19, 157.47, 153.99, 132.90, 129.93, 123.32, 122.21, 
119.65, 118.64, 40.60, 27.32. 
(108) 1-(4-phenoxyphenyl)azetidin-2-one 
NaOtBu (2.43 g, 25.3 mmol) was added to a dry flask and placed under an inert 
atmosphere. DMF (80 mL) was then added via syringe. 107 (7.71 g, 24.1 mmol) was 
dissolved in DMF (30 mL) and added dropwise. The mixture was allowed to stir at r.t. for 
2.5 h, after which time DMF was removed under reduced pressure. Crude residue was 
redissolved in EtOAc. H2O was added, and the aqueous layer was extracted with EtOAc. 
Combined organic layers were washed with brine and dried with MgSO4. Solvents were 
filtered and removed under reduced pressure, and crude residue was purified by column 
chromatography to give product as a tan solid (1.24 g, 22%). 1H-NMR (400 MHz, 
CDCl3) δ 7.35 – 7.26 (m, 4H), 7.06 (t, J = 7.4, 1H), 7.01 – 6.91 (m, 4H), 3.57 (t, J = 4.4, 
2H), 3.07 (t, J = 4.4, 2H); 13C-NMR (101 MHz, CDCl3) δ 164.09, 157.57, 152.80, 
134.42, 129.69, 122.97, 119.96, 118.13, 117.41, 38.13, 36.15. 
(109) 6-phenoxy-2,3-dihydroquinolin-4(1H)-one 
Compound 108 (1.24 g, 5.2 mmol) was dissolved in DCE (70 mL). TfOH (1.38 mL, 15.5 
mmol) was then added via syringe. The mixture was stirred at r.t. for 16 h, after which 
time it was quenched with the addition of K2CO3 (7 g) and H2O (0.5 mL) and allowed to 
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stir for 1 h. The mixture was then filtered through a plug of MgSO4 with DCM. Solvents 
were removed under reduced pressure to give product as a yellow solid (1.39 g, 100%). 
1H-NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.9, 1H), 7.28 – 7.21 (m, 2H), 7.06 – 6.97 (m, 
2H), 6.94 – 6.88 (m, 2H), 6.67 (d, J = 8.8, 1H), 4.80 (br s, 1H), 3.48 (t, J = 7.0, 2H), 2.63 
(t, 7.2, 2H); 13C-NMR (101 MHz, CDCl3) δ 193.47, 158.08, 149.15, 147.86, 129.58, 
128.29, 122.49, 119.23, 117.59, 117.40, 116.98, 42.18, 37.83. 
(110) 1-acetyl-6-phenoxy-2,3-dihydroquinolin-4(1H)-one 
Compound 109 (0.35 g, 1.47 mmol) was dissolved in pyridine (4 mL) under an inert 
atmosphere. (Ac)2O (5 mL) was then added dropwise via syringe. The mixture was 
stirred at r.t. for 16 h, after which time the mixture was poured onto H2O. Aqueous layer 
was extracted with DCM (3x). Combined organic extracts were washed with brine and 
dried with MgSO4. Solvents were filtered and removed under reduced pressure to give 
product as a yellow solid (0.38 g, 92%). 1H-NMR (400 MHz, CDCl3) δ 7.55 (d, J = 2.9, 
1H), 7.52 – 7.40 (m, 1H), 7.36 (t, J = 7.8, 2H), 7.22 (dd, J = 8.9, 3.0, 1H), 7.15 (t, J = 7.4, 
1H), 7.01 (d, J = 8.0, 2H), 4.21 (t, J = 6.1, 2H), 2.77 (t, J = 6.2, 2H), 2.34 (s, 3H); 13C-
NMR (101 MHz, CDCl3) δ 193.36, 169.23, 156.22, 154.92, 139.07, 130.01, 127.23, 
125.91, 124.50, 124.09, 119.22, 115.90, 44.19, 39.33, 23.07. 
(111) (E)-6-phenoxy-2,3-dihydroquinolin-4(1H)-one oxime 
Compound 109 (0.38 g, 1.6 mmol) was dissolved in 1:1 EtOH/H2O (30 mL). 
NH2OHHCl (0.30 g, 4.7 mmol) and NaOAc3H2O (0.64 g, 4.7 mmol) were then added. 
The mixture was heated to 90 °C and stirred for 22 h, after which time EtOH was 
removed under reduced pressure. EtOAc was added, and the aqueous layer was extracted 
with EtOAc. Combined organic extracts were washed with brine, and dried with MgSO4. 
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Solvents were filtered and removed under reduced pressure to give product (0.29 g, 
97%). 1H-NMR (500 MHz, DMSO-d6) δ 10.91 (s, 1H), 7.36 – 7.30 (m, 2H), 7.26 (d, J = 
2.8, 1H), 7.05 (t, J = 7.4, 1H), 6.92 (d, J = 7.9, 2H), 6.85 (dd, J = 8.8, 2.8, 1H), 6.71 (d, J 
= 8.7, 1H), 5.99 (s, 1H), 3.14 (td, J = 6.5, 1.9, 2H), 2.66 (t, J = 6.5, 2H); 13C-NMR (126 
MHz, DMSO-d6) δ 158.57, 149.96, 147.37, 144.74, 130.26, 122.83, 122.34, 117.80, 
117.53, 117.31, 113.87, 40.02, 23.44. 
(112) (E)-1-(4-(hydroxyimino)-6-phenoxy-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one 
Followed procedure for compound 111 with 110 (0.38 g, 1.4 mmol) to give product as a 
brown solid after purification by column chromatography (1:1 hex/EtOAc) (0.30 g, 75%). 
1H-NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 7.51 (d, J = 2.8, 1H), 7.32 (t, J = 7.8, 2H), 
7.10 (t, J = 7.4, 1H), 7.05 – 6.95 (m, 3H), 3.94 (br s, 2H), 2.89 (t, J = 6.3, 2H), 2.22 (br s, 
3H); 13C-NMR (126 MHz, CDCl3) δ 169.95, 156.66, 155.25, 151.42, 135.29, 129.87, 
127.59, 125.71, 123.71, 119.93, 119.05, 114.16, 40.68, 25.96, 22.53. 
(113) 6-phenoxy-1,2,3,4-tetrahydroquinolin-4-amine 
Compound 111 was dissolved in MeOH, and added to 10% Pd/C in a hydrogenation 
vessel. AcOH (3 drops) was then added. The mixture was shaken on the hydrogenation 
apparatus for 18 h at 35 psi, after which time the mixture was filtered through Celite, and 
MeOH was removed under reduced pressure. 1M HCl was added, and the organic layer 
was discarded. Aqueous layer was basified with solid NaOH (pH 14), and was extracted 
with DCM (3x). Combined organic extracts were dried with MgSO4, and solvents were 
filtered and removed. Crude residue was purified by column chromatography (9:1 
DCM/MeOH) to give product as a colorless oil (0.10 g, 30%). 1H-NMR (400 MHz, 
CDCl3) δ 7.23 (t, J = 7.8, 2H), 7.00 – 6.94 (m, 2H), 6.89 (d, J = 8.1, 2H), 6.73 (dd, J = 
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8.8, 2.6, 1H), 6.45 (d, J = 8.6, 1H), 4.02 (t, J = 4.8, 1H), 3.36 (td, J = 11.0, 10.5, 3.4, 1H), 
3.28 – 3.17 (m, 1H), 2.06 – 1.95 (m, 1H), 1.95 – 1.85 (m, 1H); 13C-NMR (101 MHz, 
CDCl3) δ 159.04, 147.15, 141.09, 129.58, 123.81, 122.01, 120.96, 120.90, 117.09, 
115.74, 46.95, 37.59, 29.87.  
(114) 1-(4-amino-6-phenoxy-3,4-dihydroquinolin-1(2H)-yl)ethan-1-one 
Followed procedure for 113 with 112 (0.30 g, 1.03 mmol) to give product as a colorless 
oil (0.092 g, 32%). 1H-NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.8, 2H), 7.15 – 7.08 (m, 
2H), 7.02 (d, J = 7.9, 2H), 6.88 (dd, 1H), 3.89 (br s, 1H), 3.62 (br s, 1H), 2.30 – 2.14 (m, 
4H), 1.59 (br s, 2H).  
(115) (2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-(6-phenoxy-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide 
Compound 113 (0.042 g, 0.18 mmol) was dissolved in DMF (6 mL), and placed under an 
inert atmosphere. DIPEA (0.030 mL, 1.75 mmol) was added dropwise via syringe, 
followed by PyBOP (0.091 g, 0.18 mmol) and HOBt-Cl (0.030 g, 0.18 mmol). Boc-L-
Dmt (0.072 g, 0.18 mmol) was dissolved in DMF (3 mL) and added dropwise via 
syringe. The mixture was stirred at r.t. for 5 h, after which time DMF was removed under 
reduced pressure. Crude residue was redissolved in EtOAc. 5% citric acid solution was 
added, and the aqueous layer was extracted with EtOAc. Combined organic extracts were 
washed with brine and dried with MgSO4. Solvents were filtered and removed under 
reduced pressure, and crude residue was redissolved in 1:1 DCM/TFA solution (10 mL) 
and stirred for 1.5 h. Solvents were removed under reduced pressure, and residue was 
purified by semipreparative RP-HPLC and lyophilized to give product as a white solid. 
(115E): MS(EI): 432.2 (M+H), Retention Time: 24.37 min. 1H-NMR (400 MHz, 
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CD3OD) δ (d, J = 8.0, 1H), 7.29 – 7.22 (m, 2H), 7.02 – 6.97 (m, 1H), 6.87 – 6.80 (m, 
3H), 6.73 (dd, J = 8.7, 2.7, 1H), 6.65 (d, J = 8.7, 1H), 6.49 (s, 2H), 4.98 – 4.93 (m, 1H), 
3.84 (dd, J = 11.6, 5.0, 1H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.12 – 3.04 (m, 1H), 3.01 (dd, J 
= 13.7, 5.0, 1H), 2.63 (td, J = 12.1, 11.4, 2.8, 1H), 2.28 (s, 6H), 1.82 – 1.72 (m, 1H), 1.57 
– 1.48 (m, 1H). (115L): MS(EI): 432.2 (M+H), Retention Time: 27.33 min.  
(116) (2S)-N-(1-acetyl-6-phenoxy-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for 115 with 114 (0.044 g, 0.16 mmol) to give product as a white 
solid. (116E): MS(EI): 474.2 (M+H), Retention Time: 31.01 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.19 (d, J = 8.1, 1H), 7.36 – 7.29 (m, 2H), 7.09 (t, J = 7.4, 1H), 7.01 (s, 1H), 
6.95 – 6.91 (m, 2H), 6.83 (dd, J = 8.9, 2.8, 1H), 6.52 (s, 2H), 4.99 – 4.91 (m, 1H), 3.84 
(dd, J = 11.5, 5.0, 1H), 3.25 (dd, J = 13.7, 11.5, 1H), 3.04 (dd, J = 13.7, 5.0, 1H), 2.28 (s, 
6H), 2.21 (s, 3H), 1.95 – 1.84 (m, 1H), 1.44 (br s, 1H). (116L): MS(EI): 474.2 (M+H), 
Retention Time: 32.80 min. 
(117) 3-bromo-N-(4-(2-methoxyphenoxy)phenyl)propanamide 
Followed procedure for 107 with 4-(2-methoxyphenoxy)aniline (0.70 g, 3.25 mmol) to 
give product as a pale solid (100%). 1H-NMR (400 MHz, CDCl3) δ 8.12 (brs, 1H), 7.42 
(d, J = 8.6, 2H), 7.12 (t, J = 7.0, 1H), 6.99 (d, J = 7.8, 1H), 6.81 – 6.96 (m, 4H), 3.81 (s, 
3H), 3.65 (t, J = 5.7, 2H), 2.89 (t, J = 5.9, 2H).  
(118) 3-bromo-N-(4-(3-chlorophenoxy)phenyl)propanamide 
Followed procedure for 107 with 4-(3-chlorophenoxy)aniline (0.69 g, 3.13 mmol) to give 
product as a purple solid (100%). 1H-NMR (500 MHz, CDCl3) δ 7.52 (m, 2H), 7.40 (br s, 
1H), 7.24 (t, J = 8.1, 1H), 7.06 (d, J = 7.8, 1H), 7.01 (m, 2H), 6.96 (s, 1H), 6.87 (d, J = 
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8.3, 1H), 3.73 (t, J = 6.6, 2H), 3.02 – 2.92 (m, 2H); 13C-NMR (126 MHz, CDCl3) δ 
167.95, 158.45, 152.87, 135.05, 133.44, 130.48, 123.14, 121.98, 120.12, 118.42, 116.34, 
40.58, 27.05.  
(119) 3-bromo-N-(4-(4-chlorophenoxy)phenyl)propanamide 
Followed procedure for 107 with 4-(4-chlorophenoxy)aniline (0.69 g, 3.13 mmol) to give 
product as a pale solid (1.05 g, 95%). 1H-NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.9, 
2H), 7.27 (d, J = 9.5, 2H), 6.98 (d, J = 8.9, 2H), 6.91 (d, J = 8.9, 1H), 3.72 (t, J = 6.5, 
2H), 2.95 (t, J = 6.5, 2H); 13C-NMR (101 MHz, CDCl3) δ 167.98, 156.25, 153.58, 
133.27, 129.86, 128.30, 122.07, 119.81, 40.74, 27.24.  
(120) 1-(4-(2-methoxyphenoxy)phenyl)azetidin-2-one 
Followed procedure for 108 with 117 (1.0 g, 0.35 mmol) to give product as a orange solid 
which was not characterized and used without further purification.  
(121) 1-(4-(3-chlorophenoxy)phenyl)azetidin-2-one 
Followed procedure for 108 with 118 (1.05 g, 2.96 mmol) to give product as a dark 
purple solid (82%). 1H-NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 7.37 (d, J = 8.8, 2H), 
7.23 (t, J = 8.1, 1H), 7.07 – 6.97 (m, 3H), 6.92 (s, 1H), 6.87 – 6.81 (m, 1H), 3.64 (t, J = 
4.4, 2H), 3.13 (t, J = 4.4, 2H). 
(122) 1-(4-(4-chlorophenoxy)phenyl)azetidin-2-one 
Followed procedure for 108 with 119 (1.05 g, 2.96 mmol) to give product as a light 
orange solid (0.71 g, 87%). 1H-NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.8, 2H), 7.25 (d, 
J = 8.8, 2H), 6.98 (d, J = 8.8, 2H), 6.88 (d, J = 8.8, 2H), 3.61 (t, J = 4.4, 2H), 3.11 (t, J = 
4.4, 2H); 13C-NMR (101 MHz, CDCl3) δ 164.28, 156.39, 152.53, 134.81, 129.73, 127.98, 
120.14, 119.41, 117.61, 38.28, 36.28.  
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(123) 6-(2-methoxyphenoxy)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 109 with 120 (0.80 g, 2.97 mmol) to give product as a 
yellow oil (20-65%). 1H-NMR (500 MHz, CDCl3) δ 7.39 (d, J = 2.9, 1H), 7.11 – 7.04 (m, 
2H), 6.97 (d, J = 7.8, 1H), 6.86 (d, J = 3.9, 2H), 6.66 (d, J = 8.8, 1H), 3.90 – 3.77 (m, 3H), 
3.54 (t, J = 7.1, 2H), 2.66 (t, J = 7.1, 2H); 13C-NMR (101 MHz, CDCl3) δ 193.27, 150.81, 
149.45, 148.43, 146.15, 127.09, 124.10, 121.06, 119.65, 119.48, 117.29, 115.27, 112.72, 
55.98, 42.55, 38.06.  
(124) 6-(3-chlorophenoxy)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 109 with 121 (0.80 g, 2.9 mmol) to give product as a 
yellow oil (33-65%). 1H-NMR (500 MHz, CDCl3) δ 7.51 (d, J = 2.9, 1H), 7.19 (t, J = 8.1, 
1H), 7.05 (dd, J = 8.6, 2.7, 1H), 7.00 (d, J = 7.8, 1H), 6.88 (s, 1H), 6.82 (d, J = 8.3, 1H), 
6.71 (d, J = 8.8, 1H), 4.50 (brs, 1H), 3.58 (t, J = 6.4, 2H), 2.78 – 2.57 (m, 2H). 
(125) 6-(4-chlorophenoxy)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 109 with 122 (0.71 g, 2.6 mmol) to give product as a 
yellow oil (0.28 g, 39%). 1H-NMR (400 MHz, CDCl3) δ 7.47 (d, J = 2.9, 1H), 7.26 – 7.19 
(m, 2H), 7.04 (dd, J = 8.8, 2.9, 1H), 6.88 – 6.82 (m, 2H), 6.70 (d, J = 8.8, 1H), 4.58 (br s, 
1H), 3.56 (t, J = 6.8, 2H), 2.68 (t, J = 7.2, 2H); 13C-NMR (101 MHz, CDCl3) δ 193.27, 
156.90, 149.19, 147.93, 129.64, 128.20, 127.53, 119.62, 118.84, 117.69, 117.33, 42.43, 
37.97.  
(126) tert-butyl 6-(2-methoxyphenoxy)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate 
Followed procedure for compound 15 with 123 (0.080 g, 0.30 mmol) to give product as a 
yellow oil (>90%). 1H-NMR (500 MHz, CDCl3) δ 7.70 (d, J = 9.3, 1H), 7.40 (d, J = 2.9, 
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1H), 7.19 – 7.10 (m, 2H), 7.02 – 6.95 (m, 2H), 6.94 – 6.87 (m, 1H), 4.12 (t, J = 6.4, 2H), 
3.84 – 3.77 (m, 3H), 2.71 (t, J = 6.4, 2H), 1.53 (s, 9H).   
(127) tert-butyl 6-(3-chlorophenoxy)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 15 with 124 (0.12 g, 0.45 mmol) to give product as a 
yellow oil (>90%). 1H-NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.8, 1H), 7.58 (d, J = 2.9, 
1H), 7.26 – 7.23 (m, 1H), 7.20 (dd, J = 9.3, 2.9, 1H), 7.09 (d, J = 7.8, 1H), 6.97 (s, 1H), 
6.91 – 6.85 (m, 2H), 4.17 (t, J = 6.4, 2H), 2.77 (t, J = 6.1, 2H), 1.56 (s, 9H).  
(128) tert-butyl 6-(4-chlorophenoxy)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 15 with 125 (0.12 g, 0.45 mmol) to give product as a 
colorless oil after purification by column chromatography (4:1 hex/EtOAc) (0.10 g, 
62%). 1H-NMR (400 MHz, CDCl3) δ 7.78 (d, J = 9.1, 1H), 7.54 (d, J = 2.8, 1H), 7.29 (d, 
J = 8.9, 2H), 7.19 (dd, J = 9.1, 2.9, 1H), 6.93 (d, J = 8.9, 2H), 4.15 (t, J = 6.3, 2H), 2.76 (t, 
J = 6.3, 2H), 1.56 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 193.58, 155.61, 153.12, 
152.84, 140.11, 129.99, 128.77, 126.20, 125.81, 125.18, 120.15, 116.05, 82.40, 44.43, 
38.99, 28.41. 
(129) 1-acetyl-6-(2-methoxyphenoxy)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 110 with 126 (0.080 g, 0.30 mmol) to give product as 
a light yellow oil (>90%). 1H-NMR (500 MHz, CDCl3) δ 7.46 – 7.38 (m, 1H), 7.24 – 
7.12 (m, 3H), 7.02 (d, J = 8.8, 2H), 6.99 – 6.92 (m, 1H), 4.21 (br s, 1H), 3.86 – 3.77 (m, 
2H), 2.76 (t, J = 5.9, 2H), 2.32 (s, 3H).  
(130) 1-acetyl-6-(3-chlorophenoxy)-2,3-dihydroquinolin-4(1H)-one  
Followed procedure for compound 110 with 127 (0.12 g, 0.45 mmol) to give product as a 
light yellow oil that solidified upon standing (>90%). 1H-NMR (500 MHz, CDCl3) δ 7.59 
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(d, J = 2.9, 1H), 7.31 – 7.28 (m, 1H), 7.24 (dd, J = 8.8, 2.9, 1H), 7.13 (d, J = 8.3, 1H), 
7.00 (s, 1H), 6.94 – 6.88 (m, 1H), 4.28 – 4.19 (m, 2H), 2.81 (t, J = 6.1, 2H), 2.36 (s, 3H).  
(131) 1-acetyl-6-(4-chlorophenoxy)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 110 with 128 (0.13 g, 0.47 mmol) to give product as a 
colorless oil after purification by column chromatography (3:1 hex/EtOAc to 1:1 
hex/EtOAc) (0.068 g, 47%). 1H-NMR (400 MHz, CDCl3) δ 7.55 (d, J = 3.1, 1H), 7.51 (br 
s, 1H), 7.35 – 7.29 (m, 2H), 7.22 (dd, J = 8.9, 3.0, 1H), 6.99 – 6.93 (m, 2H), 4.22 (t, J = 
5.9, 2H), 2.79 (t, J = 6.2, 2H), 2.35 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 193.17, 
169.15, 154.94, 154.57, 139.41, 130.02, 129.18, 127.27, 126.02, 124.55, 120.45, 116.02, 
44.11, 39.33, 23.09.  
(132) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(2-methoxyphenoxy)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 126 (0.050 g, 0.14 mmol) to give product as a 
yellow oil (23%). 1H-NMR (400 MHz, CDCl3) δ 7.69 (d, J = 9.0, 1H), 7.16 – 7.06 (m, 
1H), 6.99 (d, J = 8.2, 1H), 6.96 – 6.79 (m, 4H), 3.92 (dt, J = 12.9, 4.5, 1H), 3.84 (s, 3H), 
3.64 – 3.50 (m, 1H), 2.25 – 2.16 (m, 1H), 2.02 – 1.90 (m, 1H), 1.50 (s, 9H), 1.18 (s, 9H).  
(133) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(3-chlorophenoxy)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 127 (0.15 g, 0.41 mmol) to give product as a 
light yellow oil (78%).  
(134) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(4-chlorophenoxy)-3,4-
dihydroquinoline-1(2H)-carboxylate 
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Followed procedure for compound 46 with 128 (0.10 g, 0.27 mmol) to give product as a 
colorless oil (0.094 g, 72%). 1H-NMR (400 MHz, CDCl3) δ 7.77 (d, J = 9.0, 1H), 7.26 (d, 
J = 8.7, 2H), 7.03 (s, 1H), 6.91 (d, J = 8.7, 3H), 4.51 (s, 1H), 4.01 – 3.88 (m, 1H), 3.71 – 
3.53 (m, 1H), 3.29 (s, 1H), 2.26 – 2.12 (m, 1H), 2.09 – 1.93 (m, 1H), 1.52 (s, 9H), 1.21 
(s, 9H); 13C-NMR (101 MHz, CDCl3) δ 156.18, 153.69, 152.46, 134.40, 130.61, 129.79, 
128.19, 125.72, 119.71, 119.06, 118.97, 81.40, 55.86, 50.65, 40.37, 29.73, 28.45, 22.70. 
(135) (R)-N-((R)-1-acetyl-6-(2-methoxyphenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 129 (0.35 g, 1.12 mmol) to give product as a 
light yellow oil which was carried forward without additional purification. 
(136) (R)-N-((R)-1-acetyl-6-(3-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 130 (0.1 g, 0.32 mmol) to give product as a 
light yellow oil (80%).  
(137) (R)-N-((R)-1-acetyl-6-(4-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 131 (0.068 g, 0.22 mmol) to give product as a 
colorless oil (0.070 g, 77%). 1H-NMR (400 MHz, CDCl3) δ 7.33 – 7.25 (m, 2H), 7.10 (d, 
J = 2.7, 1H), 6.97 – 6.89 (m, 3H), 4.50 (q, J = 4.6, 1H), 3.90 (dt, J = 11.9, 5.7, 1H), 3.79 
(ddd, J = 13.2, 8.8, 5.6, 1H), 3.37 (d, J = 4.0, 1H), 2.31 – 2.20 (m, 4H), 2.17 – 2.05 (m, 
1H), 1.20 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 169.96, 155.57, 134.12, 129.96, 
129.52, 128.79, 126.42, 120.31, 118.38, 56.01, 51.27, 40.64, 30.78, 24.33, 22.69.  
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(138) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(2-methoxyphenoxy)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 132 (0.015 g, 0.032 mmol) to give product as 
a white solid. MS(EI): 484.2 (M+Na), Retention Time: 21.39 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.30 (d, J = 7.9, 1H), 7.16 – 7.10 (m, 1H), 7.08 (d, J = 8.1, 1H), 6.94 – 6.84 
(m, 4H), 6.66 (dd, J = 8.6, 2.5, 1H), 6.50 (s, 2H), 5.01 (t, J = 5.3, 1H), 3.87 (dd, J = 11.5, 
5.1, 1H), 3.75 (s, 3H), 3.28 – 3.19 (m, 2H), 3.04 (dd, J = 13.7, 5.1, 1H), 2.76 (t, J = 11.3, 
1H), 2.28 (s, 6H), 1.94 – 1.85 (m, 1H), 1.62 – 1.54 (m, 1H).  
(139) (S)-2-amino-N-((R)-6-(3-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 133 (0.06 g, 0.13 mmol) to give product as a 
white solid. Retention Time: 28.86 min. 1H-NMR (500 MHz, CD3OD) δ 8.29 (d, J = 7.8, 
1H), 7.27 (t, J = 8.1, 1H), 7.05 (d, J = 7.8, 1H), 6.95 (s, 1H), 6.92 – 6.80 (m, 4H), 6.50 (s, 
2H), 5.03 (d, J = 5.9, 1H), 3.87 (dd, J = 11.3, 4.9, 1H), 3.29 – 3.15 (m, 2H), 3.04 (dd, J = 
13.7, 4.9, 1H), 2.77 (t, J = 10.8, 1H), 2.28 (s, 6H), 1.91 – 1.81 (m, 1H), 1.60 – 1.51 (m, 
1H).  
(140) (S)-2-amino-N-((R)-6-(4-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 134 (0.094 g, 0.20 mmol) to give product as a 
white solid. MS(EI): 488.2 (M+Na), Retention Time: 29.81 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.12 (d, J = 7.9, 1H), 7.28 – 7.20 (m, 2H), 6.85 – 6.76 (m, 3H), 6.72 (dd, J = 
8.7, 2.7, 1H), 6.59 (d, J = 8.7, 1H), 6.49 (s, 2H), 5.01 – 4.90 (m, 1H), 3.83 (dd, J = 11.6, 
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5.0, 1H), 3.24 (dd, J = 13.4, 11.7, 1H), 3.09 – 2.95 (m, 2H), 2.67 – 2.53 (m, 1H), 2.27 (s, 
6H), 1.79 – 1.66 (m, 1H), 1.58 – 1.44 (m, 1H).  
(141) (S)-N-((R)-1-acetyl-6-(2-methoxyphenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 135 (0.5 g, 1.20 mmol) to give product as a 
white solid. Retention Time: 30.19 min. 1H-NMR (500 MHz, CD3OD) δ 8.21 (d, J = 8.2, 
1H), 7.19 – 7.14 (m, 1H), 7.10 (d, J = 8.1, 1H), 6.98 – 6.90 (m, 2H), 6.57 (dd, J = 8.5, 
2.8, 1H), 6.52 (s, 2H), 4.92 (br s, 1H), 3.86 (dd, J = 11.5, 4.9, 1H), 3.75 (s, 3H), 3.25 (t, J 
= 12.6, 1H), 3.04 (dd, J = 13.7, 5.0, 1H), 2.28 (s, 6H), 2.17 (s, 3H), 1.93 – 1.84 (m, 1H), 
1.43 (br s, 1H).  
(142) (S)-N-((R)-1-acetyl-6-(3-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 136 (0.17 g, 0.41 mmol) to give product as a 
white solid. MS(EI): 530.2 (M+Na), Retention Time: 35.33 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.20 (d, J = 8.2, 1H), 7.30 (t, J = 8.1, 1H), 7.08 (dd, J = 8.1, 1.9, 1H), 7.03 (s, 
1H), 6.94 – 6.82 (m, 3H), 6.52 (s, 2H), 5.00 – 4.92 (m, 1H), 3.85 (dd, J = 11.6, 5.0, 1H), 
3.25 (dd, J = 13.7, 11.6, 1H), 3.05 (dd, J = 13.7, 5.0, 1H), 2.27 (s, 6H), 2.22 (s, 3H), 1.95 
– 1.89 (m, 1H), 1.44 (br s, 1H).   
(143) (S)-N-((R)-1-acetyl-6-(4-chlorophenoxy)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 137 (0.070 g, 0.17 mmol) to give product as a 
white solid. MS(EI): 508.2 (M+H), Retention Time: 35.52. 1H-NMR (500 MHz, CD3OD) 
δ 8.16 (d, J = 7.9, 1H), 7.48 (br s, 1H), 7.33 – 7.29 (m, 2H), 7.03 – 6.98 (m, 1H), 6.94 – 
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6.89 (m, 2H), 6.86 (dd, J = 8.9, 2.8, 1H), 6.51 (s, 2H), 4.99 – 4.91 (m, 1H), 3.83 (dd, J = 
11.5, 5.1, 1H), 3.24 (dd, J = 13.5, 11.6, 1H), 3.03 (dd, J = 13.7, 5.0, 1H), 2.27 (s, 6H), 
2.21 (s, 3H), 1.96 – 1.81 (m, 1H), 1.38 (br s, 1H).  
(144) 4-(phenylthio)aniline 
(4-nitrophenyl)(phenyl)sulfane (0.36 g, 1.54 mmol) was dissolved in 1:1 MeOH/EtOAc 
and added to a hydrogenation vessel. PtO2 was added, and the mixture was shaken on the 
hydrogenation apparatus for 30 min at 8 psi, after which time the mixture was filtered 
through a plug of Celite with DCM. Solvents were removed under reduced pressure to 
give product as a light brown solid (0.29 g, 92%). 1H-NMR (400 MHz, CDCl3) δ 7.32 (d, 
J = 8.5, 2H), 7.27 – 7.18 (m, 2H), 7.18 – 7.09 (m, 3H), 6.71 (d, J = 8.5, 2H), 4.20 (br s, 
2H); 13C-NMR (101 MHz, CDCl3) δ 146.18, 139.41, 135.94, 128.84, 127.49, 125.36, 
121.23, 116.20.  
(145) 1-nitro-4-(phenylsulfonyl)benzene 
(4-nitrophenyl)(phenyl)sulfane (0.31 g, 1.33 mmol) was dissolved in glacial acetic acid 
(10 mL) and 30% H2O2 solution (3 mL) was added. The mixture was heated to 80 °C and 
stirred for 3 h, after which time the mixture was diluted with H2O, and extracted with 
DCM. Combined organic extracts were washed with brine and dried with MgSO4. 
Solvents were filtered and removed under reduced pressure to give product as a white 
solid (0.34 g, 97%). 1H-NMR (500 MHz, CDCl3) δ 8.32 (d, J = 8.8, 2H), 8.12 (d, J = 8.7, 
2H), 7.96 (d, J = 8.0, 2H), 7.62 (t, J = 7.5, 1H), 7.54 (t, J = 7.7, 2H); 13C-NMR (126 MHz, 
CDCl3) δ 150.33, 147.31, 139.97, 134.14, 129.70, 128.98, 128.01, 124.53.  
(146) 4-(phenylsulfonyl)aniline 
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Compound 145 (0.34 g, 1.3 mmol) was dissolved in 1:1 MeOH/EtOAc, and added to a 
hydrogenation vessel. 10% Pd/C was then added, and the mixture was shaken on the 
hydrogenation apparatus for 30 min at 20 psi, after which time the mixture was filtered 
through a plug of Celite with DCM. Solvents were removed under reduced pressure to 
give product as a white solid (0.28 g, 93%). 1H-NMR (500 MHz, CDCl3) δ 7.90 – 7.86 
(m, 2H), 7.68 (d, J = 8.7, 2H), 7.52 – 7.42 (m, 3H), 6.64 (d, J = 8.7, 2H), 4.25 (br s, 2H); 
13C-NMR (126 MHz, CDCl3) δ 151.19, 142.92, 132.50, 132.32, 129.83, 129.07, 127.01, 
114.16.  
(147) 3-bromo-N-(4-(phenylthio)phenyl)propanamide 
Followed procedure for compound 107 with 144 (0.35 g, 1.75 mmol) to give product as a 
white solid (0.54 g, 92%). 1H-NMR (500 MHz, CDCl3) δ 7.58 (s, 1H), 7.49 (d, J = 8.5, 
2H), 7.34 (d, J = 8.6, 2H), 7.28 (d, J = 4.3, 3H), 7.24 – 7.18 (m, 1H), 3.69 (t, J = 6.5, 2H), 
2.94 (t, J = 6.5, 2H); 13C-NMR (126 MHz, CDCl3) δ 168.11, 136.79, 136.45, 132.75, 
130.79, 130.12, 129.16, 126.75, 120.87, 40.59, 26.96.  
(148) 3-bromo-N-(4-(phenylsulfonyl)phenyl)propanamide 
Followed procedure for compound 107 with 146 (0.29 g, 1.24 mmol) to give product as a 
white solid (0.45 g, 99%). 1H-NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.0, 2H), 7.88 (d, J 
= 8.6, 2H), 7.68 (d, J = 8.5, 2H), 7.58 – 7.54 (m, 1H), 7.52 – 7.47 (m, 2H), 3.68 (t, J = 
6.4, 2H), 2.97 (t, J = 6.5, 2H); 13C-NMR (126 MHz, CDCl3) δ 168.34, 141.88, 141.64, 
136.53, 133.17, 129.31, 129.03, 127.44, 119.81, 40.60, 26.50.  
(149) 1-(4-(phenylthio)phenyl)azetidin-2-one 
Followed procedure for compound 108 with 147 (0.54 g, 1.61 mmol) to give product as a 
colorless oil that solidified upon standing (0.17 g, 42%). 1H-NMR (400 MHz, CDCl3) δ 
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7.40 – 7.35 (m, 2H), 7.34 – 7.29 (m, 2H), 7.29 – 7.21 (m, 4H), 7.21 – 7.15 (m, 1H), 3.59 
(t, J = 4.5, 2H), 3.10 (t, J = 4.5, 2H); 13C-NMR (101 MHz, CDCl3) δ 164.47, 138.03, 
137.02, 133.62, 133.41, 129.52, 129.15, 126.53, 116.99, 38.15, 36.31.  
(150) 1-(4-(phenylsulfonyl)phenyl)azetidin-2-one 
Followed procedure for compound 108 with 148 (0.43 g, 1.16 mmol) to give product as a 
white solid (0.13 g, 38%). 1H-NMR (500 MHz, CDCl3) δ 7.87 (t, J = 8.5, 4H), 7.54 – 
7.50 (m, 1H), 7.49 – 7.42 (m, 2H), 7.40 (d, J = 8.6, 2H), 3.64 (t, J = 4.7, 2H), 3.13 (t, J = 
4.7, 2H); 13C-NMR (126 MHz, CDCl3) δ 164.94, 142.20, 141.84, 135.70, 133.08, 129.28, 
129.21, 127.34, 116.36, 38.43, 36.62.  
(151) 6-(phenylthio)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 109 with 149 (0.17 g, 0.67 mmol) to give product as a 
yellow oil (0.13 g, 75%). 1H-NMR (500 MHz, CDCl3) δ 8.02 (d, J = 2.2, 1H), 7.37 (dd, J 
= 8.5, 2.2, 1H), 7.22 (t, J = 7.6, 2H), 7.17 (d, J = 6.8, 2H), 7.13 (t, J = 7.2, 1H), 6.68 (d, J 
= 8.5, 1H), 4.87 (br s, 1H), 3.60 (t, J = 7.0, 2H), 2.71 (t, J = 7.0, 2H); 13C-NMR (126 
MHz, CDCl3) δ 192.73, 151.53, 140.66, 138.25, 133.61, 128.94, 128.27, 125.87, 121.71, 
119.81, 117.26, 41.94, 37.67.  
(152) 6-(phenylsulfonyl)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 109 with 150 (0.13 g, 0.45 mmol) to give product as a 
yellow solid (0.052 g, 41%). 1H-NMR (500 MHz, CDCl3) δ 8.36 (d, J = 2.2, 1H), 7.88 (d, 
J = 8.2, 2H), 7.72 (dd, J = 8.8, 2.3, 1H), 7.54 – 7.49 (m, 1H), 7.49 – 7.43 (m, 2H), 6.71 
(d, J = 8.8, 1H), 5.29 (br s, 1H), 3.60 (t, J = 7.1, 2H), 2.68 (t, J = 7.0, 2H); 13C-NMR (126 
MHz, CDCl3) δ 191.93, 154.47, 142.24, 133.13, 132.83, 129.48, 129.22, 128.91, 127.20, 
118.02, 116.51, 41.10, 37.07.  
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(153) tert-butyl 4-oxo-6-(phenylthio)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 126 with 151 (0.13 g, 0.51 mmol) to give product as a 
colorless oil (0.088 g, 49%). 1H-NMR (500 MHz, CDCl3) δ 8.00 (d, J = 2.3, 1H), 7.75 (d, 
J = 8.8, 1H), 7.45 (dd, J = 8.8, 2.4, 1H), 7.34 – 7.26 (m, 4H), 7.26 – 7.21 (m, 1H), 4.14 (t, 
J = 6.4, 2H), 2.75 (t, J = 6.3, 2H), 1.55 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 193.27, 
152.54, 143.21, 136.73, 135.43, 131.10, 130.83, 130.03, 129.27, 127.21, 125.28, 124.50, 
82.47, 44.20, 38.79, 28.26.  
(154) tert-butyl 4-oxo-6-(phenylsulfonyl)-3,4-dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 126 with 152 (0.052 g, 0.18 mmol) to give product as 
a colorless oil (0.031 g, 44%). 1H-NMR (500 MHz, CDCl3) δ 8.55 – 8.53 (m, 1H), 8.01 
(s, 2H), 7.95 (d, J = 7.6, 2H), 7.59 – 7.54 (m, 1H), 7.53 – 7.47 (m, 2H), 4.16 (t, J = 6.5, 
2H), 2.78 (t, J = 6.5, 2H), 1.55 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 192.04, 152.15, 
147.77, 141.32, 136.64, 133.29, 132.18, 129.36, 127.78, 127.67, 124.55, 124.18, 83.44, 
44.15, 38.37, 28.17. 
(155) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(phenylthio)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 153 (0.088 g, 0.25 mmol) to give product as a 
colorless oil (0.061 g, 54%). 1H-NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.8, 1H), 7.36 (d, 
J = 2.2, 1H), 7.31 – 7.22 (m, 5H), 7.22 – 7.16 (m, 1H), 4.49 (q, J = 3.5, 1H), 3.94 (dt, J = 
12.8, 4.6, 1H), 3.59 (ddd, J = 12.7, 11.2, 3.9, 1H), 3.26 (s, 1H), 2.22 (dq, J = 13.8, 4.2, 
1H), 2.01 – 1.91 (m, 1H), 1.51 (s, 9H), 1.18 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 
153.38, 137.94, 136.37, 132.00, 131.81, 130.27, 129.60, 129.52, 129.10, 126.76, 124.65, 
81.47, 55.71, 50.07, 40.16, 29.02, 28.30, 22.57.  
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(156) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(phenylsulfonyl)-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 154 (0.031 g, 0.080 mmol) to give product as 
a colorless oil (0.023 g, 59%). 1H-NMR (500 MHz, CDCl3) δ 8.02 (d, J = 8.9, 1H), 7.96 – 
7.93 (m, 2H), 7.90 (d, J = 2.3, 1H), 7.82 (dd, J = 8.9, 2.3, 1H), 7.57 – 7.53 (m, 1H), 7.52 
– 7.47 (m, 2H), 4.56 (q, J = 3.8, 1H), 3.90 (dt, J = 12.9, 4.8, 1H), 3.65 (ddd, J = 12.9, 
11.0, 4.4, 1H), 3.36 (d, J = 2.8, 1H), 2.29 (dq, J = 13.8, 4.5, 1H), 2.01 – 1.92 (m, 1H), 
1.51 (s, 9H), 1.21 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.14, 142.94, 141.74, 
135.46, 133.04, 129.41, 129.26, 128.28, 127.64, 124.07, 82.32, 55.98, 50.33, 40.62, 
28.51, 28.20, 22.59.  
(157) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(phenylthio)-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 155 (0.061 g, 0.13 mmol) to give product as a 
white solid. MS(EI): 448.2 (M+H), Retention Time: 33.90 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.13 (d, J = 8.1, 1H), 7.18 (d, J = 2.1, 1H), 7.16 (t, J = 7.7, 2H), 7.09 – 7.02 
(m, 2H), 7.00 (dd, J = 8.3, 1.2, 2H), 6.51 (d, J = 8.4, 1H), 6.48 (s, 2H), 4.97 – 4.90 (m, 
1H), 3.84 (dd, J = 11.6, 5.0, 1H), 3.24 (dd, J = 13.6, 11.6, 1H), 3.08 – 2.96 (m, 2H), 2.53 
(td, J = 12.0, 3.0, 1H), 2.27 (s, 6H), 1.72 – 1.62 (m, 1H), 1.54 – 1.45 (m, 1H).  
(158) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(phenylsulfonyl)-
1,2,3,4-tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 156 (0.023 g, 0.047 mmol) to give product as 
a white solid. MS(EI): 480.2 (M+H), Retention Time: 28.37 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.19 (d, J = 7.9, 1H), 7.83 – 7.80 (m, 2H), 7.58 – 7.54 (m, 1H), 7.53 – 7.48 
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(m, 3H), 7.43 (dd, J = 8.7, 2.3, 1H), 6.52 (d, J = 8.8, 1H), 6.47 (s, 2H), 4.95 (t, J = 4.0, 
1H), 3.85 (dd, J = 11.6, 5.0, 1H), 3.26 (dd, J = 13.6, 11.7, 1H), 3.07 – 2.99 (m, 2H), 2.45 
(td, J = 12.8, 12.3, 3.3, 1H), 2.27 (s, 6H), 1.66 – 1.57 (m, 1H), 1.54 – 1.47 (m, 1H).  
(159) tert-butyl 4-oxo-6-phenyl-3,4-dihydroquinoline-1(2H)-carboxylate 
To a 10 mL microwave flask equipped with a stir bar was added tert-butyl 6-bromo-4-
oxo-3,4-dihydroquinoline-1(2H)-carboxylate (0.051 g, 0.16 mmol), phenylboronic acid 
pinacol ester (0.048 g, 0.24 mmol), K2CO3 (0.065 g, 0.47 mmol) and Pd(dppf)Cl2 (0.012 
g, 0.016 mmol) and placed under an inert atmosphere. 3:1 acetone/H2O (degassed and 
saturated with Ar gas) was then added via syringe. The mixture was stirred under 
microwave irradiation for 30 min at 100 °C, after which time solvents were removed 
under reduced pressure, and crude residue was purified by column chromatography (8:1 
hex/EtOAc) to give product as a white solid (0.041 g, 82%). 1H-NMR (500 MHz, CDCl3) 
δ 8.24 (dd, J = 2.4, 1.0, 1H), 7.86 (d, J = 8.4, 1H), 7.75 (ddd, J = 8.7, 2.4, 1.1, 1H), 7.63 – 
7.58 (m, 2H), 7.47 – 7.40 (m, 2H), 7.38 – 7.31 (m, 1H), 4.19 (t, J = 5.8, 2H), 2.81 (t, J = 
5.8, 2H), 1.58 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 194.12, 152.72, 143.25, 139.40, 
136.63, 132.42, 128.86, 127.56, 126.78, 125.41, 124.99, 124.07, 82.31, 44.29, 38.98, 
28.31. 
(160) 1-acetyl-6-phenyl-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 159 with 1-acetyl-6-bromo-2,3-dihydroquinolin-
4(1H)-one to give product as a colorless oil (0.092 100%). 1H-NMR (400 MHz, CDCl3) δ 
8.25 (d, J = 2.3, 1H), 7.79 (dd, J = 8.5, 2.3, 1H), 7.64 – 7.56 (m, 2H), 7.54 (br s, 1H), 7.49 
– 7.42 (m, 2H), 7.42 – 7.35 (m, 1H), 4.27 (t, J = 6.2, 2H), 2.84 (t, J = 6.2, 2H), 2.39 (s, 
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3H); 13C-NMR (126 MHz, CDCl3) δ 193.94, 169.36, 142.90, 138.99, 138.40, 132.56, 
128.89, 127.88, 126.73, 126.15, 125.80, 124.51, 43.92, 39.50, 23.16. 
(161) 7-phenyl-3,4-dihydronaphthalen-1(2H)-one 
Followed procedure for compound 159 with 7-bromo-3,4-dihydronaphthalen-1(2H)-one 
(0.13 g, 0.56 mmol) stirring at 110 °C to give product as a white solid (0.10 g, 82%). 1H-
NMR (400 MHz, CDCl3) δ 8.28 (d, J = 2.1, 1H), 7.69 (dd, J = 7.9, 2.1, 1H), 7.63 – 7.56 
(m, 2H), 7.42 (t, J = 7.6, 2H), 7.37 – 7.27 (m, 2H), 2.97 (t, J = 6.1, 2H), 2.67 (t, J = 6.4, 
2H), 2.14 (p, J = 6.3, 2H); 13C-NMR (101 MHz, CDCl3) δ 198.41, 143.47, 140.03, 
139.65, 132.92, 131.96, 129.44, 128.90, 127.62, 127.01, 125.49, 39.28, 29.47, 23.33. 
(162) 6',7'-dihydro-[1,2'-binaphthalen]-8'(5'H)-one 
Followed procedure for compound 159 with 7-bromo-3,4-dihydronaphthalen-1(2H)-one 
(0.12 g, 0.55 mmol) and 1-naphthylboronic acid (0.14 g, 0.82 mmol) stirring at 110 °C to 
give product as a colorless oil (0.14 g, 91%). 1H-NMR (400 MHz, CDCl3) δ 8.21 (d, J = 
1.7, 1H), 7.90 – 7.80 (m, 3H), 7.57 (dd, J = 7.7, 2.1, 1H), 7.51 – 7.35 (m, 4H), 7.32 (d, J 
= 7.9, 1H), 2.99 (t, J = 6.1, 2H), 2.69 (t, J = 6.4, 2H), 2.15 (p, J = 6.4, 2H); 13C-NMR 
(101 MHz, CDCl3) δ 198.67, 143.58, 139.28, 139.06, 135.15, 133.83, 132.58, 131.44, 
128.89, 128.51, 128.42, 128.02, 127.10, 126.28, 125.90, 125.67, 125.43, 39.29, 29.53, 
23.34. 
(163) 6,7-dihydro-[2,2'-binaphthalen]-8(5H)-one 
Followed procedure for compound 159 with 7-bromo-3,4-dihydronaphthalen-1(2H)-one 
(0.14 g, 0.62 mmol) and 2-naphthylboronic acid (0.16 g, 0.93 mmol) stirring at 110 °C to 
give product as a white solid (0.14 g, 83%). 1H-NMR (400 MHz, CDCl3) δ 8.45 (d, J = 
1.4, 1H), 8.09 (s, 1H), 7.94 – 7.87 (m, 2H), 7.87 – 7.82 (m, 1H), 7.77 (dd, J = 8.5, 1.6, 
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2H), 7.57 – 7.47 (m, 2H), 7.35 (d, J = 8.0, 1H), 2.99 (t, J = 6.1, 2H), 2.72 (t, J = 6.5, 2H), 
2.22 – 2.12 (m, 2H); 13C-NMR (101 MHz, CDCl3) δ 198.68, 143.58, 139.43, 137.20, 
133.64, 132.90, 132.73, 132.17, 129.52, 128.59, 128.26, 127.66, 126.40, 126.13, 125.72, 
125.67, 125.17, 39.25, 29.42, 23.28. 
(164) tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-phenyl-3,4-
dihydroquinoline-1(2H)-carboxylate 
Followed procedure for compound 46 with 159 (0.041 g, 0.13 mmol) to give product as a 
colorless oil (0.043 g, 80%). 1H-NMR (500 MHz, CDCl3) δ 7.89 (d, J = 8.6, 1H), 7.61 (s, 
1H), 7.58 (d, J = 8.3, 2H), 7.51 (dd, J = 8.8, 1.8, 1H), 7.42 (t, J = 7.7, 2H), 7.35 – 7.28 (m, 
1H), 4.65 (q, J = 3.6, 1H), 4.01 (dt, J = 13.0, 4.5, 1H), 3.63 (td, J = 12.0, 11.4, 3.9, 1H), 
3.36 (d, J = 2.7, 1H), 2.24 (dq, J = 14.0, 3.7, 1H), 2.06 – 1.98 (m, 1H), 1.54 (s, 9H), 1.23 
(s, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.54, 139.92, 137.68, 136.38, 128.91, 128.82, 
127.26, 127.18, 126.73, 126.68, 124.22, 81.36, 55.70, 50.75, 40.20, 29.43, 28.35, 22.62. 
(165) (R)-N-((R)-1-acetyl-6-phenyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 160 (0.090 g, 0.34 mmol) to give product as a 
colorless oil (0.098 g, 78%). 1H-NMR (500 MHz, CDCl3) δ 7.73 (s, 1H), 7.60 (d, J = 8.3, 
2H), 7.54 (d, J = 8.4, 1H), 7.44 (t, J = 7.6, 2H), 7.38 – 7.31 (m, 1H), 4.63 (q, J = 4.7, 1H), 
3.98 – 3.92 (m, 1H), 3.85 – 3.77 (m, 1H), 3.64 (d, J = 4.0, 1H), 2.34 – 2.22 (m, 4H), 2.16 
– 2.07 (m, 1H), 1.23 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 170.03, 139.63, 138.16, 
137.62, 131.77, 128.91, 127.49, 126.99, 126.77, 126.60, 125.01, 55.86, 51.51, 40.71, 
30.68, 23.45, 22.62. 
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(166) (R)-2-methyl-N-((R)-7-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)propane-2-
sulfinamide 
Followed procedure for compound 46 with 161 (0.10 g, 0.46 mmol) to give product as a 
colorless oil (0.015 g, 10%). 1H-NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 7.60 (d, J = 7.5, 
2H), 7.49 – 7.39 (m, 3H), 7.32 (t, J = 7.4, 1H), 7.19 (d, J = 8.0, 1H), 4.65 (q, J = 3.9, 1H), 
3.28 (d, J = 3.8, 1H), 2.91 – 2.71 (m, 2H), 2.13 – 2.02 (m, 1H), 2.02 – 1.86 (m, 2H), 1.86 
– 1.75 (m, 1H), 1.22 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 140.58, 139.61, 137.42, 
136.97, 129.93, 128.93, 128.29, 127.35, 127.08, 126.44, 55.63, 52.92, 30.51, 28.97, 
22.81, 18.19. 
(167) (R)-2-methyl-N-((R)-5',6',7',8'-tetrahydro-[1,2'-binaphthalen]-8'-yl)propane-2-
sulfinamide 
Followed procedure for compound 46 with 162 (0.14 g, 0.50 mmol) to give product as a 
colorless oil (0.12 g, 61%). 1H-NMR (400 MHz, CDCl3) δ 7.89 (t, J = 9.0, 2H), 7.83 (d, J 
= 8.3, 1H), 7.55 (s, 1H), 7.53 – 7.44 (m, 2H), 7.43 – 7.33 (m, 3H), 7.23 (d, J = 7.9, 1H), 
4.66 (q, J = 3.7, 1H), 3.29 (d, J = 3.0, 1H), 2.98 – 2.74 (m, 2H), 2.19 – 2.07 (m, 1H), 2.02 
– 1.89 (m, 2H), 1.87 – 1.77 (m, 1H), 1.19 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 139.63, 
139.11, 136.94, 136.89, 133.89, 131.58, 131.01, 129.57, 129.26, 128.39, 127.71, 127.08, 
126.05, 125.96, 125.78, 125.51, 55.49, 52.32, 30.23, 29.03, 22.72, 18.05.  
(168) (R)-2-methyl-N-((R)-5,6,7,8-tetrahydro-[2,2'-binaphthalen]-8-yl)propane-2-
sulfinamide 
Followed procedure for compound 46 with 163 (0.14 g, 0.51 mmol) to give product as a 
colorless oil (0.11 g, 55%). 1H-NMR (400 MHz, CDCl3) δ 8.04 (d, J = 1.9, 1H), 7.89 (d, 
J = 8.3, 2H), 7.86 – 7.79 (m, 2H), 7.75 (dd, J = 8.6, 1.8, 1H), 7.58 (dd, J = 8.0, 2.0, 1H), 
	   128	  
7.46 (pd, J = 6.9, 1.6, 2H), 7.21 (d, J = 8.0, 1H), 4.68 (q, J = 3.9, 1H), 3.31 (d, J = 3.4, 
1H), 2.93 – 2.70 (m, 2H), 2.15 – 2.05 (m, 1H), 2.04 – 1.85 (m, 2H), 1.84 – 1.73 (m, 1H), 
1.22 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 139.34, 137.80, 137.43, 137.07, 133.73, 
132.67, 130.01, 128.56, 128.40, 128.32, 127.67, 126.63, 126.30, 125.93, 125.52, 125.45, 
55.56, 52.70, 30.30, 28.92, 22.74, 18.03.  
(169) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-phenyl-1,2,3,4-
tetrahydroquinolin-4-yl)propanamide 
Followed procedure for compound 68 with 164 (0.043 g, 0.10 mmol) to give product as a 
white solid. MS(EI): 416.2 (M+H), Retention Time: 26.73 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.18 (d, J = 7.9, 1H), 7.47 (d, J = 7.4, 2H), 7.37 – 7.27 (m, 4H), 7.21 (t, J = 
7.4, 1H), 6.66 (dd, J = 8.0, 1.4, 1H), 6.49 (s, 2H), 5.07 – 4.99 (m, 1H), 3.87 (dd, J = 11.7, 
5.0, 1H), 3.25 (dd, J = 12.5, 10.5, 1H), 3.09 – 2.97 (m, 2H), 2.60 – 2.52 (m, 1H), 2.28 (s, 
6H), 1.83 – 1.74 (m, 1H), 1.59 – 1.52 (m, 1H).  
(170) (S)-N-((R)-1-acetyl-6-phenyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 165 (0.078 g, 0.27 mmol) to give product as a 
white solid. MS(EI): 458.2 (M+H), Retention Time: 31.11 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.22 (d, J = 8.1, 1H), 7.57 (d, J = 8.4, 2H), 7.53 – 7.47 (m, 2H), 7.41 (t, J = 
7.3, 2H), 7.32 (t, J = 6.7, 1H), 6.52 (s, 2H), 5.08 (t, J = 5.9, 1H), 3.90 – 3.79 (m, 2H), 3.26 
(dd, J = 12.5, 11, 1H), 3.22 – 3.14 (m, 1H), 3.04 (dd, J = 13.6, 5.0, 1H), 2.28 (s, 6H), 2.25 
(s, 3H), 1.97 – 1.88 (m, 1H), 1.53 – 1.44 (m, 1H).  
(171) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-7-phenyl-1,2,3,4-
tetrahydronaphthalen-1-yl)propanamide 
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Followed procedure for compound 68 with 166 (0.014 g, 0.040 mmol) to give product as 
a white solid. MS(EI): 415.2 (M+H), Retention Time: 38.96 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.10 (d, J = 8.4, 1H), 7.57 – 7.50 (m, 2H), 7.45 – 7.35 (m, 4H), 7.33 – 7.26 
(m, 1H), 7.12 (d, J = 8.0, 1H), 6.50 (s, 2H), 5.13 – 5.02 (m, 1H), 3.84 (dd, J = 11.5, 4.9, 
1H), 3.29 – 3.20 (m, 1H), 3.01 (dd, J = 13.6, 4.9, 1H), 2.74 – 2.64 (m, 2H), 2.28 (s, 6H), 
1.78 – 1.66 (m, 1H), 1.66 – 1.55 (m, 1H), 1.53 – 1.41 (m, 1H), 1.38 – 1.24 (m, 1H).  
(172) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-5',6',7',8'-tetrahydro-
[1,2'-binaphthalen]-8'-yl)propanamide 
Followed procedure for compound 68 with 167 (0.12 g, 0.31 mmol) to give product as a 
white solid. MS(EI): 465.3 (M+H), Retention Time: 44.74 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.11 (d, J = 8.5, 1H), 7.90 (d, J = 8.1, 1H), 7.85 (d, J = 8.3, 1H), 7.77 (d, J = 
8.5, 1H), 7.52 – 7.44 (m, 2H), 7.42 – 7.36 (m, 1H), 7.34 – 7.27 (m, 2H), 7.25 (dd, J = 7.8, 
1.8, 1H), 7.19 (d, J = 7.9, 1H), 6.51 (s, 2H), 5.15 – 5.06 (m, 1H), 3.79 (dd, J = 11.5, 5.0, 
1H), 3.23 (dd, J = 13.5, 11.7, 1H), 2.98 (dd, J = 13.7, 5.0, 1H), 2.81 – 2.69 (m, 2H), 2.27 
(s, 6H), 1.84 – 1.60 (m, 2H), 1.54 – 1.33 (m, 2H).  
(173) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-5,6,7,8-tetrahydro-[2,2'-
binaphthalen]-8-yl)propanamide 
Followed procedure for compound 68 with 168 (0.11 g, 0.28 mmol) to give product as a 
white solid. MS(EI): 487.2 (M+Na), Retention Time: 45.02 min. 1H-NMR (400 MHz, 
CD3OD) δ 8.01 (s, 1H), 7.93 – 7.83 (m, 3H), 7.71 (dd, J = 8.6, 1.6, 1H), 7.55 (d, J = 8.3, 
2H), 7.52 – 7.43 (m, 2H), 7.18 (d, J = 7.9, 1H), 6.50 (s, 2H), 5.12 (t, J = 4.8, 1H), 3.85 
(dd, J = 11.6, 4.9, 1H), 3.29 – 3.22 (m, 1H), 3.01 (dd, J = 13.6, 4.9, 1H), 2.78 – 2.66 (m, 
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2H), 2.29 (s, 6H), 1.79 – 1.70 (m, 1H), 1.68 – 1.58 (m, 1H), 1.56 – 1.45 (m, 1H), 1.39 – 
1.24 (m, 1H).  
(174) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-1,2,3,4-
tetrahydronaphthalen-1-yl)propanamide 
Followed procedure for compound 115 with (R)-1,2,3,4-tetrahydronaphthalen-1-amine 
(0.040 g, 0.27 mmol) to give product as a white solid. MS(EI): 339.2 (M+H), Retention 
Time: 27.94 min. 1H-NMR (400 MHz, CD3OD) δ 8.08 (d, J = 8.5, 1H), 7.16 (dd, J = 7.2, 
1.9, 1H), 7.08 (td, J = 6.9, 1.8, 2H), 7.00 (dd, J = 7.0, 1.9, 1H), 6.47 (s, 2H), 4.97 (dt, J = 
8.4, 5.5, 1H), 3.82 (dd, J = 11.6, 4.9, 1H), 3.24 (dd, J = 13.6, 11.6, 1H), 3.00 (dd, J = 
13.6, 4.9, 1H), 2.64 (t, J = 5.9, 2H), 2.26 (s, 6H), 1.71 – 1.51 (m, 2H), 1.45 – 1.28 (m, 
2H).  
(175) N-(4-benzylphenyl)-3-bromopropanamide 
To a dry flask was added 4-benzylaniline (5.31 g, 29.0 mmol) and K2CO3 (8.02 g, 58.0 
mmol), and placed under an inert atmosphere. DCM (85 mL) was added, and 4-
benzylaniline was allowed to dissolve. 3-bromopropionyl chloride (3.06 mL, 30.4 mmol) 
was then added dropwise via syringe. The resulting cloudy white mixture was stirred at 
r.t. for 2 h, after which time the reaction was quenched with H2O (10 mL), and washed 
with H2O (2x). Organic layer was dried with MgSO4. Solvents were filtered and removed 
to give product as a tan solid (8.63 g, 98%). 1H-NMR (400 MHz, CDCl3) δ 7.39 (d, J  = 
8.4, 2H), 7.32 – 7.25 (m, 2H), 7.21 – 7.10 (m, 5H), 3.93 (s, 2H), 3.68 (t, J  = 6.6, 2H), 
2.90 (t, J  = 6.6, 2H); 13C-NMR (101 MHz, CDCl3) δ 168.00, 141.12, 137.81, 135.57, 
129.66, 129.00, 128.63, 126.27, 120.41, 41.76, 40.81, 27.14.   
(176) 1-(4-benzylphenyl)azetidin-2-one 
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To a dry flask was added NaOtBu (2.86 g, 96.1 mmol), and placed under an inert 
atmosphere. DMF (75 mL) was then added via syringe. After dissolution of solids, 175 
was dissolved in DMF (125 mL) and added dropwise via syringe. The mixture was 
allowed to stir at r.t. for 3 h, after which time DMF was removed under reduced pressure, 
and crude residue was redissolved in EtOAc. H2O was added, and the aqueous layer was 
extracted with EtOAc. Combined organic extracts were washed with H2O and brine, and 
dried with MgSO4. Solvents were filtered and removed under reduced pressure, and 
crude residue was purified by column chromatography (1:1 hex/EtOAc) to give product 
as a white solid (3.93 g, 58%). 1H-NMR (400 MHz, CDCl3) δ 7.30 – 7.23 (m, 4H), 7.22 – 
7.12 (m, 5H), 3.94 (s, 2H), 3.60 (t, J = 4.5, 2H), 3.09 (t, J = 4.5, 2H); 13C-NMR (101 
MHz, CDCl3) δ 164.42, 141.23, 136.90, 136.84, 129.76, 128.94, 128.63, 126.26, 116.43, 
41.53, 38.16, 36.23.  
 (177) 6-benzyl-1-methyl-2,3-dihydroquinolin-4(1H)-one 
To a dry flask was added compound 14 (0.74 g, 3.1 mmol) and K2CO3 (0.86 g, 6.2 
mmol). DMF (15 mL) was then added via syringe. CH3I (0.40 mL, 6.2 mmol) was then 
added via syringe. The resulting mixture was stirred at 100 °C for 18 h, after which time 
the reaction was diluted with the addition of EtOAc (50 mL) and H2O (50 mL). The 
aqueous layer was extracted with EtOAc, and combined organic extracts were washed 
with brine, and dried with MgSO4. Solvents were filtered and removed under reduced 
pressure, and the crude residue was purified by column chromatography (3:2 hex/EtOAc) 
to give product as a yellow oil (0.46 g, 59%). 1H-NMR (400 MHz, CDCl3) δ 7.79 (d, J  = 
1.7, 1H), 7.31 – 7.14 (m, 6H), 6.65 (d, J  = 8.7, 1H), 3.88 (s, 2H), 3.41 (t, J  = 7.0, 2H), 
2.93 (s, 3H), 2.71 (t, J  = 7.0, 2H); 13C-NMR (101 MHz, CDCl3) δ 193.89, 151.43, 
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141.28, 136.31, 129.88, 128.74, 128.48, 127.80, 126.05, 119.74, 113.75, 51.51, 40.81, 
39.42, 38.37. 
(178) 6-benzyl-1-propyl-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 177 with 14 (0.17 g, 0.74 mmol) and 1-iodopropane 
(0.72 mL, 7.3 mmol), with heating at 110 °C to give product as a yellow oil (0.12 g, 
58%). 1H-NMR (400 MHz, CDCl3) δ 7.78 (d, J = 2.2, 1H), 7.28 – 7.45 (m, 2H), 7.20 – 
7.14 (m, 4H), 6.64 (d, J = 8.7, 1H), 3.86 (s, 2H), 3.47 (t, J = 6.8, 2H), 3.27 (t, J = 7.6, 
2H), 2.66 (t, J = 7.2, 2H), 1.69 – 1.56 (m, 2H), 0.98 (t, J = 7.6, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 193.73, 150.14, 141.36, 136.25, 128.74, 128.45, 127.98, 126.01, 119.30, 
113.35, 53.31, 49.18, 40.77, 38.00, 19.58, 11.52.  
(179) (E)-6-benzyl-1-methyl-2,3-dihydroquinolin-4(1H)-one oxime 
Followed procedure for compound 111 with 177 (0.13 g, 0.50 mmol) to give product as a 
yellow oil (0.41 g, 85%). 1H-NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.29 – 7.21 (m, 
2H), 7.21 – 7.11 (m, 3H), 7.04 (d, J  = 8.5, 1H), 6.62 (d, J  = 8.5, 1H), 3.87 (s, 2H), 3.13 
(t, J  = 6.5, 2H), 2.95 (t, J  = 6.6, 2H), 2.84 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 
152.86, 147.35, 141.70, 131.58, 130.60, 128.92, 128.52, 126.00, 124.51, 117.76, 113.29, 
49.94, 41.18, 39.80, 24.20.  
(180) (E)-6-benzyl-1-propyl-2,3-dihydroquinolin-4(1H)-one oxime 
Followed procedure for compound 111 with 178 (0.12 g, 0.43 mmol) to give product as a 
yellow oil (0.084 g, 66%). 1H-NMR (400 MHz, CDCl3) δ 7.67 (d, J = 2.0, 1H), 7.29 – 
7.21 (m, 2H), 7.21 – 7.12 (m, 3H), 7.00 (dd, J = 8.6, 2.1, 1H), 6.60 (d, J = 8.6, 1H), 3.85 
(s, 2H), 3.26 – 3.15 (m, 4H), 2.91 (t, J = 6.6, 2H), 1.65 – 1.52 (m, 2H), 0.93 (t, J = 7.6, 
	   133	  
3H); 13C-NMR (101 MHz, CDCl3) δ 153.11, 145.79, 141.79, 131.57, 129.42, 128.92, 
128.50, 125.95, 124.81, 116.94, 112.95, 53.49, 47.53, 41.11, 23.63, 19.28, 11.68.  
(181) 6-benzyl-1-methyl-1,2,3,4-tetrahydroquinolin-4-amine 
Followed procedure for compound 113 with 179 (0.19 g, 0.70 mmol) shaking under H2 at 
50 psi to give product as a colorless oil which was taken forward without further 
purification or characterization.   
(182) 6-benzyl-1-propyl-1,2,3,4-tetrahydroquinolin-4-amine 
Followed procedure for compound 113 with 180 (0.084 g, 0.29 mmol) to give product as 
a colorless oil (0.072 g, 90%). 1H-NMR (400 MHz, CDCl3) δ 7.32 – 7.24 (m, 2H), 7.23 – 
7.14 (m, 3H), 7.02 (d, J = 1.8, 1H), 6.92 (dd, J = 8.4, 2.0, 1H), 6.53 (d, J = 8.4, 1H), 3.91 
(t, J = 4.7, 1H), 3.87 (s, 2H), 3.37 (ddd, J = 14.8, 8.0, 3.6, 1H), 3.29 – 3.14 (m, 3H), 2.06 
– 1.94 (m, 1H), 1.86 – 1.74 (m, 1H), 1.66 – 1.57 (m, 2H), 0.93 (t, J = 7.2, 3H); 13C-NMR 
(101 MHz, CDCl3) δ 142.82, 142.11, 129.05, 128.81, 128.59, 128.31, 127.83, 126.14, 
125.73, 110.96, 53.31, 47.48, 44.73, 40.97, 31.19, 19.52, 11.57.  
(183) (2S)-2-amino-N-(6-benzyl-1-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 115 with 181 (0.083 g, 0.33 mmol) to give product as 
a white solid. (183E): MS(EI): 466.2 (M+Na), Retention Time: 33.31 min. (183L): 
MS(EI): 466.2 (M+Na), Retention Time: 34.85 min.  
(184) (2S)-2-amino-N-(6-benzyl-1-propyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 115 with 180 (0.069 g, 0.25 mmol) to give product as 
white solid. (184E): 472.3 (M+H), Retention Time: 41.75 min.  
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(185) 6-benzyl-1,2,3,4-tetrahydroquinoline 
Compound 14 was added to a hydrogenation vessel, and dissolved in MeOH. 10% Pd/C 
was added, followed by conc. HCl (6 drops). The mixture was allowed to shake on the 
hydrogenator at 45 psi for 3 h, after which time the mixture was filtered through a plug of 
Celite with MeOH. MeOH was removed under reduced pressure, and crude residue was 
redissolved in DCM. H2O was added, and the aqueous layer was extracted with DCM. 
Combined organic extracts were dried with MgSO4. Solvents were filtered and removed 
under reduced pressure to give product as a light brown oil (0.21 g, 79%). 1H-NMR (500 
MHz, CDCl3) δ 7.24 (t, J = 7.6, 2H), 7.19 – 7.10 (m, 3H), 6.76 (d, J = 7.4, 2H), 6.36 (d, J 
= 8.1, 1H), 3.80 (s, 2H), 3.49 (br s, 1H), 3.20 (t, J = 5.5, 2H), 2.67 (t, J = 6.4, 2H), 1.91 – 
1.82 (m, 2H); 13C-NMR (126 MHz, CDCl3) δ 143.03, 142.23, 130.00, 129.62, 128.86, 
128.37, 127.26, 125.79, 121.58, 114.44, 42.11, 41.21, 27.01, 22.34.  
(186) 9-benzyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-1-one 
To a stirring solution of N,N-dimethylacrylamide (0.12 mL, 1.18 mmol) in DCE (10 mL) 
at 0 °C was added trifluoromethylsulfonic anhydride (0.20 mL, 1.18 mmol) in DCE (5 
mL) dropwise. 185 (0.21 g, 0.95 mmol) in DCE (5 mL) was then added dropwise, 
resulting in a bright orange solution. The mixture was warmed to r.t. and then refluxed at 
85 °C for 3 h, after which time the mixture was cooled and poured into a stirring mixture 
of diethyl ether and aqueous K2CO3. The aqueous layer was extracted with diethyl ether. 
Combined organic extracts were dried with MgSO4, and allowed to sit overnight. 
Solvents were filtered and removed, and crude residue was purified by column 
chromatography (hex/EtOAc) to give product as a yellow oil (0.11 g, 42%). 1H-NMR 
(500 MHz, CDCl3) δ 7.60 (s, 1H), 7.29 – 7.22 (m, 2H), 7.17 (d, J = 7.4, 3H), 6.93 (s, 1H), 
	   135	  
3.81 (s, 2H), 3.33 (t, J = 7.0, 2H), 3.16 (t, J = 5.5, 2H), 2.71 – 2.66 (m, 4H), 2.06 – 1.96 
(m, 2H); 13C-NMR (126 MHz, CDCl3) δ 194.05, 148.39, 141.48, 135.72, 129.54, 128.83, 
128.54, 126.08, 125.62, 124.35, 119.14, 50.29, 50.23, 41.05, 38.14, 26.69, 21.73. 
(187) (R)-N-((R)-9-benzyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-1-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 186 (0.11 g, 0.40 mmol) to give product as a 
slightly yellow oil (0.021 g, 14%). 1H-NMR (500 MHz, CDCl3) δ 7.25 (t, J = 7.5, 2H), 
7.20 – 7.13 (m, 3H), 6.93 (d, J = 2.1, 1H), 6.69 (d, J = 2.1, 1H), 4.49 (q, J = 2.8, 1H), 3.84 
– 3.73 (m, 2H), 3.21 (td, J = 11.7, 2.9, 1H), 3.17 – 3.07 (m, 3H), 2.96 (dt, J = 11.7, 3.9, 
1H), 2.78 – 2.63 (m, 2H), 2.06 (dq, J = 13.7, 3.3, 1H), 2.02 – 1.88 (m, 3H), 1.20 (s, 9H); 
13C-NMR (126 MHz, CDCl3) δ 142.03, 141.50, 129.58, 129.08, 128.89, 128.49, 128.45, 
125.92, 122.46, 120.72, 55.40, 50.05, 49.94, 44.51, 41.10, 28.24, 27.69, 22.80, 21.99. 
(188) (S)-2-amino-N-((R)-9-benzyl-2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-
ij]quinolin-1-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 187 (0.021 g, 0.055 mmol) to give product as 
a white solid. MS(EI): 470.3 (M+H), Retention Time: 37.09 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.99 (d, J = 7.8, 1H), 7.20 (t, J = 7.5, 2H), 7.14 – 7.07 (m, 3H), 6.67 (d, J = 
2.1, 1H), 6.62 (d, J = 1.8, 1H), 6.48 (s, 2H), 4.85 – 4.82 (m, 1H) 3.83 (dd, J = 11.5, 5.0, 
1H), 3.70 (s, 2H), 3.24 (dd, J = 13.6, 11.6, 1H), 3.10 – 3.02 (m, 1H), 3.03 – 2.92 (m, 2H), 
2.76 (dt, J = 11.9, 4.2, 1H), 2.67 – 2.60 (m, 2H), 2.36 – 2.28 (m, 1H), 2.28 (s, 6H), 1.98 – 
1.82 (m, 2H), 1.82 – 1.70 (m, 1H), 1.56 – 1.47 (m, 1H).  
(190) 6-benzyl-1-propionyl-2,3-dihydroquinolin-4(1H)-one 
	   136	  
Compound 14 (0.11 g, 0.47 mmol) was dissolved in propionic anhydride (10 mL) and 
heated to 90 °C for 14 h under an inert atmosphere. The reaction mixture was cooled and 
transferred to a separatory funnel, and EtOAc and sat. NaHCO3 were added. The aqueous 
layer was extracted with EtOAc. Combined organic extracts were washed with brine and 
dried with MgSO4. Solvents were filtered and removed under reduced pressure, and crude 
residue was purified by column chromatography (2:1 hex/EtOAc) to give product as a 
colorless oil (0.12 g, 85%). 1H-NMR (500 MHz, CDCl3) δ 7.86 (d, J = 0.9, 1H), 7.39 (br 
s, 1H), 7.35 (dd, J = 8.2, 2.2, 1H), 7.29 (t, J = 7.4, 2H), 7.23 – 7.16 (m, 3H), 4.20 (t, J = 
6.2, 2H), 3.98 (s, 2H), 2.75 (t, J = 6.2, 2H), 2.58 (q, J = 7.4, 2H), 1.20 (t, J = 7.4, 3H); 
13C-NMR (126 MHz, CDCl3) δ 194.27, 173.03, 142.21, 140.13, 138.78, 134.63, 128.90, 
128.71, 127.62, 126.49, 126.11, 124.44, 43.88, 41.29, 39.62, 27.98, 9.91. 
(191) 6-benzyl-1-butyryl-2,3-dihydroquinolin-4(1H)-one  
Compound 14 (0.18 g, 0.78 mmol) was dissolved in pyridine (4 mL) and placed under an 
inert atmosphere. Butyric anhydride (5 mL) was added via syringe. The mixture was 
stirred at r.t. for 24 h, after which time it was quenched with the addition of H2O. DCM 
was added, and the aqueous layer was extracted with DCM. Combined organic extracts 
were washed with 2 M NaOH, and dried with MgSO4. Solvents were filtered and 
removed under reduced pressure, and the crude residue was purified by column 
chromatography (3:2 hex/EtOAc) to give product as an oil (0.029 g, 12%). 1H-NMR (400 
MHz, CDCl3) δ 7.87 (t, J = 1.3, 1H), 7.39 – 7.34 (m, 2H), 7.33 – 7.25 (m, 2H), 7.25 – 
7.16 (m, 3H), 4.21 (t, J = 6.2, 2H), 3.99 (s, 2H), 2.76 (t, J = 6.2, 2H), 2.54 (t, J = 8.0, 2H), 
1.79 – 1.66 (m, 2H), 0.95 (t, J = 7.4, 3H), 13C-NMR (101 MHz, CDCl3) δ 194.37, 172.35, 
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142.31, 140.18, 138.87, 134.71, 128.99, 128.80, 127.77, 126.58, 126.18, 124.55, 43.97, 
41.38, 39.82, 36.57, 19.25, 13.94.  
(192) 6-benzyl-1-(cyclopropanecarbonyl)-2,3-dihydroquinolin-4(1H)-one 
Compound 14 (0.15 g, 0.65 mmol) was dissolved in DCM (10 mL), and Et3N (0.18 mL, 
1.29 mmol) was added dropwise. The solution was stirred for 5 min at r.t., after which 
time cyclopropanecarbonyl chloride (0.12 mL, 1.29 mmol) was added dropwise via 
syringe. The reaction was stirred for 3 h, after which time sat. NaHCO3 was added. 
Aqueous layer was extracted with DCM. Combined organic extracts were washed with 
brine and dried with MgSO4. Solvents were filtered and removed under reduced pressure, 
and crude residue was purified by column chromatography (3:2 hex/EtOAc) to give 
product as a colorless oil (0.15 g, 78%). 1H-NMR (500 MHz, CDCl3) δ 7.88 (d, J = 2.2, 
1H), 7.46 (d, J = 8.3, 1H), 7.35 (dd, J = 8.4, 2.2, 1H), 7.31 – 7.26 (m, 2H), 7.22 – 7.17 
(m, 3H), 4.26 (t, J = 6.3, 2H), 3.98 (s, 2H), 2.76 (t, J = 6.3, 2H), 2.06 – 1.96 (m, 1H), 1.21 
– 1.15 (m, 2H), 0.91 – 0.82 (m, 2H); 13C-NMR (126 MHz, CDCl3) δ 194.41, 173.00, 
142.45, 140.13, 138.53, 134.49, 128.89, 128.71, 127.74, 126.49, 125.85, 124.09, 43.53, 
41.28, 39.70, 13.74, 9.77.  
(193) 6-benzyl-1-(cyclobutanecarbonyl)-2,3-dihydroquinolin-4(1H)-one 
Followed procedure for compound 192 with 14 (0.15 g, 0.62 mmol) and 
cyclobutanecarbonyl chloride (0.14 mL, 1.25 mmol) to give product as a white solid 
(0.20 g, 99%). 1H-NMR (500 MHz, CDCl3) δ 7.85 (d, J = 1.3, 1H), 7.48 – 7.37 (br s, 1H), 
7.35 (dd, J = 8.2, 2.2, 1H), 7.29 (t, J = 7.5, 2H), 7.24 – 7.13 (m, 3H), 4.12 (t, J = 6.2, 2H), 
3.98 (s, 2H), 3.52 (p, J = 8.4, 1H), 2.72 (t, J = 6.2, 2H), 2.43 (dq, J = 11.8, 9.2, 2H), 2.13 
(q, J = 9.9, 2H), 2.02 – 1.88 (m, 2H); 13C-NMR (126 MHz, CDCl3) δ 194.09, 174.02, 
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142.14, 140.14, 138.52, 134.63, 128.85, 128.64, 127.49, 126.41, 125.75, 123.84, 43.78, 
41.24, 39.57, 37.95, 25.72, 17.83.  
(195) (R)-N-((R)-6-benzyl-1-propionyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 190 (0.12 g, 0.40 mmol) to give product as a 
colorless oil (0.12 g, 78%). 1H-NMR (500 MHz, CDCl3) δ 7.31 – 7.25 (m, 3H), 7.23 – 
7.17 (m, 3H), 7.10 (dd, J = 8.3, 2.1, 1H), 4.52 (q, J = 4.2, 1H), 3.95 (s, 2H), 3.88 (dt, J = 
12.9, 5.4, 1H), 3.80 – 3.69 (m, 1H), 3.31 (d, J = 3.3, 1H), 2.53 – 2.46 (m, 2H), 2.22 (dq, J 
= 13.9, 5.0, 1H), 2.06 – 1.98 (m, 1H), 1.19 (s, 9H), 1.15 (t, J = 7.4, 3H); 13C-NMR (126 
MHz, CDCl3) δ 173.52, 140.60, 138.63, 136.66, 128.94, 128.68, 128.61, 128.59, 126.30, 
124.89, 55.78, 50.98, 41.41, 39.99, 30.62, 28.12, 22.61, 10.04.  
(196) (R)-N-((R)-6-benzyl-1-butyryl-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 191 (0.029 g, 0.094 mmol) to give product as 
a colorless oil (0.010 g, 26%). 1H-NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.24 – 
7.18 (m, 3H), 7.10 (dd, J = 8.3, 2.1, 1H), 4.53 (t, J = 4.6, 1H), 3.95 (s, 2H), 3.94 – 3.85 
(m, 1H), 3.80 – 3.68 (m, 1H), 3.34 (br s, 1H), 2.51 – 2.41 (m, 2H), 2.27 – 2.15 (m, 1H), 
2.08 – 1.97 (m, 1H), 1.74 – 1.63 (m, 2H), 1.20 (s, 9H), 0.92 (t, J = 7.4, 3H).   
(197) (R)-N-((R)-6-benzyl-1-(cyclopropanecarbonyl)-1,2,3,4-tetrahydroquinolin-4-
yl)-2-methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 192 (0.16 g, 0.51 mmol) to give product as a 
colorless oil (0.12 g, 55%). 1H-NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.2, 1H), 7.32 – 
7.26 (m, 3H), 7.23 – 7.18 (m, 3H), 7.09 (dd, J = 8.3, 2.0, 1H), 4.55 (q, J = 4.3, 1H), 4.01 
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– 3.93 (m, 3H), 3.75 (ddd, J = 12.9, 9.3, 5.6, 1H), 3.33 (d, J = 3.6, 1H), 2.23 (dq, J = 
14.9, 5.1, 1H), 2.10 – 1.89 (m, 3H), 1.20 (s, 9H), 1.14 – 1.08 (m, 2H), 0.78 (dd, J = 7.9, 
2.5, 2H); 13C-NMR (101 MHz, CDCl3) δ 173.36, 140.65, 138.53, 136.83, 131.83, 128.98, 
128.71, 128.58, 128.51, 126.36, 124.97, 55.85, 51.18, 41.47, 39.85, 30.74, 22.61, 13.65, 
9.28. 
(198) (R)-N-((R)-6-benzyl-1-(cyclobutanecarbonyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
2-methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 193 (0.20 g, 0.62 mmol) to give product as a 
colorless oil (0.16 g, 60%). 1H-NMR (500 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H), 7.23 – 
7.17 (m, 2H), 7.09 (dd, J = 8.3, 2.1, 1H), 4.51 (q, J = 4.3, 1H), 3.95 (s, 2H), 3.86 – 3.77 
(m, 1H), 3.74 – 3.63 (m, 1H), 3.50 – 3.39 (m, 2H), 2.44 – 2.30 (m 2H), 2.19 (dq, J = 14.3, 
4.9, 1H), 2.12 – 1.97 (m, 3H), 1.97 – 1.82 (m, 2H), 1.21 (s, 9H); 13C-NMR (126 MHz, 
CDCl3) δ 174.44, 140.63, 138.39, 136.58, 128.89, 128.73, 128.56, 128.50, 126.23, 
124.20, 55.77, 50.96, 41.37, 39.90, 38.22, 30.72, 25.80, 22.60, 17.84.  
(200) (S)-2-amino-N-((R)-6-benzyl-1-propionyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-
(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 195 (0.12 g, 0.31 mmol) to give product as a 
white solid. MS(EI): 486.3 (M+H), Retention Time: 35.59 min. 1H-NMR (500 MHz, 
CD3OD) δ 8.15 (d, J = 8.2, 1H), 7.42 (br s, 1H), 7.27 – 7.19 (m, 2H), 7.18 – 7.11 (m, 
4H), 7.05 (dd, J = 8.4, 2.1, 1H), 6.51 (s, 2H), 4.96 – 4.91 (m, 1H), 3.91 (s, 2H), 3.86 (dd, 
J = 11.5, 5.0, 1H), 3.78 (br s, 1H), 3.26 (dd, J = 13.6, 11.5, 1H), 3.18 – 3.10 (m, 1H), 3.03 
(dd, J = 13.7, 5.1, 1H), 2.58 – 2.39 (m, 2H), 2.27 (s, 6H), 1.90 – 1.80 (m, 1H), 1.48 – 
1.39 (m, 1H), 1.11 (t, J = 7.4, 3H).  
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(201) (S)-2-amino-N-((R)-6-benzyl-1-butyryl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 196 (0.010 g, 0.024 mmol) to give product as 
a white solid. MS(EI): 500.3 (M+H), Retention Time: 38.47 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.39 (br s, 1H), 7.27 – 7.20 (m, 2H), 7.18 – 7.11 (m, 4H), 7.06 (dd, J = 8.4, 
2.1, 1H), 6.50 (s, 2H), 4.93 (t, J = 6.5, 1H), 3.91 (s, 2H), 3.88 – 3.75 (m, 2H), 3.25 (dd, J 
= 13.6, 11.5, 1H), 3.15 – 3.11 (m, 1H), 3.02 (dd, J = 13.7, 5.1, 1H), 2.54 – 2.39 (m, 2H), 
2.27 (s, 6H), 1.91 – 1.81 (m, 1H), 1.69 – 1.58 (m, 2H), 1.44 – 1.40 (m, 1H), 0.93 (t, J = 
7.2, 3H). 
(202) (S)-2-amino-N-((R)-6-benzyl-1-(cyclopropanecarbonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 197 (0.12 g, 0.28 mmol) to give product as a 
white solid. MS(EI): 498.3 (M+H), Retention Time: 37.47 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.39 (d, J = 8.3, 1H), 7.26 – 7.20 (m, 2H), 7.19 – 7.12 (m, 4H), 7.07 (dd, J = 
8.4, 2.1, 1H), 6.50 (s, 2H), 4.96 (t, J = 6.3, 1H), 3.92 (s, 2H), 3.91 – 3.80 (m, 2H), 3.29 – 
3.20 (m, 2H), 3.07 – 2.99 (m, 1H), 2.28 (s, 6H), 1.98 – 1.92 (m, 1H), 1.89 – 1.81 (m, 1H), 
1.47 – 1.38 (m, 1H), 1.07 – 1.01 (m, 1H), 0.99 – 0.92 (m, 1H), 0.91 – 0.79 (m, 2H).  
 (203) (S)-2-amino-N-((R)-6-benzyl-1-(cyclobutanecarbonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 198 (0.16 g, 0.37 mmol) to give product as a 
white solid. MS(EI): 512.3 (M+H), Retention Time: 39.62 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.39 (br s, 1H), 7.26 – 7.21 (m, 2H), 7.18 – 7.11 (m, 4H), 7.05 (dd, J = 8.3, 
2.1, 1H), 6.50 (s, 2H), 4.98 – 4.89 (m, 1H), 3.91 (s, 2H), 3.85 (dd, J = 11.5, 5.1, 1H), 3.68 
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(br s, 1H), 3.50 (p, J = 8.5, 1H), 3.25 (dd, J = 13.6, 11.6, 1H), 3.12 – 3.01 (m, 2H), 2.35 – 
1.94 (m, 11H), 1.89 – 1.77 (m, 2H), 1.43 – 1.32 (m, 1H).  
(204) chroman-4-ol 
4-chromanone (0.52 g, 3.5 mmol) was dissolved in absolute EtOH (15 mL). NaBH4 (0.27 
g, 7.0 mmol) was then added. The reaction was stirred at r.t. for 20 min, after which time 
it was quenched with sat. NH4Cl (10 mL), and stirred vigorously for 5 min. EtOH was 
removed under reduced pressure, and the aqueous layer was extracted with EtOAc. 
Combined organic extracts were washed with brine and dried with MgSO4. Solvents were 
filtered and removed under reduced pressure to give product as a colorless oil (0.51 g, 
97%). 1H-NMR (400 MHz, CDCl3) δ 7.20 (dd, J = 7.6, 1.7, 1H), 7.17 – 7.11 (m, 1H), 
6.85 (td, J = 7.4, 1.2, 1H), 6.78 (dd, J = 8.2, 1.2, 1H), 4.58 (t, J = 4.2, 1H), 4.16 – 4.09 
(m, 2H), 3.19 (s, 1H), 2.01 – 1.92 (m, 1H), 1.88 – 1.80 (m, 1H).  
(205) 6-iodochroman-4-ol 
Compound 204 (0.51 g, 3.4 mmol) was dissolved in anhydrous DCM (15 mL). HgO 
(0.74 g, 3.4 mmol) and I2 (0.87 g, 3.4 mmol) were then added. The resulting dark purple 
mixture was stirred at r.t. for 16 h, after which time solids were removed by filtration, and 
were rinsed with DCM. Filtrate was washed with H2O, and dried with MgSO4. Solvents 
were filtered and removed, and crude residue was purified by column chromatography 
(5:1 hex/EtOAc to 2:1 hex/EtOAc) to give product as a white solid (0.70 g, 74%). 1H-
NMR (400 MHz, CDCl3) δ 7.57 (d, J = 2.2, 1H), 7.43 (dd, J = 8.7, 2.2, 1H), 6.58 (d, J = 
8.7, 1H), 4.65 (t, J = 4.3, 1H), 4.27 – 4.14 (m, 2H), 2.48 (s, 1H), 2.11 – 1.98 (m, 1H), 
1.98 – 1.87 (m, 1H); 13C-NMR (101 MHz, CDCl3) δ 154.50, 138.36, 138.23, 126.93, 
119.53, 82.33, 62.82, 62.22, 30.57.  
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(206) 6-iodochroman-4-one 
To a dry flask was added finely ground 4Å molecular sieves (1.5 g). Compound 205 
(0.70 g, 2.5 mmol) was dissolved in anhydrous DCM (15 mL) and added to the flask, 
which was placed under an inert atmosphere. PCC (0.54 g, 2.5 mmol) was added 
portionwise. The resulting black mixture was stirred at r.t. for 18 h, after which time 
solids were removed via filtration through Florisil. The filtrate was transferred to a 
separatory funnel, and H2O was added. Aqueous layer was extracted with DCM (3x). 
Combined organic extracts were dried with MgSO4. Solvents were filtered and removed 
under reduced pressure to give product as white crystals (0.63 g, 91%). 1H-NMR (400 
MHz, CDCl3) δ 8.19 (d, J = 2.3, 1H), 7.72 (dd, J = 8.7, 2.3, 1H), 6.76 (d, J = 8.7, 1H), 
4.53 (t, J = 6.4, 2H), 2.80 (t, J = 6.4, 2H); 13C-NMR (101 MHz, CDCl3) δ 190.30, 161.31, 
144.13, 135.62, 122.98, 120.30, 83.74, 67.01, 37.26. 
(207) 6-benzylchroman-4-one 
Compound 206 (0.082 g, 0.30 mmol) was dissolved in 3:1 acetone/H2O (degassed and 
saturated with Ar gas). This mixture was then transferred to a 10 mL microwave vessel 
containing K2CO3 (0.12 g, 0.90 mmol) via cannula. Pd(dppf)Cl2 (0.022 g, 0.030 mmol) 
was then added, and the flask was flushed with Ar gas. Benzylboronic acid pinacol ester 
(0.13 g, 0.60 mmol) was then added via syringe. The mixture was stirred under 
microwave irradiation for 1 h at 110 °C, after which time solvents were removed under 
reduced pressure, and crude residue was purified by column chromatography (4:1 
hex/EtOAc) to give a colorless oil (0.040 g, 56%). 1H-NMR (400 MHz, CDCl3) δ 7.75 (d, 
J = 2.3, 1H), 7.32 – 7.24 (m, 3H), 7.23 – 7.14 (m, 3H), 6.89 (d, J = 8.5, 1H), 4.51 (t, J = 
6.4, 2H), 3.92 (s, 2H), 2.79 (t, J = 6.4, 2H); 13C-NMR (101 MHz, CDCl3) δ 192.13, 
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160.54, 140.82, 136.93, 134.46, 128.91, 128.72, 126.90, 126.40, 121.18, 118.22, 67.15, 
41.14, 37.94. NMR revealed that the product co-eluted with ~20% of starting material 
206. The mixture was carried forward without additional purification. 
(208) (E)-6-benzylchroman-4-one oxime 
Followed procedure for compound 111 with 207 (0.023 g, 0.097 mmol) to give product 
as an oil (0.020 g, 83%). 1H-NMR (400 MHz, CDCl3) δ 7.67 (d, J = 2.2, 1H), 7.30 – 7.23 
(m, 2H), 7.23 – 7.15 (m, 3H), 7.07 (dd, J = 8.5, 2.3, 1H), 6.82 (d, J = 8.5, 1H), 4.21 (t, J = 
6.2, 2H), 3.90 (s, 2H), 2.96 (t, J = 6.2, 2H); 13C-NMR (101 MHz, CDCl3) δ 155.25, 
150.27, 141.24, 134.28, 132.03, 128.93, 128.63, 126.22, 124.10, 118.00, 65.10, 41.35, 
23.53.   
(209) 6-benzylchroman-4-amine 
Followed procedure for compound 113 with 208 (0.020 g, 0.079 mmol) shaking at 40 psi 
for 22 h to give product as an oil (0.0062 g, 33%). 1H-NMR (400 MHz, CDCl3) δ 7.24 – 
7.21 (m, 3H), 7.16 (d, J = 7.6, 3H), 6.98 (dd, J = 8.4, 2.1, 1H), 6.74 (d, J = 8.4, 1H), 4.26 
(ddd, J = 12.1, 9.8, 2.6, 1H), 4.18 – 4.11 (m, 2H), 3.86 (s, 2H), 2.22 – 2.11 (m, 1H), 2.02 
– 1.93 (m, 1H).  
(210) (2S)-2-amino-N-(6-benzylchroman-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
Followed procedure for compound 115 with 209 (0.0062 g, 0.026 mmol) to give product 
as a white solid. (210E): MS(EI): 453.2 (M+Na), Retention Time: 37.69 min. (210L): 
MS(EI): 453.2 (M+Na), Retention Time: 38.49 min. 1H-NMR (400 MHz, CD3OD) δ 7.26 
– 7.19 (m, 2H), 7.17 – 7.09 (m, 3H), 6.82 (dd, J = 8.5, 2.2, 1H), 6.60 (d, J = 8.4, 1H), 
6.55 (s, 2H), 6.46 (d, J = 2.2, 1H), 4.76 – 4.70 (m, 1H), 4.17 – 4.09 (m, 1H), 4.03 – 3.95 
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(m, 1H), 3.89 – 3.74 (m, 3H), 3.27 – 3.21 (m, 1H), 2.97 (dd, J = 13.8, 4.6, 1H), 2.29 (s, 
6H), 2.17 – 2.07 (m, 1H), 2.05 – 1.95 (m, 1H).  
(211) 6-(bromomethyl)thiochroman-4-one 
Followed procedure for compound 23 with 6-methylthiochroman-4-one (0.96 g, 5.4 
mmol) to give product as a white solid (0.17 g, 12%). 1H-NMR (500 MHz, CDCl3) δ 8.08 
(d, J = 2.2, 1H), 7.40 (dd, J = 7.8, 1.9, 1H), 7.25 (d, J = 8.3, 1H), 4.44 (s, 2H), 3.22 (t, J = 
6.3, 2H), 2.96 (t, J = 6.3, 2H); 13C-NMR (126 MHz, CDCl3) δ 193.41, 142.62, 134.74, 
133.79, 130.91, 129.33, 128.29, 39.30, 32.56, 26.52.  
(212) 6-benzylthiochroman-4-one 
Followed procedure for compound 159 with 211 (0.079 g, 0.31 mmol) to give product as 
a white solid (0.060 g, 77%). 1H-NMR (500 MHz, CDCl3) δ 8.02 – 7.98 (m, 1H), 7.29 (t, 
J = 7.5, 2H), 7.24 – 7.15 (m, 5H), 3.95 (s, 2H), 3.21 (t, J = 6.5, 2H), 2.96 (t, J = 6.3, 2H); 
13C-NMR (126 MHz, CDCl3) δ 194.15, 140.36, 139.77, 138.30, 134.11, 130.86, 129.26, 
128.79, 128.60, 127.87, 126.33, 41.31, 39.67, 26.64.  
(213) (R)-N-((R)-6-benzylthiochroman-4-yl)-2-methylpropane-2-sulfinamide 
Followed procedure for compound 46 with 212 (0.060 g, 0.24 mmol) to give product as a 
slightly yellow oil (0.038 g, 45%). 1H-NMR (500 MHz, CDCl3) δ 7.29 – 7.24 (m, 2H), 
7.21 – 7.14 (m, 4H), 7.03 (d, J = 8.1, 1H), 6.97 (dd, J = 8.1, 2.0, 1H), 4.60 (q, J = 3.1, 
1H), 3.90 (s, 2H), 3.28 (td, J = 12.6, 2.8, 1H), 3.16 (d, J = 2.3, 1H), 2.79 (dt, J = 12.5, 4.0, 
1H), 2.50 – 2.41 (m, 1H), 2.05 – 1.96 (m, 1H), 1.22 (s, 9H); 13C-NMR (126 MHz, 
CDCl3) δ 140.85, 137.82, 132.54, 131.65, 131.06, 129.15, 128.78, 128.50, 126.91, 
126.14, 55.59, 50.76, 41.25, 28.05, 22.62, 21.01. 
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(214) (S)-2-amino-N-((R)-6-benzylthiochroman-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
Followed procedure for compound 68 with 213 (0.038 g, 0.11 mmol) to give product as a 
white solid. MS(EI): 447.2 (M+H), Retention Time: 39.76 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.23 (t, J = 7.5, 2H), 7.17 – 7.09 (m, 4H), 7.03 (s, 1H), 6.93 (s, 1H), 6.50 (s, 
2H), 5.03 (t, J = 4.0, 1H), 3.85 (dd, J = 11.9, 5.3, 1H), 3.83 (s, 2H), 3.26 (dd, J = 13.6, 
11.7, 1H), 3.01 (dd, J = 13.6, 5.1, 1H), 2.51 (dt, J = 13.3, 4.2, 1H), 2.28 (s, 6H), 2.21 (td, 
J = 12.7, 2.8, 1H), 1.89 – 1.83 (m, 1H), 1.82 – 1.73 (m, 1H).  
(215) 6-benzylthiochroman-4-one 1,1-dioxide 
Compound 212 (0.048 g, 0.19 mmol) was dissolved in glacial AcOH (4 mL). 30% H2O2 
solution (1 mL) was then added. The mixture was stirred at 80 °C for 2 h, after which 
time the mixture was diluted with H2O. Aqueous layer was extracted with DCM. 
Combined organic extracts were washed with brine, and dried with MgSO4. Solvents 
were filtered and removed under reduced pressure to give product as a colorless oil 
(0.050 g, 93%). 1H-NMR (400 MHz, CDCl3) δ 7.95 (d, J = 1.8, 1H), 7.91 (d, J = 8.0, 1H), 
7.61 (dd, J = 8.0, 1.8, 1H), 7.31 (t, J = 7.4, 2H), 7.27 – 7.21 (m, 1H), 7.15 (d, J = 7.1, 2H), 
4.08 (s, 2H), 3.66 (t, J = 6.2, 2H), 3.38 (t, J = 6.4, 2H); 13C-NMR (101 MHz, CDCl3) δ 
190.32, 147.60, 139.20, 138.79, 135.30, 130.32, 128.90, 128.88, 126.87, 124.00, 49.25, 
41.77, 36.78. 
(216) (R)-N-((R)-6-benzyl-1,1-dioxidothiochroman-4-yl)-2-methylpropane-2-
sulfinamide 
Followed procedure for compound 46 with 215 (0.050 g, 0.18 mmol) to give product as a 
colorless oil (0.030 g, 43%). 1H-NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 8.2, 1.2, 1H), 
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7.44 (s, 1H), 7.35 – 7.25 (m, 3H), 7.24 – 7.20 (m, 1H), 7.15 (d, J = 7.5, 2H), 4.69 (q, J = 
4.1, 1H), 4.01 (s, 2H), 3.70 – 3.61 (m, 1H), 3.35 (d, J = 3.4, 1H), 3.30 – 3.23 (m, 1H), 
2.76 – 2.68 (m, 1H), 2.63 – 2.55 (m, 1H), 1.21 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 
147.47, 139.28, 136.62, 136.17, 130.43, 130.24, 128.85, 128.77, 126.68, 124.16, 56.10, 
50.87, 46.13, 41.75, 27.74, 22.53.  
(217) (S)-2-amino-N-((R)-6-benzyl-1,1-dioxidothiochroman-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
Followed procedure for compound 68 with 216 (0.030 g, 0.077 mmol) to give product as 
a white solid. MS(EI): 479.2 (M+H), Retention Time: 31.03 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.71 (d, J = 8.2, 1H), 7.34 (dd, J = 8.2, 1.7, 1H), 7.30 – 7.23 (m, 3H), 7.21 – 
7.13 (m, 3H), 6.52 (s, 2H), 5.24 (t, J = 5.0, 1H), 4.00 (s, 2H), 3.83 (dd, J = 11.5, 5.3, 1H), 
3.26 (dd, J = 14.0, 11.5, 1H), 3.18 – 3.10 (m, 1H), 3.05 (dd, J = 13.7, 5.3, 1H), 2.86 – 
2.75 (m, 1H), 2.42 – 2.32 (m, 1H), 2.28 (s, 6H), 2.02 – 1.93 (m, 1H).  
(218) 1-(3-benzylphenyl)ethan-1-one 
Followed procedure for compound 207 with 1-(3-bromophenyl)ethan-1-one (0.12 g, 0.62 
mmol) stirring at 110  °C for 75 min to give product as a colorless oil (0.058 g, 44%). 1H-
NMR (400 MHz, CDCl3) δ 7.83 – 7.76 (m, 2H), 7.38 (d, J = 5.2, 1H), 7.29 (t, J = 7.4, 
2H), 7.23 – 7.15 (m, 3H), 4.03 (s, 2H), 2.57 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 
198.40, 141.81, 140.52, 137.46, 133.85, 128.98, 128.85, 128.76, 128.73, 126.46, 41.88, 
26.84.  
(219) 6-benzyl-2,3-dihydro-1H-inden-1-one 
Followed procedure for compound 207 with 6-bromo-2,3-dihydro-1H-inden-1-one (0.14 
g, 0.65 mmol) stirring at 110  °C for 70 min to give product as a white solid (0.10 g, 
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70%). 1H-NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.45 – 7.36 (m, 2H), 7.31 – 7.24 (m, 
2H), 7.23 – 7.14 (m, 3H), 4.02 (s, 2H), 3.09 (t, J = 6.0, 2H), 2.68 (t, J = 6.0, 2H); 13C-
NMR (101 MHz, CDCl3) δ 207.22, 153.37, 140.84, 140.57, 137.48, 135.75, 128.95, 
128.73, 126.81, 126.44, 123.71, 41.67, 36.68, 25.59.  
(220) (E)-1-(3-benzylphenyl)ethan-1-one oxime 
Followed procedure for compound 111 with 218 (0.052 g, 0.25 mmol) to give product as 
an oil (0.056 g, 100%). 1H-NMR (400 MHz, CDCl3) δ 7.50 – 7.44 (m, 2H), 7.30 (td, J = 
7.5, 3.1, 3H), 7.22 – 7.19 (m, 4H), 4.02 (s, 2H), 2.28 (s, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 156.23, 141.52, 140.87, 136.82, 130.01, 129.03, 128.79, 128.65, 126.73, 
126.30, 124.07, 42.02, 12.54.  
(221) 1-(3-benzylphenyl)ethan-1-amine 
Followed procedure for compound 113 with 220 (0.054 g, 0.24 mmol), shaking at 40 psi 
for 16 h to give product as a colorless oil (0.040 g, 78%). 1H-NMR (400 MHz, CDCl3) δ 
7.31 – 7.22 (m, 3H), 7.22 – 7.16 (m, 5H), 7.06 (d, J = 7.4, 1H), 4.09 (q, J = 6.6, 1H), 3.98 
(s, 2H), 3.01 (br s, 2H), 1.39 (d, J = 6.6, 3H); 13C-NMR (101 MHz, CDCl3) δ 147.13, 
141.50, 141.16, 129.04, 128.81, 128.59, 127.75, 126.56, 126.21, 123.58, 51.33, 42.10, 
25.27.  
(222) 6-benzyl-2,3-dihydro-1H-inden-1-amine 
Compound 219 (0.045 g, 0.20 mmol) was suspended in anhydrous absolute EtOH (2 mL) 
in a 10 mL microwave tube. NH4OAc (0.23 g, 3.04 mmol) and NaBH3CN (0.015 g, 0.24 
mmol) were then added. The mixture was stirred under microwave irradiation at 130 °C 
for 5 min, after which time EtOH was removed under reduced pressure, and residue was 
redissolved in DCM. 2M HCl was added. Organic layer was discarded, and aqueous layer 
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was basified with solid NaOH pellets (pH 14). Aqueous layer was extracted with DCM 
(3x). Combined organic layers were dried with MgSO4, and solvents were filtered and 
removed under reduced pressure to give product as an oil (0.017 g, 38%). 1H-NMR (400 
MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.22 – 7.10 (m, 5H), 7.03 (d, J = 7.6, 1H), 4.31 (t, J 
= 7.5, 1H), 3.97 (s, 2H), 2.91 (ddd, J = 15.8, 8.6, 3.3, 1H), 2.81 – 2.70 (m, 1H), 2.53 – 
2.43 (m, 1H), 1.73 – 1.64 (m, 1H); 13C-NMR (101 MHz, CDCl3) δ 147.80, 141.55, 
141.02, 139.72, 129.01, 128.59, 128.10, 126.13, 124.74, 123.94, 57.28, 42.03, 37.61, 
29.87.  
(223) (2S)-2-amino-N-(1-(3-benzylphenyl)ethyl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
Followed procedure for compound 115 with 221 (0.053 g, 0.25 mmol) to give product as 
a white solid. (223E): MS(EI): 403.3 (M+H), Retention Time: 37.57 min. 1H-NMR (400 
MHz, CD3OD) δ 7.26 – 7.19 (m, 2H), 7.19 – 7.12 (m, 4H), 7.05 (d, J = 7.6, 1H), 6.88 (s, 
1H), 6.65 (d, J = 7.6, 1H), 6.32 (s, 2H), 4.95 – 4.91 (m, 1H), 3.93 (d, J = 3.9, 2H), 3.87 – 
3.74 (m, 1H), 3.12 (t, J = 12, 1H), 2.86 (d, J = 13.5, 1H), 2.02 (s, 6H), 1.31 (d, J = 6.9, 
3H). (223L): MS(EI): 403.3 (M+H), Retention Time: 38.68 min. 1H-NMR (400 MHz, 
CD3OD) δ 7.25 – 7.00 (m, 9H), 6.52 (s, 2H), 4.78 (t, J = 7.2, 1H), 3.90 (s, 2H), 3.77 (dd, 
J = 11.6, 4.6, 1H), 3.25 – 3.15 (m, 1H), 2.99 (d, J = 13.8, 4.6, 1H), 2.27 (s, 6H), 1.09 (d, J 
= 7.0, 3H).  
(224) (2S)-2-amino-N-(6-benzyl-2,3-dihydro-1H-inden-1-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide 
 Followed procedure for compound 115 with 222 (0.012 g, 0.054 mmol) to give product 
as a white solid. MS(EI): 437.2 (M+Na), Retention Time: 39.35 min. 1H-NMR (500 
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MHz, CD3OD) δ 7.27 – 7.01 (m, 14H), 6.97 (d, J = 6.4, 1H), 6.59 (s, 2H), 6.52 (s, 1H), 
6.50 (s, 2H), 5.26 (q, J = 6.8, 1H), 5.16 – 5.09 (m, 1H), 3.96 – 3.78 (m, 6H), 3.30 – 3.20 
(m, 2H), 3.01 (dt, J = 13.7, 4.9, 2H), 2.85 (ddd, J = 15.8, 8.7, 3.9, 1H), 2.81 – 2.65 (m, 
3H), 2.53 (dtd, J = 11.9, 7.7, 4.0, 1H), 2.29 (s, 6H), 2.27 (s, 6H), 2.26 – 2.20 (m, 1H), 
1.80 – 1.70 (m, 1H), 1.41 – 1.30 (m, 1H) (both diastereomers).  
(225) tert-butyl 7-chloro-5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-
carboxylate 
Followed procedure for compound 15 with 7-chloro-1,2,3,4-tetrahydro-5H-
benzo[b]azepin-5-one (0.046 g, 0.24 mmol) to give product as a white solid (0.060 g, 
43%). 1H-NMR (500 MHz, CDCl3) δ 7.82 (s, 1H), 7.44 – 7.33 (m, 2H), 3.74 (br s, 2H), 
2.76 (t, J = 6.7, 2H), 2.16 (p, J = 6.9, 2H), 1.49 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 
199.80, 153.68, 142.79, 134.22, 132.24, 131.73, 129.55, 128.70, 81.70, 48.84, 40.08, 
28.33, 24.66.  
(226) tert-butyl 7-benzyl-5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-
carboxylate 
To a dry 10 mL microwave vessel was added K2CO3 (0.084 g, 0.61 mmol), SPhos (0.016 
g, 0.040 mmol) and Pd2(dba)3 (0.019 g, 0.020 mmol). The vessel was placed under an 
inert atmosphere, and 225 (0.060 g, 0.20 mmol) dissolved in 10:1 1,4-dioxane/H2O (3 
mL, degassed and saturated with Ar gas) was added via syringe. Benzylboronic acid 
pinacol ester (0.066 g, 0.30 mmol) was then added via syringe. The mixture was stirred 
under microwave irradiation at 140 °C for 30 min, after which time solvents were 
removed under reduced pressure, and crude residue was purified by column 
chromatography (10:1 hex/EtOAc) to give product as a colorless oil (0.029 g, 28%). 1H-
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NMR (500 MHz, CDCl3) δ 7.71 (s, 1H), 7.31 – 7.25 (m, 3H), 7.22 – 7.16 (m, 3H), 3.98 
(s, 2H), 3.72 (br s, 2H), 2.74 (t, J = 6.6, 2H), 2.16 – 2.08 (m, 2H), 1.47 (s, 9H); 13C-NMR 
(126 MHz, CDCl3) δ 201.34, 154.12, 140.45, 139.12, 133.09, 132.48, 129.11, 129.01, 
128.69, 128.20, 126.42, 81.28, 48.82, 41.40, 40.27, 28.40, 24.69.  
(227) tert-butyl (R)-7-benzyl-5-(((R)-tert-butylsulfinyl)amino)-2,3,4,5-tetrahydro-
1H-benzo[b]azepine-1-carboxylate 
Followed procedure for compound 46 with 226 (0.029 g, 0.083 mmol) to give a colorless 
oil that was not characterized and used without further purification. 
(228) (S)-2-amino-N-((R)-7-benzyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 68 with 227 (0.007 g, 0.015 mmol) to give product as 
a white solid. MS(EI): 444.3 (M+H), Retention Time: 26.04 min. 1H-NMR (500 MHz, 
CD3OD) δ 7.26 – 7.22 (m, 2H), 7.18 – 7.13 (m, 4H), 7.08 – 7.02 (m, 2H), 6.53 (s, 2H), 
5.05 (dd, J = 8.4, 2.3, 1H), 3.95 (dd, J = 11.6, 4.8, 1H), 3.91 (s, 2H), 3.23 (dd, J = 13.7, 
11.7, 1H), 3.18 – 3.12 (m, 1H), 3.11 – 3.02 (m, 2H), 2.28 (s, 6H), 1.81 – 1.71 (m, 1H), 
1.61 – 1.50 (m, 2H), 1.48 – 1.39 (m, 1H).  
(229) 6-benzyl-N-methyl-1,2,3,4-tetrahydroquinolin-4-amine 
To a stirring solution of methylamine hydrochloride (1.78 g, 26.4 mmol), Et3N (3.68 
mmol, 26.4 mmol) and 14 (3.14 g, 13.2 mmol) in absolute EtOH (70 mL) was added 
Ti(OiPr)4 (7.81 mL, 26.4 mmol). The reaction was allowed to stir at r.t for 24 h. NaBH4 
(0.749 g, 19.8 mmol) was then added to the reaction mixture, and was allowed to stir for 
an additional 8 h. The reaction was then quenched by pouring into aqueous ammonia (10 
mL). The resulting inorganic precipitate was filtered off and washed with DCM. The 
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organic layer was separated, and the aqueous layer was washed again with DCM. The 
organic layers were combined and extracted once with 1M HCl. The acidic aqueous 
extract was washed once with DCM then treated with 2M NaOH until the solution 
reached pH 12. The aqueous layer was then extracted with DCM (3x). The combined 
organic extracts were washed with brine, dried with MgSO4, and solvents were removed 
under reduced pressure to give a yellow oil (1.05 g) which was used without any further 
purification.  
(230) 6-benzyl-N-cyclopropyl-1,2,3,4-tetrahydroquinolin-4-amine 
To a 10 mL microwave vessel was added 14 (0.11 g, 0.46 mmol) and absolute EtOH (2 
mL). Cyclopropylamine (0.27 g, 4.6 mmol) was then added via syringe. NaBH3CN 
(0.035 g, 0.56 mmol) was then added. The mixture was stirred under microwave 
irradiation at 130 °C for 10 min, after which time EtOH was removed under reduced 
pressure, and crude residue was redissolved in DCM. 1M HCl was added, and the organic 
layer was removed. Aqueous layer was basified with solid NaOH pellets (pH 14), and 
was extracted with DCM (3x). Combined organic extracts were dried with MgSO4. 
Solvents were filtered and removed, and crude residue was purified by column 
chromatography (20:1 DCM/MeOH) to give product as a white solid (0.011 g, 9%). 1H-
NMR (400 MHz, CDCl3) δ 7.32 – 7.22 (m, 2H), 7.22 – 7.12 (m, 3H), 6.97 (d, J = 2.1, 
1H), 6.85 (dd, J = 8.2, 2.1, 1H), 6.44 (d, J = 8.2, 1H), 3.87 – 3.81 (m, 3H), 3.39 (td, J = 
11.6, 3.1, 1H), 3.23 (dt, J = 11.4, 4.2, 1H), 2.25 – 2.09 (m, 2H), 1.97 – 1.87 (m, 1H), 0.57 
– 0.37 (m, 4H); 13C-NMR (101 MHz, CDCl3) δ 142.72, 142.25, 130.39, 129.29, 129.03, 
128.90, 128.43, 125.89, 122.26, 114.76, 53.77, 41.20, 37.42, 28.57, 26.93, 7.16, 5.90. 
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(231) (2S)-2-amino-N-(6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)-N-methylpropanamide 
Followed procedure for compound 115 with 229 (0.10 g, 0.41 mmol) to give product as a 
white solid. (231E): MS(EI): 466.2 (M+Na), Retention Time: 27.25 min. (231L): 
MS(EI): 466.2 (M+Na), Retention Time: 29.16 min.  
(232) (2S)-2-amino-N-(6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-N-cyclopropyl-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide 
Followed procedure for compound 115 with 230 (0.011 g, 0.041 mmol) to give product 
as a white solid. (232E): MS(EI): 492.3 (M+Na), Retention Time: 28.05 min. 1H-NMR 
(400 MHz, CD3OD) δ 7.23 – 7.16 (m, 2H), 7.13 – 7.03 (m, 3H), 6.80 (dd, J = 8.1, 1.9, 
1H), 6.67 (s, 1H), 6.56 (d, J = 8.2, 1H), 6.52 (s, 2H), 5.67 – 5.59 (m, 1H), 5.07 (dd, J = 
11.6, 4.7, 1H), 3.77 (s, 2H), 3.39 – 3.33 (m, 3H), 3.17 (dd, J = 13.8, 4.8, 1H), 2.32 (s, 
6H), 2.25 – 2.10 (m, 1H), 1.83 – 1.71 (m, 1H), 1.35 – 1.24 (m, 1H), 0.88 – 0.78 (m, 1H), 
0.59 – 0.49 (m, 1H), 0.42 – 0.30 (m, 2H). (232L): MS(EI): 492.3 (M+Na), Retention 
Time: 30.18 min. 1H-NMR (400 MHz, CD3OD) δ 7.26 – 7.18 (m, 2H), 7.16 – 7.06 (m, 
3H), 6.82 (dd, J = 8.2, 1.9, 1H), 6.62 (d, J = 8.2, 1H), 6.56 (s, 2H), 6.35 (s, 1H), 5.49 – 
5.41 (m, 1H), 5.06 (dd, J = 11.5, 4.5, 1H), 3.82 (d, J = 6.1, 2H), 3.40 (dd, J = 13.7, 11.5, 
1H), 3.27 (dd, J = 8.0, 3.5, 2H), 3.09 (dd, J = 13.7, 4.5, 1H), 2.35 (s, 6H), 1.82 – 1.72 (m, 
1H), 0.88 – 0.74 (m, 1H), 0.68 – 0.56 (m, 1H), 0.52 – 0.37 (m, 1H), 0.24 – 0.11 (m, 1H).  
3.6.2 Microsomal Stability  
To a mixture of 10 µL of pooled mouse liver microsomes (20 mg/mL, Xenotech, 
lot#105861) and 366 µL 0.1 M phosphate buffer containing 3.3 mM MgCl2 are added 4 
µL test compound (at 100 µM in MeOH/H2O). The solution mixture is pre-incubated in a 
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water bath at 37 °C for 3 min. Next, a solution of 16.7 mg/mL (20 mM) NADPH in 0.1 
M phosphate buffer containing 3.3 mM MgCl2 is made. Following preparation, 20 µL of 
the NADPH solution is added to the solution containing the test compound to initiate the 
reaction (the final concentration of test compound 1 µM). The stability of the compound 
is tested at T (min)= 0,1,3,5,10,30 and 60 by removing a 30 µL aliquot, and quenching it 
with 90 µL of cold MeCN. The quenched samples are centrifuged at 14000 rpm for 5 
min, and then 5 µL of the supernatant is used for LC/MS/MS analysis. 
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CHAPTER 4 
SYNTHESIS OF 2’,6’-DIMETHYL-L-TYROSINE DERIVATIVES AND 
INCORPORATION INTO OPIOID PEPTIDOMIMETICSc 
 
4.1 Introduction 
The unnatural amino acid 2’,6’-dimethyl-L-tyrosine (Dmt)9 has found widespread 
use in the synthesis of opioid peptides and small molecules.36,39,57,95 Typically, opioid 
ligands containing Dmt in place of tyrosine (Tyr) at the N-terminus display increased 
affinity for the mu opioid receptor (MOR)27,96,97 and many Dmt-containing ligands 
reported in the literature are potent and efficacious analgesics in preclinical pain 
models.31,59 Additionally, Dmt is a component of Dmt-Tic, a delta opioid receptor (DOR) 
antagonist pharmacophore that is incorporated in many biologically active compounds.98 
Dmt is also an important building block for the synthesis of the mixed Mu-Delta opioid 
ligand Eluxadoline®, a small molecule opioid recently approved for the treatment of 
irritable bowl syndrome.64,99 Moreover, peptides containing this amino acid have also 
been shown to have antioxidant properties.100 
Several synthetic routes to Dmt have previously been published. In one such 
synthesis, the key step for installing the desired L stereochemistry is the asymmetric 
hydrogenation of (Z)-2-acetamido-3-(4-acetoxy-2,6-dimethylphenyl)-2-propenoate, using 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
c See reference 109. In vitro assays were performed by Nick Griggs, Tyler Trask, and Chao Gao. In vivo 
work was done by Jessica Anand. 
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the expensive chiral catalyst [Rh(1,5-COD)(R,R-DIPAMP)]BF4.101 Other strategies 
involve the alkylation of a Ni(II) complex of the chiral Schiff base derived from glycine 
and (S)-o-[N-(N-benzylprolyl)amino]benzophenone102 and a stereocontrolled alkylation 
of a chiral 2,5-diketopiperazine synthon.103 Although these routes are synthetically 
viable, we sought to develop a shorter and more direct approach for the expedient 
synthesis of Dmt and other novel unnatural Tyr derivatives. Additionally, the 
development of a synthesis in which the desired L stereochemistry is incorporated from 
the beginning, and does not need to be installed with the use of a chiral auxiliary or 
catalyst, would be desirable.  
 
RESULTS AND DISCUSSION 
4.2 Synthesis of 2’,6’-dimethyl-L-tyrosine Analogues via Negishi Coupling  
Jackson and colleagues have disclosed that the use of Pd2(dba)3 and SPhos104 in a 
1:2 molar ratio is a highly efficient precatalyst for the Negishi coupling of aryl halides 
with an organozinc reagent derived from iodoalanine intermediate 233.105 This strategy 
was shown to be effective for both aryl iodides and bromides, as well as aryl halides 
featuring unprotected phenols and ortho substitutions. Given the synthetic utility of this 
approach, it was reasoned that a Negishi coupling between 233 and commercially 
available 3,5-dimethyl-4-iodophenol was a feasible approach toward the synthesis of 
Dmt.  
 Iodoalanine intermediate 233 was synthesized under Appel conditions as 
previously reported starting from commercially available Boc-protected L-serine methyl 
ester (Boc-Ser-OMe) (Scheme 22).106 After the synthesis of 233, conditions for the 
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Negishi coupling with 3,5-dimethyl-4-iodophenol were explored. Jackson and colleagues 
observed that the best yields for the coupling of mono-ortho-substituted aryl halides with 
233 were obtained by using 2.5 mol % of Pd2(dba)3 and 5 mol % of SPhos with stirring at 
room temperature overnight. For the coupling between 233 and 3,5-dimethyl-4-
iodophenol, these conditions led to the formation of desired product 234 in 16% yield. It 
was reasoned that the additional steric hindrance of this system contributed to the 
observed low yield, and a more efficient approach was desired. 
Scheme 22. Synthesis of Boc-2’,6’-dimethyl-L-tyrosine 
 
 
 
 
 
The use of microwave-assisted synthesis has been shown to be highly effective 
for challenging Negishi cross-coupling reactions107,108 and the reaction was next run 
under microwave irradiation at 110 °C to give 234 in 40% yield. Increasing the mol % of 
Pd2(dba)3 and SPhos to 5% and 10% respectively under these conditions gave 234 in 56% 
yield.109 Subsequent methyl ester hydrolysis gave Boc-2’,6’-dimethyl-L-tyrosine 235. 
Attention was next turned to using the microwave-assisted Negishi cross coupling 
reaction for the synthesis of other unnatural tyrosine and phenylalanine derivatives 
(Scheme 23). 
 4’-hydroxy-2’-methylphenyl (Mmt) analogue 241 has been previously reported in 
synthetic endomorphin110 and DALDA-based85 peptides, and showed comparable binding 
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affinity at MOR relative to the Dmt counterpart compounds. 2’,6’-dimethyl-L-
phenylalanine (Dmp) analogue 244 has also been incorporated into the endomorphin 
scaffold, and has been shown to improve binding affinity at MOR and DOR compared to 
the naturally occurring endomorphins when substituted at the third position.111 
Additionally, phenylalanine and derivatives can sometimes serve as suitable replacements 
for the N-terminal tyrosine in opioid peptides, while still maintaining biological 
activity.112,113 Compounds 242, 243 and 245 had not been examined as Tyr replacements 
in opioid ligands. The synthesis of all analogues using the microwave-assisted Negishi 
coupling proved straightforward. In the case of analogue 238, aryl iodide 252 was 
synthesized from 3,5-dichloroanisole as previously described (Scheme 24).114 In the case 
of analogue 240, aryl bromide 253 was synthesized via halogenation and aromatization of 
commercially available 7-bromo-3,4-dihydronaphthalen-1(2H)-one (Scheme 25). After 
methyl ester hydrolysis, all analogues were coupled to 6-benzyl-1-(tert-butoxycarbonyl)-
1,2,3,4-tetrahydroquinolin-4-aminium chloride (Chapter 2) under standard amide 
coupling conditions (Scheme 23) to give final tetrahydroquinolines 246-250 after Boc-
deprotection, and in the case of 248, after an additional deprotection of the aryl methoxy 
group with BBr3 (Scheme 23).  
 
 
 
 
 
 
	   158	  
Scheme 23. Synthesis of Analogues 246-251 
 
 
 
 
 
 
 
 
Additionally, 234 was carried forward using previously described chemistry99 and 
coupled to 6-benzyl-1-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroquinolin-4-aminium 
chloride to give carboxamido analogue 251, a replacement that has been shown to be an 
effective bioisostere for phenol moieties (Scheme 23).115 Lastly, in an attempt to further 
explore chloro substitutents and phenol replacements, 6-benzyl-1-(tert-butoxycarbonyl)-
1,2,3,4-tetrahydroquinolin-4-aminium chloride was coupled to commercially available 
Boc-2’4’-dichloro-L-phenylalanine and deprotected under standard conditions to give 
final analogue 254 (Scheme 26). Final analogues were then purified by semipreparative 
RP-HPLC and lyophilized to give enough material for in vitro testing. 
Scheme 24. Synthesis of Intermediate 252 
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Scheme 25. Synthesis of Intermediate 253 
 
 
 
Scheme 26. Synthesis of Analogue 254 
 
 
 
 
 
 
As seen in Table 8, MOR binding affinity is reduced by approximately an order of 
magnitude for analogues 246 and 247 in which the 2’-methyl group is maintained, and 
the second aryl methyl is either deleted (246) or moved to the 5’ position (247). MOR 
affinity for 2’,6-dichloro analogue 248 is comparable to the parent peptidomimetic 1 
(Chapter 2), which is not entirely surprising given the similar size of the methyl and 
chloro substituents. Analogues 249 and 250 display a more pronounced decrease in MOR 
binding, and analogues 247, 249 and 250 lose significant binding affinity at DOR. The 
data in Table 8 show that analogues 246-249 and 251 all maintain a high level of agonist 
efficacy (as measured by [35S]GTPγS binding) compared to DAMGO at MOR, but with 
reduced potency as compared to 1. In particular, carboxamido analogue 251 maintains 
high binding affinity and good potency at MOR, further highlighting the utility of this 
phenol bioisostere for the development of opioid ligands.  The 2’,5’-dimethyl analogue 
Br
O
Br
OH
253
1) NBS, CCl4, reflux
2) LiBr, Li2CO3, DMF
N
H
HN
O
NH2
Cl
Cl
N
NH3
Cl
OH
Cl
Cl
NHBoc
O
1) PyBOP, HOBt-Cl, DIPEA, 
DMF
2) TFA, DCM
254
Boc
	   160	  
247 displays reduced potency at DOR as compared to 1, but with higher maximal 
stimulation (53% compared to the full agonist DPDPE). The naphthol analogue 250 
shows a significant decrease in binding affinity for all three receptors, and thus was not 
evaluated in the [35S]GTPγS assay.  
Scheme 27. Synthesis of Analogue 257 
 
  
 
 
 
 
 With its ability to maintain the high MOR affinity and potency in this series and 
provide considerable selectivity over DOR and KOR, the results show that Boc-2’,6’-
dichloro-L-tyrosine may prove useful for the development of opioids with improved 
metabolic stability toward benzylic oxidation.  
In an attempt to combine this unnatural chlorinated amino acid with previously 
discussed modifications aimed at improving metabolic stability (see Chapter 3), 243 was 
also coupled to amine scaffold 256 (prepared from chiral sulfonamide 255 from 
commercially available 7-phenoxy-3,4-dihydronaphthalen-1(2H)-one, Scheme 27) to 
give final diarylether analogue 257 (Table 8), a compound which displays reduced 
binding affinity for both MOR and DOR as compared to 1. Unfortunately, t1/2 for 
analogue 257 was also found to be < 5 min in mouse liver microsomes.  
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Table 8. Opioid Receptor Binding Affinities and Efficacies for Analogues 246-251, 254 
and 257a 
 
    MOR DOR KOR 
 R1 R2 R3 Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim 
1 CH2 NH 
 
0.22 ± 0.02 1.6 ± 0.3 81 ± 2 9.4 ± 0.8 110 ± 6 16 ± 2 68 ± 2 540 ± 72 22 ± 2 
246 CH2 NH 
 
1.7 ± 0.2 44 ± 20 69 ± 6 42 ± 9 dns dns 96 ± 20 2350 ± 80 41 ± 8 
247 CH2 NH 
 
6.5 ± 2 39 ± 8 89 ± 8 390 ± 120 
5900 ± 
2200 
53 ± 8 
730 ± 
80 
370 ± 200 22 ± 6 
248 CH2 NH  
0.47 ± 0.04 33 ± 4 83 ± 3 37 ± 8 dns dns 35 ± 5 
1150 ± 
290 
32 ± 4 
249 CH2 NH 
 
18 ± 4 280 ± 50 86 ± 8 660 ± 120 dns dns 
130 ± 
50 
4750 ± 
1100 
38 ± 5 
250 CH2 NH 
 
440 ± 70 - - 
1620 ± 
120 
- - 
2500 ± 
450 
- - 
251 CH2 NH 
 
0.6 ± 0.1 9.2 ± 5 98 ± 5 33 ± 8 
1590 ± 
740** 
25 ± 
3** 
170 ± 
50 
dns dns 
254 CH2 NH 
 
51 ± 10 >1000** >13** 2087* dns* dns* - - - 
257 O CH2 
 
1.5 ± 0.6 118 ± 80 21 ± 3 105 ± 10 dns dns - - - 
a. dns = does not stimulate. See Table 1 for further in vitro details. Dashed line indicates compound was not 
tested. * = n of 1, ** = n of 2. 
 
 
 
4.3 In Vivo Studies on Analogue 251 
 On the basis of its good binding affinity and potent [35S]GTPγS simulation of 
MOR, compound 251 was chosen for in vivo studies. In the mouse warm water tail 
withdrawal (WWTW) assay, 251 was fully efficacious, and produced dose-dependent 
increases in latency to tail flick (Figure 21).  
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Figure 21. Cumulative Antinociceptive Dose-Response Curve for Analogue 251 in the 
Mouse WWTW Assay After ip Administration (n = 3)a  
 
 
 
 
 
 
a. Data are plotted as mean ± SEM. 
To determine the duration of action of compound 251, tail withdrawal latencies 
were measured at intervals following the administration of the 10 mg/kg dose (Figure 
22). Compound 251 showed a full antinociceptive response for just under 100 minutes 
before returning to baseline. Compared with compounds 86 and 102 (Figure 17, Chapter 
2) and compound 214 (Figure 20, Chapter 3) this compound displayed a shorter total 
duration of action (Figure 22), comparable to compound 1 (Figure 17, Chapter 2).  
 
Figure 22. Time Course of Antinociceptive Response For Analogue 251 in the Mouse 
WWTW Assay After ip Administration of a 10 mg/kg Dose  
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In this chapter, a 3-step synthesis of Boc-2’,6’-dimethyl-L-tyrosine (Dmt) 
featuring a microwave-assisted Negishi coupling is described, which ultimately led to the 
expedient synthesis of a number of novel tyrosine analogues that were incorporated into 
the peptidomimetic scaffold. Of particular interest is 2’,6’-dichloro-L-tyrosine 
intermediate 243, which may be useful for the development of peptidomimetics with 
reduced liability for oxidative metabolism on the aryl methyl groups, and carboxamido 
peptidomimetic 251, which shows a total duration of action in vivo that is comparable to 
lead compound 1. Given this result, this carboxamido substitution may prove useful as a 
substitution on other peptidomimetic scaffolds reported in previous chapters as a means 
to improve upon the duration of action in vivo, by preventing phase 2 metabolic 
glucoronidation on the 4’ hydroxyl. 
 
4.4 Experimental Procedures  
4.4.1 Chemistry 
Specific rotations were recorded on a Jasco P2000 instrument at 589 nm with a path 
length of 100 mm. Chiral purity of analogues Boc-protected amino acid derivatives was 
determined with a Lux 5µ Amylose-2 column by Phenomenex, with a linear gradient of 
0% solvent B (acetonitrile with 0.1% AcOH and 0.02% TFA) in Solvent A (water with 
0.1% AcOH and 0.02% TFA) to 70% solvent B, with a flow rate of 1 mL/min (gradient 
was optimized using a sample of Boc-DL-2’,4’,6’-trimethylphenylalanine which gave 
good separation, t1 = 45.04 min, t2 = 46.17 min). Data was analyzed with a Waters 
Alliance 2690 analytical HPLC at 230 nm. For further general chemistry, in vitro and in 
vivo experimental detail, see section 2.4. 
	   164	  
 (233) methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate 
To a dry flask was added PPh3 (2.96 g, 11.3 mmol) and imidazole (0.77 g, 11.3 mmol). 
The flask was placed under an inert atmosphere, and DCM (30 mL) was added via 
syringe. After dissolution of solids, I2 (3.45 g, 13.6 mmol) was added portionwise. The 
mixture was allowed to stir for 5 min, after which time Boc-L-Ser-OMe (2.49 g, 11.3 
mmol) was dissolved in DCM (20 mL) and added dropwise via syringe. The mixture was 
stirred at r.t. for 4 h, after which time it was transferred to a separatory funnel and washed 
with H2O, sat. sodium thiosulfate, and brine. The organic layer was dried with MgSO4, 
and solvents were filtered and removed. Crude residue was purified by column 
chromatography (5:1 hex/EtOAc) to give product as a colorless oil that solidified upon 
standing (2.66 g, 72%). 1H-NMR (400 MHz, CDCl3) δ 5.47 (d, J = 7.8, 1H), 4.53 (dt, J = 
7.9, 4.0, 1H), 3.80 (s, 3H), 3.61 – 3.53 (m, 2H), 1.46 (s, 9H); 13C-NMR (101 MHz, 
CDCl3) δ 169.96, 154.77, 80.32, 53.70, 52.97, 28.25, 7.80.  
(234) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)propanoate  
To a dry 10 mL microwave flask equipped with a stir bar was added Zn dust (0.13 g, 1.93 
mmol) and placed under an inert atmosphere. DMF (0.5 mL) was added via syringe, 
followed by a catalytic amount of I2 (30 mg). The mixture was stirred vigorously, during 
which time the color changed to yellow and back to colorless. Compound 233 (0.21 g, 
0.64 mmol) in DMF (2 mL) was added via syringe, immediately followed by another 
portion of catalytic I2 (30 mg). The mixture was stirred vigorously for 10 min, after 
which time Pd2(dba)3 (0.029 g, 0.032 mmol), SPhos (0.026 g, 0.064 mmol) and 3,5-
dimethyl-4-iodophenol (0.21 g, 0.84 mmol) were added quickly. The resulting mixture 
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was transferred to the microwave reactor under an inert atmosphere, and stirred for 2 h at 
110 °C, after which time the reaction mixture was added directly to a silica column and 
purified (4:1 to 2:1 hex/EtOAc) to give product as a colorless oil (0.12 g, 56%). MS(EI): 
346.2 (M+Na). 1H-NMR (400 MHz, CDCl3) δ 6.48 (s, 2H), 5.29 (brs, 1H), 5.08 (d, J = 
8.7, 1H), 4.48 (q, J = 8.1, 1H), 3.65 (s, 3H), 3.08 – 2.86 (m, 2H), 2.27 (s, 6H), 1.41 (s, 
9H); 13C-NMR (101 MHz, CDCl3) δ 173.49, 155.17, 154.18, 138.73, 125.31, 115.18, 
80.15, 53.34, 52.43, 32.75, 28.40, 20.40.  
(235) (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2,6-
dimethylphenyl)propanoic acid  
To a solution of 234 (0.11 g, 0.34 mmol) in THF (2 mL) was added a solution of LiOH 
(0.044 g, 1.71 mmol) in H2O (2 mL) dropwise. The mixture was stirred at r.t. for 1 h, 
after which time 1M HCl was added until the solution reached pH 4. The mixture was 
transferred to a separatory funnel, and the aqueous layer was extracted with EtOAc.  
Combined organic extracts were dried with MgSO4, and solvents were filtered and 
removed to give product as a colorless oil (0.10 g, 94%). 1H-NMR (400 MHz, CDCl3) δ 
6.60 (d, J = 8.3), 5.20 (d, J = 8.7) (1H), 6.51, 6.48 (2s, 2H), 4.56 – 4.34 (m, 1H), 3.11 (dd, 
J = 14.4, 5.4), 2.96 (dd, J = 14.4, 9.6) (2H), 2.29, 2.27 (2s, 6H), 1.37, 1.19 (2s, 9H); 13C-
NMR (101 MHz, CDCl3) δ 177.33, 176.42, 156.64, 155.59, 154.22, 138.93, 138.72, 
125.73, 125.01, 115.34, 115.26, 81.73, 80.68, 54.41, 53.58, 33.33, 32.39, 28.36, 27.85, 
20.45, 20.40. [α]D20 -9.74° (c 1.0, MeOH), literature value [α]D20 -11.7° (c 1.0, MeOH)116. 
Elution times (Lux 5µ Amylose-2): tmajor: 31.42 min, tminor: 30.36 min, e.r. 96:4. 
(236) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2-
methylphenyl)propanoate 
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Followed procedure for compound 234 with 233 (0.15 g, 0.44 mmol) and 4-iodo-3-
methylphenol (0.14 g, 0.58 mmol) to give product as a colorless oil (0.074 g, 54%). 1H-
NMR (500 MHz, CDCl3) δ 6.87 (d, J = 8.3, 1H), 6.64 (d, J = 2.7, 1H), 6.57 (d, J = 7.7, 
1H), 6.34 (br s, 1H), 5.06 (d, J = 8.5, 1H), 4.51 (q, J = 7.3, 1H), 3.68 (s, 3H), 3.06 (dd, J = 
14.2, 6.1, 1H), 2.92 – 2.84 (m, 1H), 2.25 (s, 3H), 1.40 (s, 9H); 13C-NMR (126 MHz, 
CDCl3) δ 173.04, 155.27, 155.09, 138.11, 130.92, 125.82, 117.38, 112.87, 80.17, 53.95, 
52.26, 35.27, 28.28, 19.41. 
(237) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2,5-
dimethylphenyl)propanoate 
Followed procedure for compound 234 with 233 (0.13 g, 0.41 mmol) and 4-iodo-2,5-
dimethylphenol (0.13 g, 0.53 mmol) to give product as a colorless oil (0.052 g, 39%). 1H-
NMR (400 MHz, CDCl3) δ 6.76 (s, 1H), 6.54 (s, 1H), 5.76 (br s, 1H), 5.07 (d, J = 8.4, 
1H), 4.50 (q, J = 7.6, 1H), 3.69 (s, 3H), 3.04 (dd, J = 14.3, 6.1, 1H), 2.85 (dd, J = 14.2, 
7.1, 1H), 2.21 (s, 3H), 2.15 (s, 3H), 1.41 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 173.13, 
155.23, 153.00, 135.25, 132.48, 125.73, 121.21, 116.84, 80.07, 54.01, 52.31, 35.24, 
28.28, 18.97, 15.38. 
(238) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2,6-dichloro-4-
methoxyphenyl)propanoate 
Followed procedure for compound 234 with 233 (0.21 g, 0.64 mmol) and 252 (0.19 g, 
0.64 mmol) to give product as a colorless oil (0.038 g, 16%). 1H-NMR (400 MHz, 
CDCl3) δ 6.87 (s, 2H), 5.15 (d, J = 9.1, 1H), 4.68 (td, J = 9.3, 5.9, 1H), 3.77 (s, 3H), 3.74 
(s, 3H), 3.32 (dd, J = 13.9, 5.9, 1H), 3.22 (dd, J = 13.8, 9.5, 1H), 1.35 (s, 9H); 13C-NMR 
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(101 MHz, CDCl3) δ 172.41, 158.71, 154.96, 136.34, 124.74, 114.26, 79.74, 55.69, 
52.50, 33.54, 28.20. 
(239) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2,6-dimethylphenyl)propanoate 
Followed procedure for compound 234 with 233 (0.16 g, 0.48 mmol) and 2-iodo-1,3-
dimethylbenzene (0.14 g, 0.62 mmol) to give product as a colorless oil (0.053 g, 36%). 
1H-NMR (400 MHz, CDCl3) δ 7.07 – 6.96 (m, 3H), 5.09 (d, J = 8.7, 1H), 4.54 (q, J = 8.1, 
1H), 3.63 (s, 3H), 3.15 – 3.00 (m, 2H), 2.34 (s, 6H), 1.36 (s, 9H); 13C-NMR (101 MHz, 
CDCl3) δ 173.32, 155.00, 137.14, 133.37, 128.41, 126.81, 79.92, 53.05, 52.33, 33.40, 
28.36, 20.30. 
(240) methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(8-hydroxynaphthalen-2-
yl)propanoate  
Followed procedure for compound 234 with 233 (0.16 g, 0.47 mmol) and 253 (0.14 g, 
0.62 mmol) to give product as a yellow oil (0.068 g, 42%). 1H-NMR (500 MHz, CDCl3) 
δ 8.00 (s, 1H), 7.72 (d, J = 8.4, 1H), 7.35 (d, J = 8.2, 1H), 7.29 – 7.21 (m, 2H), 7.19 (br s, 
1H), 6.84 (d, J = 7.5, 1H), 5.08 (d, J = 8.3, 1H), 4.67 (q, J = 7.2, 1H), 3.72 (s, 3H), 3.33 – 
3.17 (m, 2H), 1.40 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 172.70, 155.42, 152.17, 
133.91, 132.62, 128.05, 127.73, 125.98, 124.75, 122.39, 119.73, 108.84, 80.20, 54.74, 
52.41, 38.77, 28.40. 
(241) (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2-methylphenyl)propanoic 
acid  
Followed procedure for compound 235 with 236 (0.073 g, 0.24 mmol) to give product as 
a white solid (0.050 g, 71%). 1H-NMR (500 MHz, CDCl3) δ 6.93 (d, J = 8.3, 1H), 6.64 
(d, J = 6.2, 1H), 6.55 (d, J = 9.5, 1H), 6.25 (d, J = 8.0), 5.10 (d, J = 8.4) (1H), 4.53 (q, J = 
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7.2), 4.36 (q, J = 7.2) (1H), 3.14 (dd, J = 14.3, 5.6), 2.95 – 2.90 (m) (2H), 2.26, 2.24 (2s, 
3H), 1.40, 1.30 (2s, 9H); 13C-NMR (126 MHz, CDCl3) δ 176.39, 176.10, 156.63, 155.75, 
154.84, 138.49, 138.31, 131.73, 131.20, 126.48, 126.20, 117.59, 117.52, 113.14, 81.91, 
80.76, 55.03, 54.10, 36.03, 34.96, 28.44, 28.12, 19.60. [α]D20 -4.60° (c 0.81, MeOH), 
literature value [α]D25 -8.0° (c 0.813, MeOH)110. Elution times (Lux 5µ Amylose-2): tmajor: 
29.36 min, tminor: 30.05 min, e.r. 98:2. 
(242) (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2,5-
dimethylphenyl)propanoic acid  
Followed procedure for compound 235 with 237 (0.052 g, 0.16 mmol) to give product as 
a slightly yellow oil (0.043 g, 86%). 1H-NMR (500 MHz, CDCl3) δ 6.84 (d, J = 13.2, 
1H), 6.56 (d, J = 9.5, 1H), 6.36 (d, J = 8.0), 5.06 (d, J = 8.3) (1H), 4.51 (q, J = 7.2), 4.35 
(br s) (1H), 3.13 (dd, J = 14.2, 5.4), 2.91 – 2.70 (m) (2H), 2.22 (s, 3H), 2.14 (s, 3H), 1.40, 
1.26 (2s, 9H); 13C-NMR (126 MHz, CDCl3) δ 176.61, 176.29, 156.53, 155.66, 152.97, 
135.57, 135.46, 133.06, 132.67, 126.62, 126.04, 121.37, 117.15, 117.06, 81.60, 80.55, 
55.31, 54.05, 36.28, 35.01, 28.42, 28.01, 19.08, 15.42. [α]D20 +1.29 (c 0.50, MeOH). 
Elution times (Lux 5µ Amylose-2): tmajor: 32.67 min, tminor: 31.71 min, e.r. 98:2. 
(243) (S)-2-((tert-butoxycarbonyl)amino)-3-(2,6-dichloro-4-
methoxyphenyl)propanoic acid  
Followed procedure for compound 235 with 238 (0.038 g, 0.10 mmol) to give product as 
a colorless oil (0.037 g, 100%). 1H-NMR (500 MHz, CDCl3) δ 6.88 (s, 2H), 5.14 (d, J = 
8.9, 1H), 4.74 – 4.60 (m, 1H), 3.78 (s, 3H), 3.46 – 3.21 (m, 2H), 1.35 (s, 9H); 13C-NMR 
(126 MHz, CDCl3) δ 176.59, 175.86, 158.96, 155.48, 136.80, 136.52, 125.29, 124.73, 
114.51, 114.48, 81.22, 80.30, 55.90, 55.86, 53.73, 52.83, 34.38, 33.22, 28.34, 28.04. 
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[α]D20 -14.34° (c 0.72, MeOH). Elution times (Lux 5µ Amylose-2): tmajor: 46.87 min, 
tminor: 47.74 min, e.r. 91:9. 
(244) (S)-2-((tert-butoxycarbonyl)amino)-3-(2,6-dimethylphenyl)propanoic acid 
Followed procedure for compound 235 with 239 (0.057 g, 0.19 mmol) to give product as 
a colorless oil (0.054 g, 100%). 1H-NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.2), 5.05 (d, J 
= 8.6) (1H), 7.09 – 6.98 (m, 3H), 4.57 (ddd, J = 11.6, 8.1, 3.6, 1H), 3.26 – 3.07 (m, 2H), 
2.41 (s, 6H), 1.35, 1.04 (2s, 9H); 13C-NMR (101 MHz, CDCl3) δ 175.69, 156.99, 137.58, 
134.58, 128.43, 126.67, 81.38, 54.19, 34.88, 27.64, 20.54. [α]D20 -14.43 (c 0.41, MeOH), 
literature value [α]D25 -17.85° (c 0.41, MeOH)111. Elution times (Lux 5µ Amylose-2): 
tmajor: 43.04 min, tminor: 41.73 min, e.r. 99:1. 
(245) (S)-2-((tert-butoxycarbonyl)amino)-3-(8-hydroxynaphthalen-2-yl)propanoic 
acid 
Followed procedure for compound 235 with 240 (0.068 g, 0.20 mmol) to give product as 
a yellow oil (0.049 g, 75%). 1H-NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 7.69 (d, J = 8.6, 
1H), 7.36 – 7.24 (m, 2H), 7.21 (t, J = 7.7, 1H), 6.82 (d, J = 7.7, 1H), 5.15 (d, J = 8.2, 1H), 
4.70 (q, J = 6.6, 1H), 3.36 – 3.19 (m, 2H), 1.38, 1.27 (2s, 9H); 13C-NMR (126 MHz, 
CDCl3) δ 175.99, 155.92, 152.04, 133.89, 132.70, 128.97, 128.87, 128.06, 127.59, 
126.02, 124.88, 122.82, 122.26, 119.81, 109.57, 109.19, 81.89, 80.55, 56.23, 54.76, 
39.00, 38.32, 28.40, 28.11. [α]D20 +40.21 (c 0.37, MeOH). Elution times (Lux 5µ 
Amylose-2): tmajor: 40.52 min, tminor: 39.15 min, e.r. 99:1. 
(246) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2-
methylphenyl)propanamide 
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To a dry flask containing 241 (0.028 g, 0.095 mmol) was added DMF (9 mL) via syringe. 
DIPEA (0.17 mL, 0.95 mmol) was then added dropwise via syringe, followed by PyBOP 
(0.049 g, 0.095 mmol) and 6-Cl-HOBt (0.016 g, 0.095 mmol). 6-benzyl-1-(tert-
butoxycarbonyl)-1,2,3,4-tetrahydroquinolin-4-aminium chloride (0.036 g, 0.095 mmol) 
was then dissolved in DMF (3 mL) and added dropwise via syringe. The resulting 
mixture was allowed to stir at r.t. for 15 h, after which time DMF was removed under 
reduced pressure, and the crude residue was passed through silica (1:1 hex/EtOAc). The 
crude residue was redissolved in a 1:1 mixture of TFA and DCM (10 mL) and stirred at 
r.t. for 20 min. DCM and TFA were then removed under reduced pressure, and crude 
residue was purified by semi-prep RP-HPLC and lyophilized to give product as a white 
solid. Retention Time: 23.21 min. (MS)EI: 438.2 (M+Na). 1H-NMR (500 MHz, CD3OD) 
δ 8.40 (d, J = 7.6, 1H), 7.24 – 7.20 (m, 2H), 7.16 – 7.11 (m, 3H), 7.01 (d, J = 2.0, 1H), 
6.98 – 6.94 (m, 2H), 6.69 (d, J = 8.2, 1H), 6.64 (d, J = 2.6, 1H), 6.58 (dd, J = 8.2, 2.6, 
1H), 4.94 (t, J = 4.7, 1H), 3.88 (t, J = 8.2, 1H), 3.83 (s, 2H), 3.09 (dt, J = 12.3, 4.3, 1H), 
3.04 (d, J = 8.2, 2H), 2.70 – 2.62 (m, 1H), 2.28 (s, 3H), 1.86 – 1.77 (m, 1H), 1.66 – 1.59 
(m, 1H). 
(247) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,5-dimethylphenyl)propanamide 
Followed procedure for compound 246 with 242 (0.043 g, 0.14 mmol) to give product as 
a white solid. Retention Time: 25.52 min. (MS)EI: 430.2 (M+H). 1H-NMR (500 MHz, 
CD3OD) δ 8.40 (d, J = 7.8, 1H), 7.25 – 7.19 (m, 2H), 7.16 – 7.10 (m, 3H), 7.03 (d, J = 
2.0, 1H), 6.99 (dd, J = 8.3, 2.0, 1H), 6.83 (s, 1H), 6.73 (d, J = 8.2, 1H), 6.59 (s, 1H), 4.95 
(t, J = 4.6, 1H), 3.88 – 3.85 (m, 1H), 3.84 (s, 2H), 3.13 – 3.06 (m, 1H), 3.06 – 2.95 (m, 
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2H), 2.69 – 2.61 (m, 1H), 2.24 (s, 3H), 2.12 (s, 3H), 1.87 – 1.79 (m, 1H), 1.64 – 1.56 (m, 
1H). 
(248) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(2,6-dichloro-
4-hydroxyphenyl)propanamide 
Followed procedure for compound 246 with 243 (0.043 g, 0.12 mmol) with the following 
modification: after semi-prep RP-HPLC purification, residue was dissolved in DCM (5 
mL) and cooled to 0 °C. BBr3 (0.11 mL, 1.0 M solution in DCM) was then added 
dropwise. The solution was warmed to r.t. and stirred for 1 h, after which time it was 
quenched with the slow addition of MeOH. Further purification by RP-HPLC gave 
product as a white solid. Retention Time: 26.90 min. MS(EI): 492.1 (M+Na). 1H-NMR 
(400 MHz, CD3OD) δ 7.25 – 7.18 (m, 2H), 7.16 – 7.10 (m, 3H), 7.04 – 6.96 (m, 1H), 
6.96 – 6.88 (m, 1H), 6.86 (s, 2H), 6.67 (d, J = 8.2, 1H), 5.04 (t, J = 5.2, 1H), 4.00 (dd, J = 
10.7, 4.6, 1H), 3.82 (d, J = 5.3, 2H), 3.55 (dd, J = 13.5, 10.9, 1H), 3.26 – 3.12 (m, 2H), 
2.89 – 2.75 (m, 1H), 1.98 – 1.88 (m, 1H), 1.88 – 1.78 (m, 1H). 
(249) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(2,6-
dimethylphenyl)propanamide  
Followed procedure for compound 246 with 244 (0.014 g, 0.048 mmol) to give product 
as a white solid. Retention Time: 30.98 min. MS(EI): 436.2 (M+Na). 1H-NMR (400 
MHz, CD3OD) δ 8.17 (d, J = 7.9, 1H), 7.25 – 7.19 (m, 2H), 7.16 – 7.00 (m, 6H), 7.00 – 
6.96 (m, 1H), 6.92 (dd, J = 8.3, 2.0, 1H), 6.63 (d, J = 8.2, 1H), 4.99 – 4.92 (m, 1H), 3.92 
(dd, J = 11.6, 5.0, 1H), 3.81 (s, 2H), 3.41 – 3.33 (m, 1H), 3.11 (dd, J = 13.5, 5.0, 1H), 
3.00 (dt, J = 12.2, 4.3, 1H), 2.52 – 2.40 (m, 1H), 2.35 (s, 6H), 1.80 – 1.68 (m, 1H), 1.53 – 
1.41 (m, 1H). 
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(250) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(8-
hydroxynaphthalen-2-yl)propanamide  
Followed procedure for compound 246 with 245 (0.029 g, 0.088 mmol) to give product 
as a white solid. Retention Time: 30.35 min. MS(EI): 452.2 (M+H). 1H-NMR (500 MHz, 
CD3OD) δ 8.06 (s, 1H), 7.78 (d, J = 8.4, 1H), 7.36 – 7.27 (m, 3H), 7.23 – 7.19 (m, 2H), 
7.15 – 7.09 (m, 3H), 6.94 (d, J = 2.0, 1H), 6.90 (dd, J = 8.3, 2.1, 1H), 6.84 (dd, J = 7.3, 
1.2, 1H), 6.57 (d, J = 8.3, 1H), 4.91 (t, J = 4.5, 1H), 4.04 (dd, J = 8.7, 6.7, 1H), 3.80 (s, 
2H), 3.27 (dd, J = 7.7, 5.6, 2H), 2.61 (dt, J = 12.2, 4.3, 1H), 2.29 (td, J = 11.7, 2.8, 1H), 
1.75 – 1.65 (m, 1H), 1.64 – 1.55 (m, 1H). 
(251) 4-((S)-2-amino-3-(((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)amino)-3-
oxopropyl)-3,5-dimethylbenzamide 
Followed procedure for compound 246 with (S)-2-((tert-butoxycarbonyl)amino)-3-(4-
carbamoyl-2,6-dimethylphenyl)propanoic acid99 (0.028 g, 0.083 mmol) to give product as 
a white solid. Retention Time: 22.24 min. MS(EI): 457.3 (M+H). 1H-NMR (500 MHz, 
CD3OD) δ 8.24 (d, J = 7.8, 1H), 7.55 (s, 2H), 7.21 (t, J = 7.5, 2H), 7.15 – 7.08 (m, 3H), 
6.98 (d, J = 2.0, 1H), 6.93 (dd, J = 8.3, 2.0, 1H), 6.64 (d, J = 8.3, 1H), 4.98 – 4.91 (m, 
1H), 3.93 (dd, J = 11.7, 5.0, 1H), 3.81 (s, 2H), 3.42 (dd, J = 13.3, 11.7, 1H), 3.17 (dd, J = 
13.4, 5.0, 1H), 3.00 (dt, J = 12.3, 4.6, 1H), 2.42 (s, 6H), 2.41 – 2.35 (m, 1H), 1.79 – 1.70 
(m, 1H), 1.48 – 1.41 (m, 1H). 
(252) 1,3-dichloro-2-iodo-5-methoxybenzene 
To a stirring solution of 3,5-dichloroanisole (0.54 g, 3.02 mmol) in MeCN (20 mL) was 
added Ag2SO4 (1.41 g, 4.53 mmol) and I2 (0.84 g, 3.34 mmol). The resulting mixture was 
stirred at r.t. under an inert atmosphere for 3 days, after which time MeCN was removed 
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under reduced pressure, and residue was redissolved in DCM. Sat. sodium thiosulfate 
was added, and the aqueous layer was extracted with DCM. Combined organic extracts 
were washed with brine, and dried with MgSO4. Solvents were filtered and removed to 
give product as a tan solid (0.71 g, 77%). 1H-NMR (400 MHz, CDCl3) δ 6.91 (s, 2H), 
3.77 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 160.10, 140.62, 113.82, 92.22, 55.93. 
(253) 7-bromonaphthalen-1-ol 
To a dry flask was added 7-bromo-3,4-dihydronaphthalen-1(2H)-one (0.53 g, 2.36 mmol) 
and NBS (0.44 g, 2.48 mmol) and placed under an inert atmosphere. CCl4 (20 mL) was 
then added via syringe, and the mixture was stirred at reflux for 18 h. After cooling to r.t., 
the mixture was filtered through a plug of Celite with DCM. Organic extract was washed 
with sat. NaHCO3 and brine, and dried with MgSO4. Solvents were filtered and removed, 
and crude residue was purified by column chromatography (8:1 hex/EtOAc) to give 
product as a white solid (0.50 g, 70%), which was confirmed by NMR analysis to be the 
desired α-brominated intermediate. This intermediate was redissolved in DMF (15 mL). 
LiBr (0.046 g, 5.25 mmol) and Li2CO3 (0.026 g, 3.45 mmol) were then added, and the 
mixture was stirred at 140 °C for 2 h, after which time it was cooled to r.t. Solids were 
removed by filtration, and washed with EtOAc. Filtrate was washed with H2O (3x) and 
brine, and organic layer was dried with MgSO4. Solvents were filtered and removed, and 
crude residue was purified by column chromatography (5:1 hex/EtOAc) to give product 
as a light brown solid (0.29 g, 78%). 1H-NMR (500 MHz, CDCl3) δ 8.36 (d, J = 2.2, 1H), 
7.65 (d, J = 8.7, 1H), 7.54 (dd, J = 8.8, 2.1, 1H), 7.38 (d, J = 8.3, 1H), 7.31 – 7.29 (m, 
1H), 6.81 (d, J = 7.4, 1H), 5.45 (s, 1H); 13C-NMR (126 MHz, CDCl3) δ 150.69, 133.24, 
129.96, 129.43, 126.41, 125.61, 124.47, 120.63, 119.42, 109.62. 
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(254) (S)-2-amino-N-((R)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(2,4-
dichlorophenyl)propanamide 
Followed procedure for compound 246 with (S)-2-((tert-butoxycarbonyl)amino)-3-(2,4-
dichlorophenyl)propanoic acid (0.029 g, 0.088 mmol) to give product as a white solid. 
Retention Time: 32.65 min. MS(EI): 476.1 (M+Na). 1H-NMR (400 MHz, CD3OD) δ 7.53 
(d, J = 2.0, 1H), 7.34 (dd, J = 8.3, 2.1, 1H), 7.29 (d, = 8.3, 1H), 7.24 – 7.18 (m, 2H), 7.15 
– 7.09 (m, 3H), 6.98 (d, J = 2.0, 1H), 6.93 (dd, J = 8.3, 2.1, 1H), 6.64 (d, J = 8.2, 1H), 
4.97 (t, J = 4.7, 1H), 4.02 (dd, J = 9.6, 6.1, 1H), 3.81 (s, 2H), 3.27 – 3.08 (m, 3H), 2.75 – 
2.65 (m, 1H), 1.87 – 1.83 (m, 1H), 1.72 – 1.61 (m, 1H). 
(255) (R)-2-methyl-N-((R)-7-phenoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propane-2-
sulfinamide 
Followed procedure for compound 46 with 7-phenoxy-3,4-dihydronaphthalen-1(2H)-one 
(0.10 g, 0.42 mmol) to give product as a colorless oil (0.049 g, 34%). 1H-NMR (400 
MHz, CDCl3) δ 7.34 – 7.25 (m, 2H), 7.11 (d, J = 2.4, 1H), 7.10 – 7.04 (m, 2H), 6.97 (d, J 
= 7.8, 2H), 6.86 (dd, J = 8.4, 2.5, 1H), 4.52 (q, J = 3.5, 1H), 3.22 (d, J = 2.6, 1H), 2.80 
(dt, J = 16.7, 5.0, 1H), 2.70 (ddd, J = 16.4, 8.9, 5.6, 1H), 2.09 – 2.00 (m, 1H), 1.99 – 1.87 
(m, 2H), 1.82 – 1.72 (m, 1H), 1.20 (s, 9H); 13C-NMR (101 MHz, CDCl3) δ 157.59, 
155.49, 138.45, 132.85, 130.68, 129.80, 123.14, 119.88, 118.84, 118.56, 55.61, 52.56, 
30.25, 28.64, 22.76, 18.37. 
(256) (R)-7-phenoxy-1,2,3,4-tetrahydronaphthalen-1-aminium chloride 
Compound 255 (0.049 g, 0.14 mmol) was dissolved in 1,4-dioxane (7 mL). Conc. HCl 
(0.071 mL, 0.86 mmol) was added dropwise. The resulting solution was stirred at r.t. for 
1.5 h, after which time dioxane and HCl were removed under reduced pressure. Et2O was 
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added, precipitating a white solid, which was subsequently washed 3x with Et2O and 
dried (0.028 g, 72%) and used without further purification.  
(257) (S)-2-amino-3-(2,6-dichloro-4-hydroxyphenyl)-N-((R)-7-phenoxy-1,2,3,4-
tetrahydronaphthalen-1-yl)propanamide 
Followed procedure for compound 68 with 256 (0.008 g, 0.029 mmol) and 243 (0.011 g, 
0.029 mmol) with the following modification: after TFA deprotection and RP-HPLC 
purification, residue was dissolved in dry DCM (3 mL) and cooled to 0 °C under an inert 
atmosphere. BBr3 (0.062 mL, 1.0 M solution in DCM) was then added dropwise via 
syringe. The solution was allowed to warm to r.t. and was stirred overnight. The reaction 
mixture was then quenched with the addition of MeOH, and solvents were removed 
under reduced pressure. Crude residue was purified by RP-HPLC to give product as a 
white solid. MS(EI): 493.1 (M+Na).  
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CHAPTER 5 
4-SUBSTITUTED PIPERIDINES AND PIPERAZINES AS MIXED EFFICACY 
MOR/DOR LIGANDSd 
 
5.1 Introduction 
In an effort to further develop drug-like MOR/DOR bifunctional ligands, we 
turned our attention to compound 258 (Figure 23) a previously synthesized opioid ligand 
that displays equal binding affinity for both MOR and DOR, as well as KOR (Ki (MOR) 
= 25.8 nM; (DOR) = 33.0 nM; (KOR) = 36.5 nM, unpublished observations). Given the 
relative simplicity of the compound and its nonselective binding profile, it was reasoned 
that the compound would be a good starting point for derivatization. Computational 
modeling suggested that position 4 would be the optimal point for diversification (Figure 
23), as an aromatic moiety at this position would be ideally situated to interact with 
Asn125, Thr218, and Lys303 in the MOR active site, and the resulting compound would thus 
function as a MOR agonist.40,59 
Figure 23. Chemical Structure of Compound 258 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
d See reference 95. In vitro assays were performed by Mary Clark. Compound 285 was synthesized by 
Michael Agius. 
O
H2N
OH
N4
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5.2 Synthesis and Evaluation of 4-Substituted Piperidine and Piperazine Opioid 
Ligands 
Compound 258 was initially substituted with a benzyl group at the 4 position to 
give analogue 261. The synthesis of 261 began by subjecting tert-butyl 4-oxo-3,4-
dihydroquinoline-1(2H)-carboxylate (synthesized in a similar manner as compound 22 in 
Scheme 3, Chapter 2) to a Wittig reaction to yield alkene 259 as a mixture of E and Z 
isomers, which was subsequently hydrogenated and deprotected to give amine 260, to 
which was coupled Boc-L-Dmt and deprotected with TFA in DCM (Scheme 28). 
Compared to 258, the resulting compound 261 displayed no significant change in binding 
affinity for MOR and DOR, but showed decreased affinity for KOR (Table 9).  
Scheme 28. Synthesis of Analogue 261 
 
 
 
 
 
 
Unfortunately, 261 also displayed no notable efficacy at MOR as determined by the 
[35S]GTPγS assay. Because the synthesis of 261 proved somewhat laborious, and the 
resulting diastereomers could not be resolved by RP-HPLC, it was reasoned that 
synthesis of further analogues could be simplified by the replacement of the 
tetrahydroquinoline (THQ) core of 261 with a piperidine, effectively eliminating a 
N
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bromide, n-BuLi, THF, reflux
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stereocenter. The resulting compound 262 displayed roughly a tenfold increase in binding 
affinity for MOR and DOR, but still lacked any efficacy at MOR. The remainder of the 
SAR campaign was focused on changing the length and flexibility profile of the side 
chain in an attempt to not only retain strong binding affinity for both MOR and DOR, but 
to increase efficacy at MOR. For purposes of synthetic utility as well as increased 
solubility, the piperidine core was also replaced with a piperazine for most of the 
analogues, the results of which are summarized in Table 9. 
Scheme 29. Synthesis of Analogues 262-265 
 
 
 
 
 
 
Compounds 262-265 were synthesized by coupling a commercially available 
piperidine or piperazine derivative with Boc-2’,6’-dimethyl-L-tyrosine, followed by 
TFA-mediated deptrotection and RP-HPLC purification to yield the final compounds 
(Scheme 29). In the case of 268 and 269, a commercially available primary alcohol was 
first mesylated and refluxed with excess piperazine117 to give intermediates 266 and 267, 
which were then coupled with Boc-2’,6’-dimethyl-L-tyrosine and deprotected under 
similar conditions (Scheme 30).  
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Scheme 30. Synthesis of Analogues 268 and 269 
 
 
 
 
Unsaturated analogues 276 and 277 were synthesized as shown in Scheme 31. 
The appropriate commercially available aldehyde was subjected to a Horner–
Wadsworth–Emmons type olefination to give 270 and 271, which were then reduced to 
the corresponding alcohols using either DIBAL-H (for the formation of allylic alcohols) 
or LAH (for the formation of saturated alcohols). Additionally, before reduction, alkene 
271 was first hydrogenated to give saturated ester 278, ultimately leading to final 
analogue 281 (Scheme 32). All intermediates were then carried forward in a similar 
manner as in Schemes 29 and 30 to give finished products. 
Scheme 31. Synthesis of Analogues 276 and 277 
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Scheme 32. Synthesis of Analogue 281 
 
 
 
 
 
 
 
Z-alkene analogue 285 was synthesized as shown in Scheme 33 by subjecting a 
commercially available aldehyde (the same as in the case of intermediate 270) to a Still-
modified Horner-Wadsworth-Emmons olefination.118 Lastly, commercially available 1-
([1,1'-biphenyl]-4-yl)piperazine was coupled to Boc-L-Dmt (Scheme 34) to give final 
analogue 286. 
Scheme 33. Synthesis of Analogue 285 
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Scheme 34. Synthesis of Analogue 286 
 
 
 
 
 
The synthesized analogues in Table 9 display a broad range of binding affinities 
for MOR (29–0.29 nM), and to a lesser extent, DOR (115–6.6 nM). Extension of the side 
chain of 262 from 1 to 3 methylene units did little to change binding at MOR or DOR, 
but encouragingly, the resulting compound (263) behaved as a weak partial agonist at 
MOR. Replacement of the piperidine core of 263 with a piperazine (264) proved 
inconsequential, and the continued balanced MOR/DOR binding profile of this analogue 
led to the pursuit of other aromatic moieties separated by three methylene units from the 
piperazine core. Analogue 281 in particular showed an improved balanced MOR/DOR 
binding profile, and also displayed a partial agonist profile at MOR. Interestingly, 
compound 277, in which the 1-naphthyl side chain of 281 is constrained with an 
additional double bond, showed no efficacy in the [35S]GTPγS assay at all three 
receptors, with an additional loss of binding affinity for KOR. The insertion of an extra 
aromatic moiety as in the case of the diphenylmethyl analogue 269 did little to increase 
binding affinity for either MOR or DOR. Further extension of the distance between the 
aromatic side chain and the piperazine core (265) resulted in a boost in MOR binding, 
without drastically affecting DOR. Although these 4 carbon analogues (265, 276, 285) 
suffered a slight loss of MOR/DOR affinity balance, all displayed good efficacy at MOR, 
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particularly the unsaturated analogues 276 and 285 (20 and 41 nM, respectively). Side 
chain extension to 5 methylene units (268) did little to improve upon the profile of 276 or 
285. 
Table 9. Opioid Receptor Binding Affinities and Efficacies for Analogues 261-265, 268, 
269, 276, 277, 281, 285, 286a 
 
   MOR DOR KOR 
 R x Ki (nM) EC50 (nM) % stim Ki (nM) EC50 (nM) % stim Ki (nM) 
EC50 
(nM) 
% 
stim 
261 Scheme 28 29 ± 9 dns 11 ± 6 14 ± 2 dns dns 310 ± 50 dns dns 
262 
 
CH 1.4 ± 0.1 dns dns 7.8 ± 0.9 dns dns 140 ± 24 dns dns 
263 
 
CH 2.0 ± 0.8 119 ± 39 26 ± 2 12 ± 2 dns dns 110 ± 11 dns dns 
264 
 
N 3.8 ± 0.8 150 ± 49 23 ± 2 36 ± 4 dns dns 250 ± 51 dns dns 
265  N 
0.45 ± 
0.3 
64 ± 3 43 ± 6 9.9 ± 2 dns dns 30 ± 6 dns 12 ± 1 
268  N 
0.42 ± 
0.15 
53 ± 23 42 ± 1 6.9 ± 1.7 dns dns 39 ± 15 
660 ± 
80 
12 ± 5 
269 
 
N 1.1 ± 0.2 dns dns 21 ± 7 dns dns 150 ± 42 dns dns 
276 
 
N 
0.29 ± 
0.07 
20 ± 3.6 36 ± 4 23 ± 8.9 dns dns 89 ± 23 
1500 ± 
120 
16 ± 3 
277 
 
N 6.4 ± 0.1 dns dns 
11 ± 
0.65 
dns dns 330 ± 92 dns dns 
281 
 
N 1.1 ± 0.3 85 ± 10 17 ± 3 6.6 ± 2 dns dns 78 ± 15 dns dns 
285 
 
N 0.3 ± 0.1 41 ± 15 49 ± 5 28 ± 6.8 dns dns 54 ± 3.2 dns 11 ± 7 
286 Scheme 34 11 ± 2 
2500 ± 
800 
15 ± 8 115 ± 42 dns dns 320 ± 80 dns dns 
a. dns = does not stimulate. See Table 1 for further in vitro details. 
X
N
NH2R OH
O
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Structurally, these analogues exhibit some similarities to the class of trans-3,4-
dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists originally described by 
Zimmerman119 and explored by others.120 In this series, the 3-hydroxyphenyl moiety is 
replaced by 2’,6’-dimethyl-L-tyrosine, and the piperidine (or piperazine) core is left 
unsubstituted. In both series, receptor selectivity is modulated by the nature of the 
lipophilic side chain attached para to the phenolic component of the molecule. The 
piperidine and piperazine analogues of THQ compound 258 described here display a 
favorable balance between binding affinity at MOR and DOR, and several display 
improved potency at MOR as compared to morphine (Ki (MOR) = 6.3 nM, (DOR) = 171 
nM; EC50 (MOR) = 194 nM).42 Unfortunately, compound 268 proved to be inactive in 
the WWTW assay at 10 mg/kg, and further in vivo studies on this class of analogues 
were not pursued.  
 
5.3 Experimental Section  
5.3.1 Chemistry   
For further general chemistry, in vitro and in vivo experimental detail, see section 2.4. 
 (259) tert-butyl 4-benzylidene-3,4-dihydroquinoline-1(2H)-carboxylate 
To a suspension of triphenylphosphoniumbenzyl bromide (2.44 g, 5.6 mmol) in dry THF 
(20 mL) was added n-BuLi (2.70 mL, 6.8 mmol) dropwise at 0°C. The red mixture was 
allowed to stir for 1 h. tert-butyl 4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (1.46 g, 
5.9 mmol) was then added dropwise at 0 °C. The mixture was then warmed to 70 °C, and 
refluxed overnight. The mixture was then quenched with sat. ammonium chloride (5 mL) 
and the aqueous layer was extracted with EtOAc. Combined organic extracts were 
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washed with brine and dried with MgSO4. Residue was purified by column 
chromatography (9:1 hexanes/EtOAc) to give product as a colorless oil (0.44 g, 50%). 
1H-NMR (400 MHz, CDCl3) revealed an inseparable 3:1 mixture of E:Z isomers, which 
was carried forward without additional purification. 
(260) 4-benzyl-1,2,3,4-tetrahydroquinoline 
Compound 259 (0.286 g, 0.89 mmol) was dissolved in MeOH (40 mL) and added to 10% 
Pd/C (400 mg) in a hydrogenation vessel. The mixture was shaken under 50 psi H2 gas 
for 24 h, after which time the mixture was filtered through a plug of Celite, and MeOH 
was removed. Residue was redissolved in EtOAc, and H2O was added. Aqueous layer 
was extracted with EtOAc, and combined organic layers were dried with MgSO4. 
Solvents were filtered and removed to afford a colorless oil which was dissolved in a 1:1 
mixture of TFA/DCM (6 mL) and stirred for 30 min. Solvents were removed, and residue 
was extracted from 2M NaOH with EtOAc and dried with MgSO4. Solvents were filtered 
and removed to give product as a colorless oil (0.12 g, 61%). 1H-NMR (400 MHz, 
CDCl3) δ 7.30 (t, J  = 7.4, 2H), 7.21 (t, J  = 8.8, 3H), 7.04 – 6.95 (m, 2H), 6.61 (t, J  = 
7.4, 1H), 6.49 (d, J  = 7.9, 1H), 3.41 – 3.32 (m, 1H), 3.21 (dt, J  = 9.7, 4.6, 1H), 3.12 (dd, 
J  = 13.3, 5.1, 1H), 3.08 – 3.00 (m, 1H), 2.71 (dd, J  = 13.3, 10.0, 1H), 1.82 – 1.66 (m, 
2H); 13C-NMR (101 MHz, CDCl3) δ 144.42, 140.58, 129.43, 128.43, 127.13, 126.12, 
124.79, 116.87, 114.36, 43.33, 38.29, 37.55, 25.33. 
(261) (2S)-2-amino-1-(4-benzyl-3,4-dihydroquinolin-1(2H)-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propan-1-one 
To a solution of Boc-L-Dmt (0.056 g, 0.14 mmol) and 5Ǻ molecular sieves in anhydrous 
DMF (2 mL) and DCM (5 mL) was added DIPEA (0.20 mL, 1.1 mmol), followed by 10 
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min of stirring. HATU (0.043 g, 0.11 mmol) and HOBt-Cl (0.019 g, 0.11 mmol) were 
then added, followed by an additional 20 min of stirring. Compound 260 (0.025 g, 0.11 
mmol) in DMF (2 mL) was then added via syringe. The reaction was heated to 40 °C and 
allowed to stir overnight. Solvents were removed, and crude residue was redissolved in 
EtOAc. H2O was added, and extracted with EtOAc. Combined organic extracts were 
washed with brine and dried with MgSO4. Solvents were filtered and removed, and 
residue was purified by column chromatography (7:1 hexanes/EtOAc). Purified residue 
was then redissolved in a 1:1 mixture of DCM/TFA (10 mL), and allowed to stir for 1 h. 
Solvents were removed to give product as an oily solid. Retention Time: 39.60 min. 
MS(EI): 437.2 (M+Na).  
(262) (S)-2-amino-1-(4-benzylpiperidin-1-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propan-1-one 
To a solution of 4-benzylpiperidine (0.100 g, 0.57 mmol), Boc-L-Dmt (0.234 g, 0.57 
mmol) and DIPEA (1.00 mL, 5.7 mmol) was added HATU (0.217 g, 0.571 mmol) and 
HOBt-Cl (0.097 g, 0.57 mmol) and allowed to stir at r.t. for 15 h. H2O was then added, 
and extracted with EtOAc. Combined organic layers were washed with brine and dried 
with MgSO4. Solvents were filtered and removed, and residue was redissolved in 1:1 
DCM/TFA (6 mL) and allowed to stir for 1 h. Solvents were removed, and residue was 
purified by RP-HPLC to give product as a white solid. Retention Time: 32.45 min. 
MS(EI): 389.2 (M+Na). 1H-NMR (400 MHz, CDCl3) revealed a 2:1 ratio of conformers.  
(263) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(3-
phenylpropyl)piperidin-1-yl)propan-1-one  
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Followed procedure for compound 262 with 4-(3-phenylpropyl)piperidine (0.087 g, 0.42 
mmol) with the following modification: reaction was stirred at r.t. for 2 h and purified by 
RP-HPLC to give product as a white solid. Retention Time: 39.15 min. MS(EI): 394.2 
(M+H). 1H-NMR (400 MHz, CDCl3) revealed a 3:2 ratio of conformers.  
(264) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(3-
phenylpropyl)piperazin-1-yl)propan-1-one 
Followed procedure for compound 262 with 1-(3-phenylpropyl)piperazine (0.091 g, 0.45 
mmol) to give product as a white solid. Retention Time: 20.29 min. MS(EI): 396.3 
(M+H). 1H-NMR (500 MHz, CD3OD) δ 7.30 – 7.21 (m, 2H), 7.21 – 7.12 (m, 3H), 6.55 
(s, 2H), 4.55 (dd, J = 11.8, 4.8, 1H), 3.37 – 2.87 (m, 12H), 2.63 (t, J = 7.6, 2H), 2.24 (s, 
6H), 2.00 – 1.87 (m, 2H).  
(265) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(4-phenylbutyl)piperazin-
1-yl)propan-1-one 
Followed procedure for compound 262 with 1-(4-phenylbutyl)piperazine (0.045 g, 0.21 
mmol) to give product as a white solid. Retention Time: 26.71 min. MS(EI): 410.3 
(M+H). 1H-NMR (500 MHz, CD3OD) δ 7.27 (t, J = 7.5, 2H), 7.23 – 7.15 (m, 3H), 6.57 
(s, 2H), 4.56 (dd, J = 12.1, 4.6, 1H), 3.54 – 2.87 (m, 12H), 2.67 (t, J = 6.7, 2H), 2.28 (s, 
6H), 1.69 – 1.61 (m, 4H).  
(266) 1-(5-phenylpentyl)piperazine 
5-phenylpentanol (0.506 g, 3.08 mmol) was dissolved in DCM (15 mL). Et3N (0.86 mL, 
6.2 mmol) was then added via syringe. The mixture was cooled to 0 °C, and MsCl (0.406 
mL, 5.2 mmol) was added dropwise. The yellow mixture was stirred at 0 °C for 1 h, after 
which time it was washed with H2O (15 mL)
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organic solvents were filtered and removed to give crude mesylate as a yellow oil. 
Mesylate was redissolved in THF (15 mL) and piperazine (1.32 g) was added. The 
mixture was refluxed at 70 °C for 16 h, after which time THF was removed and residue 
was redissolved in DCM. 2M HCl was added, and the organic layer was discarded. 
Aqueous layer was basified with solid NaOH to pH 14, and extracted with DCM. 
Combined organic extracts were dried with MgSO4, and solvents were filtered and 
removed to afford product as a colorless oil (0.50 g, 69%). 1H-NMR (400 MHz, CDCl3) δ 
7.29 – 7.21 (m, 2H), 7.19 – 7.12 (m, 3H), 2.86 (t, J = 5.0, 4H), 2.59 (t, J = 7.6, 2H), 2.37 
(brs, 4H), 2.31 – 2.23 (m, 2H), 1.62 (p, J = 7.6, 2H), 1.51 (p, J = 7.6, 2H), 1.33 (p, J = 
7.7, 2H); 13C-NMR (101 MHz, CDCl3) δ 142.37, 128.14, 128.00, 125.39, 59.11, 54.37, 
45.85, 35.67, 31.21, 27.04, 26.33. 
(267) 1-(3,3-diphenylpropyl)piperazine 
Followed procedure for compound 266 with 3,3-diphenylpropan-1-ol (0.54 g, 2.56 mmol) 
to give product as a colorless oil (0.56 g, 78%). 1H-NMR (400 MHz, CDCl3) δ 7.27 – 
7.23 (m, 8H), 7.19 – 7.11 (m, 2H), 3.99 (t, J = 6.8, 1H), 2.86 (t, J = 4.9, 4H), 2.36 (s, 4H), 
2.27 – 2.22 (m, 4H); 13C-NMR (101 MHz, CDCl3) δ 144.85, 128.47, 127.84, 126.14, 
57.42, 54.41, 49.06, 45.97, 32.55. 
(268) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(5-
phenylpentyl)piperazin-1-yl)propan-1-one  
Followed procedure for compound 262 with 266 (0.058 g, 0.25 mmol) with the following 
modifications: reaction was stirred at r.t. for 8 h with PyBOP instead of HATU and 
purified by RP-HPLC to give product as a white solid. Retention time: 28.63 min. 
MS(EI): 424.3 (M+H). 1H-NMR (400 MHz, CD3OD) δ 7.25 (t, J = 7.4, 2H), 7.20 – 7.11 
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(m, 3H), 6.57 (s, 2H), 4.57 (dd, J = 12.1, 4.6, 1H), 3.22 (t, J = 12.8, 1H), 3.12 (dd, J = 
13.6, 4.5, 1H), 3.07 – 2.85 (m, 10H), 2.63 (t, J = 7.5, 2H), 2.27 (s, 6H), 1.74 – 1.58 (m, 
4H), 1.43 – 1.29 (m, 2H).  
(269) (S)-2-amino-1-(4-(3,3-diphenylpropyl)piperazin-1-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propan-1-one 
Followed procedure for compound 262 with 267 (0.091 g, 0.33 mmol) with the following 
modifications: reaction was stirred at r.t. for 2 h with HBTU instead of HATU and 
purified by RP-HPLC to give product as a white solid. Retention Time: 32.23 min. 
MS(EI): 472.3 (M+H). 1H-NMR (400 MHz, CD3OD) δ 7.33 – 7.26 (m, 10H), 6.53 (s, 
2H), 4.53 (dd, J = 12.0, 4.7, 1H), 3.97 (t, J = 7.9, 1H), 3.25 – 2.34 (m, 14H), 2.24 (s, 6H).  
(270) (E)-methyl 4-phenylbut-2-enoate  
To 60% NaH (0.190 g, 4.8 mmol) in THF (12 mL) was added methyl 
diethylphosphonoacetate (0.87 mL, 4.8 mmol) dropwise at 0 °C. The mixture was 
allowed to stir for 5 min, after which time the ice bath was removed and 
phenylacetaldehyde (0.56 mL, 4.8 mmol) was added dropwise over a period of 10 min. 
The mixture was stirred for 1 h, and was then quenched with sat. ammonium chloride. 
The aqueous layer was extracted with Et2O. Combined organic extracts were dried with 
MgSO4, and solvents were filtered and removed. Residue was purified by column 
chromatography (8:1 hexanes/EtOAc) to afford product as a colorless oil (0.62 g, 74%). 
1H-NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 7.23 – 7.17 (m, 1H), 7.16 – 7.04 (m, 
3H), 5.80 (dt, J = 15.6, 1.4, 1H), 3.67 (s, 3H), 3.46 (dd, J = 6.9, 0.8, 2H); 13C-NMR (101 
MHz, CDCl3) δ 166.78, 147.59, 137.65, 128.78, 128.69, 126.68, 121.94, 51.40, 38.43. 
(271) (E)-methyl 3-(naphthalen-1-yl)acrylate 
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Followed procedure for compound 270 with 1-naphthaldehyde (0.74 g, 4.76 mmol) to 
afford product as a colorless oil (0.88 g, 87%). 1H-NMR (400 MHz, CDCl3) δ 8.47 (d, J 
= 15.8, 1H), 8.08 (d, J = 8.0, 1H), 7.80 – 7.71 (m, 2H), 7.59 (d, J = 7.2, 1H), 7.51 – 7.38 
(m, 2H), 7.33 (t, J = 7.7, 1H), 6.46 (d, J = 16.0, 1H), 3.78 (s, 3H); 13C-NMR (101 MHz, 
CDCl3) δ 167.08, 141.57, 133.48, 131.41, 131.22, 130.39, 128.57, 126.69, 126.04, 
125.26, 124.80, 123.13, 120.15, 51.59. 
(272) (E)-4-phenylbut-2-en-1-ol 
To a solution of compound 270 (0.60 g, 3.4 mmol) in anhydrous DCM (10 mL) was 
added DIBAL (15 mL, 15 mmol, 1.0 M in THF) at -78°C. The mixture was allowed to 
stir at -78 °C for 15 min, after which time the mixture was quenched with EtOAc (5 mL) 
and H2O (5 mL) and allowed to stir for 1 h at r.t. The mixture was filtered through a plug 
of Celite, and the aqueous layer was extracted with EtOAc. Combined organic extracts 
were washed with brine and dried with MgSO4. Solvents were filtered and removed, and 
residue was purified by column chromatography (3:1 hexanes/EtOAc) to afford product 
as a colorless oil (0.26 g, 52%). 1H-NMR (400 MHz, CDCl3) δ 7.30 – 7.23 (m, 2H), 7.20 
– 7.13 (m, 3H), 5.85 – 5.75 (m, 1H), 5.69 – 5.59 (m, 1H), 4.04 (dd, J = 5.8, 0.9 2H), 3.40 
(d, J = 6.7, 2H); 13C-NMR (101 MHz, CDCl3) δ 140.08, 131.36, 130.39, 128.59, 128.49, 
126.16, 63.30, 38.67. 
(273) (E)-3-(naphthalen-1-yl)prop-2-en-1-ol 
Followed procedure for compound 272 with 271 (0.86 g, 4.04 mmol) to give product as a 
colorless oil (0.62 g, 83%). 1H-NMR (400 MHz, CDCl3) δ 8.05 – 7.98 (m, 1H), 7.76 – 
7.70 (m, 1H), 7.65 (d, J = 8.2, 1H), 7.43 (d, J = 7.2, 1H), 7.40 – 7.32 (m, 2H), 7.31 – 7.21 
(m, 2H), 6.29 – 6.19 (m, 1H), 4.18 (dd, J = 5.6, 1.2, 2H); 13C-NMR (101 MHz, CDCl3) δ 
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134.34, 133.51, 131.69, 131.04, 128.44, 127.85, 127.66, 125.97, 125.68, 125.55, 123.75, 
123.66, 63.46. 
(274) (E)-1-(4-phenylbut-2-en-1-yl)piperazine 
Followed procedure for compound 266 with 272 (0.14 g, 0.96 mmol) to give product as a 
colorless oil (0.11 g, 51%). 1H-NMR (400 MHz, CDCl3) δ 7.35 – 7.25 (m, 2H), 7.24 – 
7.14 (m, 3H), 5.82 – 5.71 (m, 1H), 5.63 – 5.51 (m, 1H), 3.47 (s, 2H), 3.38 (d, J = 6.4, 
2H), 3.03 – 2.91 (m, 4H), 2.47 (s, 4H); 13C-NMR (101 MHz, CDCl3) δ 140.30, 133.44, 
128.60, 128.53, 127.57, 126.15, 61.24, 53.58, 45.67, 38.97. 
(275) (E)-1-(3-(naphthalen-1-yl)allyl)piperazine 
Followed procedure for compound 266 with 273 (0.62 g, 3.34 mmol) to give product as a 
colorless oil (0.40 g, 48%). 1H-NMR (400 MHz, CDCl3) δ 8.08 (d, J = 8.2, 1H), 7.79 (d, 
J = 7.6, 1H), 7.72 (d, J = 8.2, 1H), 7.58 (d, J = 7.1, 1H), 7.50 – 7.36 (m, 3H), 7.24 (d, J = 
15.6, 1H), 6.27 (dt, J = 15.5, 6.8, 1H), 3.20 (d, J = 6.8, 2H), 2.87 (t, J = 4.9, 4H), 2.47 (s, 
4H); 13C-NMR (101 MHz, CDCl3) δ 134.49, 133.43, 130.89, 129.98, 129.67, 128.38, 
127.68, 125.85, 125.58, 125.51, 123.67, 123.58, 61.78, 54.33, 45.92. 
(276) (S,E)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(4-phenylbut-2-en-1-
yl)piperazin-1-yl)propan-1-one 
Followed procedure for compound 262 with 274 (0.070 g, 0.32 mmol) to give product as 
a white solid. Retention Time: 26.28 min. MS(EI): 408.3 (M+H). 1H-NMR (500 MHz, 
CD3OD) δ 7.30 (t, J = 7.5, 2H), 7.21 (t, J = 6.4, 3H), 6.55 (s, 2H), 6.25 – 6.16 (m, 1H), 
5.53 – 5.44 (m, 1H), 4.55 (dd, J = 12.1, 4.6, 1H), 3.80 (d, J = 7.2, 1H), 3.65 – 2.86 (m, 
13H), 2.26 (s, 6H).  
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(277) (S,E)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(3-(naphthalen-1-
yl)allyl)piperazin-1-yl)propan-1-one 
Followed procedure for compound 262 with 275 (0.12 g, 0.47 mmol) to give product as a 
white solid. Retention Time: 30.95 min. MS(EI): 444.3 (M+H). 1H-NMR (500 MHz, 
CD3OD) δ 8.20 (d, J = 8.4, 1H), 7.90 (t, J = 7.8, 2H), 7.76 – 7.68 (m, 2H), 7.62 – 7.47 
(m, 3H), 6.61 (s, 2H), 6.28 – 6.18 (m, 1H), 4.57 (dd, J = 12.1, 4.6, 1H), 3.98 – 3.89 (m, 
1H), 3.77 – 3.00 (m, 11H), 2.28 (s, 6H).  
(278) methyl 3-(naphthalen-1-yl)propanoate 
Compound 271 (0.574 g, 2.7 mmol) was dissolved in abs. EtOH, and added slowly to 
10% Pd/C (200 mg). The mixture was allowed to shake under 15 psi H2 gas for 2 h, after 
which time it was filtered through a plug of Celite, and EtOH was removed. Residue was 
redissolved in EtOAc, and H2O was added. Aqueous layer was extracted with EtOAc. 
Combined organic extracts were dried with MgSO4, and solvents were filtered and 
removed to give pure product as a colorless oil (0.555 g, 96%). 1H-NMR (400 MHz, 
CDCl3) δ 8.09 (d, J = 8.2, 1H), 7.90 (d, J = 7.9, 1H), 7.78 (d, J = 8.0, 1H), 7.61 – 7.49 
(m, 2H), 7.48 – 7.37 (m, 2H), 3.74 (s, 3H), 3.48 (t, J = 7.9, 2H), 2.82 (t, J = 7.9, 2H); 13C-
NMR (101 MHz, CDCl3) δ 173.35, 136.43, 133.85, 131.56, 128.86, 127.12, 126.05, 
125.87, 125.57, 125.54, 123.33, 51.61, 34.91, 28.07. 
(279) 3-(naphthalen-1-yl)propan-1-ol 
To a stirring suspension of LAH (0.197 g, 5.2 mmol) in dry THF (15 mL) was added 
compound 278 (0.555 g, 2.6 mmol) in THF (10 mL) dropwise at 0 °C. The reaction 
mixture was warmed to r.t., and was stirred vigorously for 1 h, after which time it was 
quenched with H2O (10 mL) and was filtered through a plug of Celite with Et2O. 
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Aqueous layer was extracted with Et2O, and combined organic extracts were dried with 
MgSO4. Solvents were filtered and removed to afford pure product as a colorless oil 
(0.450 g, 95%). 1H-NMR (400 MHz, CDCl3) δ 8.02 – 7.96 (m, 1H), 7.81 – 7.76 (m, 1H), 
7.65 (d, J = 8.1, 1H), 7.47 – 7.37 (m, 2H), 7.32 (t, J = 6.8, 1H), 7.25 (d, J = 6.7, 1H), 3.61 
(t, J = 6.4, 2H), 3.07 (t, J = 7.6, 2H), 1.98 – 1.86 (m, 2H); 13C-NMR (101 MHz, CDCl3) δ 
137.97, 133.88, 131.82, 128.78, 126.66, 125.97, 125.80, 125.55, 125.48, 123.78, 62.25, 
33.43, 29.14.  
(280) 1-(3-(naphthalen-1-yl)propyl)piperazine 
Followed procedure for compound 266 with 279 (0.46 g, 2.46 mmol) to give product as a 
colorless oil (0.49 g, 79%). 1H-NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.1, 1H), 7.85 – 
7.78 (m, 1H), 7.67 (d, J = 8.1, 1H), 7.50 – 7.40 (m, 2H), 7.35 (t, J = 7.2, 1H), 7.29 (d, J = 
6.8, 1H), 3.05 (t, J = 8.0, 2H), 2.89 (t, J = 4.9, 4H), 2.50 – 2.34 (m, 6H), 1.95 – 1.84 (m, 
2H); 13C-NMR (101 MHz, CDCl3) δ 138.15, 133.75, 131.76, 128.65, 126.49, 125.84, 
125.63, 125.42, 125.34, 123.72, 58.51, 53.51, 45.33, 30.55, 27.63. 
(281) (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(3-(naphthalen-1-
yl)propyl)piperazin-1-yl)propan-1-one  
Followed procedure for compound 262 with 280 (0.088 g, 0.35 mmol) with the following 
modifications: reaction was stirred at r.t. for 3 h with HBTU instead of HATU and 
purified by RP-HPLC to give product as a white solid. Retention Time: 30.22 min. 
MS(EI): 446.3 (M+H). 1H-NMR (400 MHz, CD3OD) δ 8.06 (d, J = 8.5, 1H), 7.86 (d, J = 
7.9, 1H), 7.75 (d, J = 8.0, 1H), 7.51 (dt, J = 23.7, 7.0, 2H), 7.44 – 7.33 (m, 2H), 6.56 (s, 
2H), 4.54 (dd, J = 11.8, 4.4, 1H), 3.26 – 2.91 (m, 14H), 2.55 (s, 6H), 2.11 – 2.02 (m, 2H).  
(282) (Z)-methyl 4-phenylbut-2-enoate 
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Followed procedure for compound 270 with phenylacetaldehyde (0.38 g, 3.14 mmol) 
with the following modifications: methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate 
was used instead of methyl diethylphosphonoacetate and the reaction was allowed to stir 
for 30 minutes to give product as a colorless oil (0.43 g, 78%). 1H-NMR (400 MHz, 
CDCl3) δ 7.33 – 7.25 (m, 2H), 7.25 – 7.17 (m, 3H), 6.40 – 6.30 (m, 1H), 5.86 (d, J = 
11.4, 1H), 4.02 (d, J = 7.3, 2H), 3.74 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 166.85, 
148.41, 139.45, 128.71, 128.69, 126.43, 119.54, 51.26, 35.22. 
(283) (Z)-4-phenylbut-2-en-1-ol 
Followed procedure for compound 272 with 282 (0.43 g, 2.42 mmol) to give product as a 
colorless oil (0.26 g, 72%). 1H-NMR (400 MHz, CDCl3) δ 7.31 – 7.25 (m, 2H), 7.22 – 
7.14 (m, 3H), 5.74 – 5.69 (m, 2H), 4.30 – 4.27 (m, 2H), 3.42 (d, J = 5.8, 2H); 13C-NMR 
(101 MHz, CDCl3) δ 140.26, 130.97, 129.43, 128.60, 128.37, 126.18, 58.49, 33.70. 
(284) (Z)-1-(4-phenylbut-2-en-1-yl)piperazine 
Followed procedure for compound 266 with 283 (0.23 g, 1.54 mmol) to give product as a 
colorless oil (0.23 g, 68%). 1H-NMR (400 MHz, CDCl3) δ 7.34 – 7.24 (m, 2H), 7.23 – 
7.13 (m, 3H), 5.82 – 5.70 (m, 1H), 5.67 – 5.55 (m, 1H), 3.43 (s, 2H), 3.22 – 3.08 (m, 2H), 
3.01 – 2.71 (m, 4H), 2.48 (s, 4H); 13C-NMR (101 MHz, CDCl3) δ 140.49, 131.54, 
128.48, 128.30, 126.88, 126.02, 55.63, 54.19, 45.82, 33.76. 
(285) (S,Z)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-1-(4-(4-phenylbut-2-en-1-
yl)piperazin-1-yl)propan-1-one 
Followed procedure for compound 262 with 284 (0.065 g, 0.30 mmol) to give product as 
a white solid. Retention Time: 25.09 min. MS(EI): 408.3 (M+H). 1H-NMR (400 MHz, 
CD3OD) δ 7.30 (m, 2H), 7.24 – 7.16 (m, 3H), 6.54 (s, 2H), 6.19 (m, 1H), 5.52 (m, 1H), 
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4.57 (dd, J = 11.9, 4.7, 1H), 3.77 (d, J = 7.4, 2H), 3.50 (d, J = 7.7, 2H), 3.38 – 2.93 (m, 
10H), 2.25 (s, 6H).  
(286) (S)-1-(4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propan-1-one 
Followed procedure for compound 262 with 1-([1,1'-biphenyl]-4-yl)piperazine (0.047 g, 
0.20 mmol) with the following modifications: reaction was reaction was stirred at r.t. for 
3 h with HBTU instead of HATU and purified by RP-HPLC to give product as a white 
solid. Retention Time: 37.86 min. MS(EI): 430.3 (M+H). 1H-NMR (500 MHz, CD3OD) δ 
7.54 (d, J = 7.6, 2H), 7.50 (d, J = 7.2, 2H), 7.38 (t, J = 6.0, 2H), 7.26 (t, J = 7.4, 1H), 6.93 
(d, J = 6.8, 2H), 6.53 (s, 2H), 4.57 (dd, J = 12.1, 4.3, 1H), 3.91 – 3.83 (m, 1H), 3.56 – 
3.47 (m, 1H), 3.29 – 3.06 (m, 4H), 2.90 – 2.80 (m, 2H), 2.80 – 2.73 (m, 1H), 2.29 (s, 6H), 
2.04 – 1.96 (m, 1H). 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
General Summary. The previous chapters have described both (1) the synthesis, 
in vitro and in vivo evaluation of a class of mixed efficacy opioid ligands based on 
compound 1 (Figure 11, Chapter 2) featuring 2’,6’-dimethyl-L-tyrosine (Dmt) attached to 
a tetrahydroquinoline (THQ) or related core (Chapters 2-4) and (2) the synthesis, in vitro 
and in vivo evaluation of a class of opioids featuring piperidine and piperazine cores 
(Chapter 5). The SAR campaign for both classes of compounds has yielded analogues 
that are potent MOR agonists (and DOR antagonists) in vitro, as well as several 
analogues that display potent, dose-dependent antinociception in mouse models, 
particularly isoindoline 86, tetrahydroisoquinoline 102, thiochroman 214 and 
carboxamide 251. These analogues are therefore promising candidates for further 
dependence and tolerance studies in mice.  
 Binding Affinity and Sodium. Because it is known that sodium ions can bind to 
an allosteric site in DOR and reduce the binding affinity of certain DOR ligands,121 86, 
102, 214 and 251 were tested for DOR binding affinity in the presence of 100 mM Na, 
which is roughly the physiological concentration. Under these conditions, it was found 
that the DOR binding affinity of 86 is 102.4 nM, a 6.8 fold decrease in affinity from 15 
nM in Tris buffer. Conversely, the binding affinity for 102 in the presence of Na was 
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found to be 2.8 nM, only a 3.1 fold decrease from 0.89 nM. It was found that in the 
presence of Na, the DOR binding affinity for 214 became 34.6 nM, a roughly 7-fold 
decrease from 4.8 nM in Tris buffer. Preliminary studies on the binding of carboxamide 
251 in the presence of 100 mM sodium at DOR have shown the compound’s binding 
affinity to be 91 nM, comparable to isoindoline 86. If the theory that MOR agonist/DOR 
antagonist ligands with superior binding affinity at both MOR and DOR under 
physiological conditions are able to mitigate the negative side effects associated with 
selective MOR agonists, 102 may be an especially promising candidate for future in vivo 
studies. 
Synthesis of New THQ Core-Based Analogues (Chapters 2-4). The analogues 
synthesized in Chapter 2 feature a substituent at the 6 position of a THQ or substituted 
THQ core. It would therefore be an interesting endeavor to combine a 6-position pendant 
substitution that yielded good dose-dependent antinociception in vivo 
(tetrahydroisoquinoline 102, isoindoline 86, see Chapter 2) with the thiochroman core of 
analogue 214 (Chapter 3). Such an analogue may show a cumulative effect and be even 
more potent in vivo than either of its parent compounds, or may conversely show no 
effect at all (in keeping with the unpredictable results seen in vivo thus far). Either way, 
the synthesis of this type of additive compound has not yet been attempted, and the 
results would provide new information concerning the efficacy of this type of scaffold in 
vivo.  
Given the robust dose-dependent analgesia exhibited by carboxamide compound 
251 (Chapter 4), this analogue is also an interesting candidate for further in vivo studies, 
particularly chronic tolerance and dependence in mice. Additionally, this unnatural amino 
	   197	  
acid (S)-2-((tert-butoxycarbonyl)amino)-3-(4-carbamoyl-2,6-dimethylphenyl)propanoic 
acid99 could also be examined on scaffolds featuring different pendant modifications at 
the 6 position (see Chapter 2), particularly the aforementioned pendant modifications that 
also gave good dose-pendent analgesia in mice (86 and 102).  
Additionally, because ligands with selectivity for MOR and KOR over DOR (with 
KOR agonist activity) such as nalbuphine have shown promise for the treatment of drug 
dependence (specifically cocaine self administration),83 further SAR studies on analogue 
89 (Chapter 2) are warranted. 89 shows potent stimulation of KOR in the [35S]GTPγS 
binding assay, but does not stimulate MOR. Using similar LAH-reduction chemistry on 
different commercially available imides (see Scheme 6) other saturated spiro amines of 
varying ring sizes could be synthesized (2-azaspiro[4.5]decane, 8-azaspiro[4.5]decane, 7-
azaspiro[4.5]decane, etc.).77 These types of substitutions would serve as a useful starting 
point for the development of an analogue that retains or improves on the potent KOR 
stimulation of compound 89, while maintaining selective affinity for MOR and KOR 
over DOR.  
Synthesis of New Piperazine Core-Based Analogues (Chapter 5). Although the 
extension of the lipophilic side chain to 5 methylene units of piperazine analogue 268 
(Chapter 5) did not improve upon the MOR agonist/DOR antagonist profile of compound 
265, bulkier aromatic groups were not examined on chain lengths of 4 methylene units or 
greater from the piperazine core in this series of analogues. Such compounds could 
feasibly be synthesized by refluxing the appropriate commercially available 1-naphthyl or 
2-naphthyl derivatized alcohol or halide with piperazine in THF.117 Additionally, 
alternative nitrogen-containing heterocycles have not yet been examined in place of the 
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piperazine core. Replacement with a 7-membered piperazine derivative (homopiperazine) 
or similarly larger or smaller saturated nitrogen-containing heterocycles would provide 
interesting analogues in which the angle of the lipophilic side chain would necessarily be 
changed relative to the Dmt-containing portion of the ligand. Such analogues could 
potentially boost the modest MOR agonist activity of the previously synthesized 
compounds. 
 Negishi Coupling Optimization. Although the microwave-assisted Negishi 
coupling described in Chapter 4 can provide access to Dmt and its derivatives in a rapid 
manner, the reaction does require further optimization. The modest yield of 56% could 
potentially be improved with the use of a different Pd catalyst/ligand system, and further 
screening of commercially available catalytic systems would provide further insight into 
strategies for yield improvement. Additionally, although this reaction is effective on a 
relatively small scale (< 400 mg of serine derivative 233), operation of the reaction on a 
gram scale has proven difficult, and only trace amounts of product have thus far been 
isolated. Optimization of the reaction setup and microwave conditions (reaction time, 
temperature) will therefore require further study for large batches of these useful 
intermediates.  
 Peripherally Active Compounds for the Treatment of IBS. Although many of the 
THQ-based peptidomimetics discussed in Chapters 2 and 3 show optimal MOR 
agonist/DOR antagonist profiles in vitro, only a select few of the compounds showed 
dose-dependent antinociception in mice after ip administration. Alternatively, compounds 
with no activity after this route of administration (meaning no BBB penetration) are 
promising candidates for the treatment of IBS (see the development of Eluxadoline, 
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Chapter 1.5). Representative analogues modified at the 6-position that would be viable 
candidates for such studies are 2-benzofuranyl compound 75, tetrahydroisoquinoline 
compounds 82 and 83, and decahydroisoquinoline compound 87 (Chapter 2). All of these 
compounds have good binding affinities at MOR and DOR (with some selectivity for 
MOR), and show potent stimulation of MOR in the [35S]GTPγS assay. Many of the 
analogues with modifications to the THQ core discussed in Chapter 3 would also be good 
candidates for further studies in the area of peripherally active MOR agonist/DOR 
antagonists, namely sulfone analogue 217. 217 shows especially potent stimulation of 
MOR (EC50 0.72 nM, 94% stimulation), and good binding affinity at DOR (2.3 nM). 
Furthermore, the sulfone moiety (in place of the THQ aniline) prevents oxidative 
aromatization of the molecule’s core, and lends the compound an especially high polar 
surface area (109.5), which is favorable for a lack of BBB penetration and overall 
metabolic stability. 
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